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1 Summary 
Rhabdomyosarcoma is a malignant tumor deriving from muscle progenitor cells. Four histologically 
different subtypes of RMS are known, the most common are the embryonal (eRMS) and alveolar 
(aRMS) forms. About 80% of all aRMS cases are associated with a specific translocation t(2;13) or 
(1;13) leading to the formation of a fusion gene, PAX3/FKHR or PAX7/FKHR. PAX3(7)/FKHR is a 
strong transactivator and has previously been shown to activate a number of antiapoptotic pathways 
and modify growth and differentiation of cancer cells, thus contributing to the oncogenic behaviour of 
these cells. Furthermore, recent data indicate that PAX3FKHR target genes are also implicated in the 
- compared to eRMS much larger - invasive and metastatic potential of aRMS. Direct targets and 
molecular mechanism of these pathways though are largely unknown; therefore the identification of 
direct targets of PAX3/FKHR was the main goal of this project.  
For the identification of direct PAX3/FKHR targets a microarray approach was chosen. This initial 
screen was complemented by functional analysis of interesting target genes to elucidate the 
oncogenic mechanisms of PAX3/FKHR. As cellular model for this screening, the PAX3/FKHR-positive 
aRMS cell line Rh4 was chosen. The transcriptome of this cell line most closely reflects an in vivo 
PAX3/FKHR-specific gene signature found in a recent study of aRMS biopsies. 
In the present work, endogenous PAX3/FKHR was downregulated by RNAi in Rh4 cells, followed by a 
gene expression profiling using Affymetrix HGU133A arrays. In accordance with previous studies, 
analysis of cell growth and apoptosis rate upon downregulation of PAX3/FKHR demonstrated a stong 
influence of PAX3/FKHR on viability of Rh4 cells. The measured gene expression profiles were then 
compared with the in vivo expression signatures specific for PAX3(7)/FKHR-translocations. By this 
analysis, 51 putative target genes physiologically relevant for development of rhabdomyosarcoma 
could be identified.  
One identified target gene, namely TFAP2B, was further characterized as PAX3/FKHR target. First, 
direct DNA binding of the PAX3/FKHR protein to the promoter of one identified direct target gene, 
TFAP2B, was analyzed by promoter studies, chromatin immunoprecipitation and EMSA. These 
methods validated TFAP2B as PAX3/FKHR target. Furthermore, functional studies revealed that 
TFAP2B acts as an essential mediator of PAX3/FKHR oncogenic properties.  
The identification of physiologically relevant PAX3/FKHR target genes is crucial for understanding the 
oncogenic mechanisms involved in the development of rhabdomyosarcoma. Functional studies of 
PAX3/FKHR target genes could also reveal novel targets for specific cancer treatment. 
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2 Zusammenfassung 
 
Das Rhabdomyosarkom (RMS) ist ein maligner Tumor, der aus Muskelzellvorläufern entsteht. RMS 
werden in vier Subtypen unterteilt, dabei sind das embryonale RMS (eRMS) und das alveoläre RMS 
(aRMS) am häufigsten vertreten. Etwa 80% der alveolären RMS weisen die chromosomale 
Translokation t(2;13)(q35;q14) auf, das daraus resultierende Fusionsgen wird als PAX3/FKHR 
bezeichnet. PAX3/FKHR wirkt als starker Transkriptionsfaktor, dessen onkogener Mechanismus 
allerdings nicht gänzlich aufgeklärt werden konnten, da erst einige wenige Zielgene charakterisiert 
wurden. 
Es gibt einige Hinweise darauf, dass die Zielgene des PAX3-FKHR für die hohe Rezidivrate und 
Metastasierung dieser Krebsart mitverantwortlich sind. Daher wurden im Rahmen dieses Projektes 
solche direkten Zielgene des PAX3/FKHR Fusionsproteins charakterisiert. Zur Realisierung des 
Projektes wurden zwei experimentelle Ansätze verfolgt, zum einen die Charaterisierung der Zielgene 
von PAX3/FKHR durch Microarray-Analysen und komplementär dazu die Klärung der onkogenen 
Mechanismen durch funktionelle Untersuchungen der Zielgene. 
In der vorangegangenen Expressionsanalyse von eRMS und aRMS Tumorbiopsien wurde ein für 
translokations-positive Proben typisches Genexpressionsmuster gefunden. Diese Gensignatur konnte 
auch weitgehend für die Rh4-Zellen, einer Modellzellinie für aRMS, bestätigt werden. Nun wurde mit 
Hilfe der RNA-Interferenz Technik die Expression des PAX3/FKHR Gens in Rh4-Zellen vermindert 
und daraufhin auftretende Veränderungen in der Expression der aRMS-spezifischen Gensignatur 
untersucht. Veränderungen im Expressionsprofil führten zur Identifikation von 51 Kandidatengenen, 
die Zielgene der PAX3 und PAX3/FKHR Transkriptionsfaktoren darstellen und daher mit wichtigen 
phänotypischen Charakteristika dieser Tumorzellen assoziiert sind. 
Komplementär zu den Expressionsanalysen wurde die Protein-DNA Interaktion zwischen dem 
PAX3/FKHR Protein und den spezifisch gebundenen Sequenzen der DNA eines Zielgens, 
TFAP2beta, mittels Promoteranalyse und Chromatin Immunopräzipitation erforscht, um Rückschlüsse 
auf die Mechanismen der Zielgenaktivierung ziehen zu können. Diese Methode erlaubte zudem eine 
zusätzliche Verifizierung von Zielgenen und erlaubte die Untersuchung ihrer Rolle und Relevanz bei 
onkogenen Vorgängen. 
Die Auswirkungen der durch RNA-Interferenz verminderten Expression der PAX3 und PAX3/FKHR 
Gene und somit veränderte Expression derer Zielgene auf physiologische Prozesse in den eRMS und 
aRMS Zellen wurden ebenfalls untersucht. Von besonderem Interesse waren hier die Veränderungen 
in der Proliferations- und Apoptoserate der Zellen, da es einige Hinweise darauf gab, dass 
PAX3/FKHR Wachstumsfaktoren und anti-apoptotische Proteine aktivieren könnte. Die Zellwachstum 
fördernde Eigenschaft von PAX3 und PAX3/FKHR konnte bestätigt sowie die Beteiligung von 
TFAP2beta in diesem Prozess gesichert werden. 
Protein-DNA Interaktionen spielen eine essentielle Rolle in allen Bereichen der Genregulation, daher 
ist die Charakterisierung der Zielgene von PAX3/FKHR besonders wichtig für das Verständnis der 
onkogenen Mechanismen, die das Rhabdomyosarkom verursachen. Die funktionelle Untersuchung 
 6
der Zielgene von PAX3/FKHR könnte in der Zukunft neue Ziele für spezifischere Krebstherapien 
liefern und wäre für die Entwicklung von neuen Krebstherapeutika von Bedeutung. 
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3 Introduction 
 
The multiplication of cells is one of the most important and sensitive processes in the body and is 
therefore carefully regulated. There are various mechanisms and controls to balance these processes 
of cell birth and death to produce a steady state. For some cell types, such as epithelial cells, there is 
a rapid renewal, some others rarely die or, as in the case of brain cells, little or no replacement of 
those cells occurs. Very rarely, the numerous controls that regulate cell multiplication break down and 
an uncontrolled cell growth and division begins. When such a cell gives rise to a cell population that 
inherit the propensity to grow without responding to regulation, this may lead to tumor formation. The 
genetic and physiological events that lead to transformation of normal cells are crucial for tumor 
formation and thus, the understanding of those processes is very important for diagnosis and 
treatment of cancer. 
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3.1 Cancer 
 
Cancer development in humans is a slow process: For most solid human tumors, there is a period of 
years needed for tumor formation. Cancer research of past decades revealed cancer as a genetic 
disease involving multistep processes, where each step reflects genetic alterations that drive the 
transformation of normal human cells into highly malignant cells. A great effort has been done in last 
years to understand genetic processes which lead to tumor formation and progression. 
Already in 1971, a mechanism for tumor formation was proposed by Alfred G. Knudson in his two-hit 
theory. Analyzing clinical and statistical data of patients with retinoblastoma, he noted that as normal 
individuals have two normal copies of an tumor suppressor gene, two independent ‘hits’ (mutations) 
are required in the same cell which then lead to neoplastic development. Knudson’s two-hit theory, 
first stated for retinoblastoma, turned out to be correct for essentially all cancer types, although it has 
been shown later that in most cases more than two hits are required for tumor formation. However, 
recently published findings suggest that also monoallelic single-hit events inactinvating a tumor 
suppressor gene might be sufficient for development of Wilms tumor if the inactivation occurs on the 
single X chromosome in tumors from males and the active X chromosome in tumor from females 
(Rivera et al., 2007). The multistep development of cancer is now a more accepted model of 
tumorigenesis. The multi-hit hypothesis proposed by Vogelstein and Kinzler in 1993 suggests that 
multiple mutations (three to six) have to occur over longer period of time in a single cell to form cancer.  
D. Hanahan and R. A. Weinberg postulated six alterations in cell physiology as hallmarks of cancer 
cells which are most likely shared by all types of human tumors. These six characteristics of cancer 
cells are: self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of 
programmed cell death, limitless replicative potential, sustained angiogenesis, and tissue invasion and 
metastasis as shown in Figure 1 (Hanahan, Weinberg, 2000).  
 
 
 
Figure1 Acquired capabilities of cancer (Hanahan, Weinberg, 2000)  
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The mechanisms how these six hallmark capabilities are acquired by cancer cells differ significantly. 
There are different pathways involved in tumorigenesis, varying in both, mechanism and chronology. 
The order in which these tumor characteristics are acquired can vary in different cancer types, as 
shown in Figure 2. 
 
  
   
 
Tissue invasion and metastasis 
Sustained angiogenesis 
Limitless replicative potential 
Evading apoptosis 
Self-sufficiency in growth signals 
Insensitivity to anti-growth signals 
 
Figure 2 Possible assembly of pathways leading to cancer formation (adapted from Hanahan, 
Weinberg, 2000) 
 
There is increasing evidence that human tumors are genetically unstable and that most mutations are 
acquired, directly or indirectly, through changes in the genome of cancer cells. However, the normal 
mutation rates are insufficient to account for the numerous mutations detected in human cancers, as a 
complex genomic integrity maintenance system exists in each cell. Therefore, mutations that increase 
mutation rates and the malfunction of the components of the genomic “caretaker” systems are 
essential to account for the large number of mutations observed in human tumors. According to this 
hypothesis, the term of mutator phenotype of cancer cells has been stated for mutations in genes that 
maintain genetic stability, as genes that control the DNA replication and efficacy of DNA repair. 
Additionally, mutations in genes that encode for components that maintain normal DNA sequence in 
cells also contribute to mutator phenotype (Loeb et. al, 2003). The genomic instability which enables 
acquirement of cancer related characteristics exists at two distinct levels. First, the instability at 
nucleotide level which involves base substitutions or deletions or insertions of a few nucleotides. 
Second, the instability at the chromosomal level, resulting in numeral and structural alterations of 
chromosomal material and therefore gains and losses of whole chromosomes or portions thereof also 
leads to tumor formation (Lengnauer, Kinzler, Vogelstein 1998). Genes which are responsible for 
tumorigenesis can be divided into three groups: oncogenes, tumor-suppressor genes and stability 
genes. Cytogenetic changes and mechanisms leading to alterations in these genes and thus to 
tumorigenesis as well as most important genes will be discussed below. 
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3.2 Cytogenetic changes in cancer 
 
Generally, there are three main cytogenetic changes occurring in cancer cell: deletions, amplifications, 
translocations and inversions (Rabbitts, 1994). Deletions often lead to the loss of tumor-suppressor 
gene, translocations and inversions can lead to gene activation and to gene fusion, as shown in Figure 
3. Gene activation occurs mostly through a translocation or inversion event, joining the gene (proto-
oncogene) to immunoglobulin or T-cell receptor gene, thereby activating it. Immunoglobulin and T-cell 
receptor genes are often involved in chromosomal aberrations because they are naturally rearranged, 
therefore this gene activation event is observed frequently in leukaemia and lymphomas, as for 
example the juxtaposition of c-MYC and immunoglobulin heavy-chain (H) genes in Burkitt’s lymphoma 
(Rabbits, Boehm, 1991) or juxtaposition of HOX11 gene and T-cell receptor in T-cell acute leukaemia 
(T-ALL) (Dube et al., 1991).  
     
      A 
 
 
 
      B 
 
 
 
Figure 3 Chromosomal abberations shown schematically for two hypothetical genes. (A) Gene 
activation by joining of the oncogene (green exons) to diversity (D) or joining region (J) 
segments, depicted in yellow. (B) Gene fusion of two hypothetical genes (green and red), which 
became joined as a result of translocation or inversion. Transcription of the resultant fusion 
gene results in mRNA encoding a fusion protein comprising parts of both green and red 
protein (adapted from Rabbitts, 1994). 
 
Additionally to the commonly occurring cytogenetic events, a novel mechanism of formation of a fusion 
gene has been shown recently in T-ALL (Graux et al., 2004). As shown in Figure 4, the fusion of the 
NUP214-ABL1 gene is not created by a chromosomal translocation or inversion of interstitial 
deletions. In this case, both genes NUP214 and ABL1 are located at chromosome 9q34 and the fusion 
is mediated by extrachromosomal amplification which is not detectable by conventional cytogenetic 
analysis. However, by the use of novel methods like FISH, amplifications or losses of chromosome 
regions can be detected with high resolution, which is an important tool for diagnosis of cytogenetic 
aberrations in cancer. 
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Figure 4 Mechanism of formation of NUP214-ABL1. (a) Circularization on episome shown 
schematically for an hypothetical gene. (b) Scheme of the amplified region and the structure 
proposed by Craux et al.  
 
Gene fusion, resulting in synthesis of fusion genes encoding for chimearic proteins, in most cases 
generates abberant transcription factors. However, the first documented example of such an abberant 
fusion gene was described as an abnormal small chromosome 22 in the cells of chromic myelogenous 
leukaemia (CML), subsequently called the Philadelphia (Ph) chromosome (Nowell, Hungerford, 1960). 
In the Ph chromosome, the translocation between chromosomes 9 and 22 leads to the fusion of c-ABL 
to the BCR gene, the chimaeric protein encoded by the BCR-ABL fusion gene is a tyrosine kinase 
(Epner, Koeffler, 1990) which activates a number of cell cycle-controlling proteins and enzymes, 
speeding up cell division. This is an early genetic event which is an important contributor to the 
development of the CML.  
Some examples of genes often associated with cancer and commonly affected by deletions, 
translocations and inversions (here grouped together as chromosomal translocations) will be shortly 
described below. 
3.3 Deletions 
 
Tumor suppressor genes are negative regulators of cellular proliferation, their inactivation, in most 
cases through deletions results in loss of the “brake” on tumor growth. To date, numerous tumor 
suppressor genes have been identified, 174 of them are listed in the tumor suppressor gene database 
(TSGDB), which contains updated information about putative tumor suppressor genes from human 
beings and other organisms. This number however most likely will increase in the future. Different 
tumor suppressor genes have been identified in different spectrum of human cancers, with the 
probably most prominent retinoblastoma (RB) and p53 genes encoding for pRb and p53 proteins. RB 
was the first gene proposed to have a tumor-suppressor function (Comings 1973). The second tumor-
suppressor gene p53 was described in 1979, but originally believed to have an oncogene function. 
Further characterization of this gene in the following 10 year showed however the tumor-suppresive 
role of p53. 
Mutations in the p53 protein are observed in more than 50% of human cancers (Hollstein et al., 1991), 
there are however different mechanisms how this protein contributes to tumorigenesis, as the loss of 
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p53 can facilitate resistance to apoptosis, angiogenesis or can lead to genomic instability in cells. As a 
key component of the DNA damage sensor cascade, inactivation of p53 can prevent the induction of 
the apoptotic effector cascade (Harris, 1996). On the other hand, p53 positively regulates 
thrombospondin-1, an inhibitor of angiogenesis. Consequently, the loss of p53 causes low levels of 
thrombosponin-1, which then leads to release of epithelial cells (Dameron et al., 1994). Furthermore, 
p53 is considered as stability gene, thus the loss of p53 leads to aneuploidy of cultured cells (Harvey 
et. al., 1993). Furthermore, p53 is one of the cell-cycle checkpoint genes mostly via stimulation of p21, 
an inhibitor of cyclin-dependent kinases (CDKs). Through its negative effects on various CDKs, p21 
inhibits both the G1/S and the G2/M transitions. Failure of the cell-cycle checkpoint results in loss of 
the quality-control system which coordinates sequential events within the cell cycle. Thus, DNA 
damage during either G1 or G2 phase of the cell cycle triggers a cell-cycle arrest (which requires the 
p53 tumor-suppressor gene) to repair the genotoxic damage or to block further cell proliferation if the 
damage is irreparable (Levine, 1997). As most human cancers are dependent on sustained p53 
inactivation for tumour maintenance (oncogene-addiction), restoring of p53 function has been 
proposed as new therapeutical approaches, supported by recent study showing tumor regression in 
vivo after restoration of p53 (Ventura et al., 2007). 
 
3.4 Chromosomal translocations 
 
Chromosomal translocation is an event commonly found in cancer cells, generating gene activation 
and gene fusion, as mentioned above. Yet, gene fusion, resulting in the synthesis of chimaeric 
proteins, appears to be the main cause of abnormalities involved in cancer development. Gene 
fusions have been detected in numerous cancer types of both, haematopoietic and solid tumors. It is a 
common event leading to formation of tumors; however, the mechanisms how gene fusions contribute 
to tumorigenesis are greatly different. One of them, activation of a proto-oncogene as a result of 
chromosomal translocation or inversion was already mentioned.  
However, in most cases chromosomal translocations lead to activation of genes or gene fusions 
encoding for aberrant transcription factors as the consequence. Transcription factors regulate many 
pathways associated with cell viability like cell growth, differentiation or apoptosis by binding to 
specific DNA sequences within the promoter regions of corresponding genes and modulating the 
expression of these genes. Binding of a transcription factor to the specific promoter region can control 
the switch from inactive to active chromatin, stabilize the transcription complex (which includes RNA 
polymerase II and initiation factors) on the promoter DNA. Moreover, recruitment of other factors to the 
complex is another important function of a transcription factor. In most cases such aberrant 
transcription factors consist of an activation domain linked to a DNA-binding domain or to domains that 
interact with proteins which then bind DNA (Sánchez-García, Rabbits, 1994).  
Numerous abnormal transcription factors are strongly associated with formation and progression of 
distinct cancer types. Thus, some of the most important members of transcription factor families and 
the associated cancer types will be described in a separate section. 
 
 
 13
3.5 Most important transcription factor - families in cancer 
 
The simple model describing the binding of a transcription factor (TF) to the promoter region of its 
target gene is complicated by the fact that mammalian TFs are often members of large protein families 
that bind to similar DNA sequences. There are three most prominent TF-families associated with 
deregulated activity in cancer, namely the Ets, E2F and Myc family.  
 
3.5.1 The Ets transcription factor family 
 
Members of the Ets family play important roles in organogenesis, hematopoiesis, B-cell development 
and signal transduction (Dittmer, Nordheim, 1998). The Ets DNA binding domain is composed of 85 
amino acids forming a helix-turn-helix structure. Some members of Ets family, which are often found 
as fusion proteins with another protein in various leukemias and as a rare event also in solid tumors, 
are summarized in Table 1.  
 
Table 1. Ets transcription family members and associated cancer type 
 
TF- family Affected fusion genes Associated cancer type 
TEL 
AML1 
ALL 
ABL 
TEL 
AML 
PDGF-β 
TEL 
CMML 
AML1 
EAP 
MDS 
Ets 
EWS/FLI1 
EWS/ERG 
Ewing’s sarcoma 
 
ALL,acute lymphoblastic leukemia 
AML, acute myelogenous leukemia 
CMML, chronic myelomonocytic leukaemia 
MDS, myelodysplastic syndrome 
 
It is likely that inappropriate regulation of genes containing Ets binding sites in their promoter leads to 
the transformation of cells bearing a fusion protein containing an Ets member. The mechanisms of 
transformation by fusion proteins differ however in distinct cancer types. In ALL, which in about 25% is 
associated with TEL/AML1 fusion protein, deregulation of AML1 target genes is thought to cause the 
neoplastic transformation. It appears that the fusion protein downregulates all AML-regulated genes 
and that the loss of AML-activated gene expression leads to leukemia development. In the case of 
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EWS/FLI1 fusion protein in Ewing’s sarcoma, inappropriate activation of FLI1 targets leads to 
transformation of cells.  
 
3.5.2 The E2F transcription factor family 
 
The E2F family of transcription factors consists of eight members (E2F1, E2F2, E2F3, E2F4, E2F5, 
E2F6, E2F7 and E2F8) that function as heterodimers and bind to a consensus sequence known as 
E2F site in the promoter region of the target genes. All E2F members contain a DNA binding and a 
dimerization domain and a C terminal transactivation domain (with the exception of E2F6, which does 
not have a C terminal transactivation domain). A subset of E2F family members, E2F1, E2F2 and 
E2F3 also contain N-terminal protein interaction domain. Moreover, within the transactivation domain 
of E2F proteins is a protein interaction domain that enables the binding to Rb family of proteins. E2F1-
E2F6 members of E2F family bind to DNA as heterodimers with DP (DP1-4, TFDP1-4: transcription 
factor Dp-1-4; E2F dimerization partner1-4) family proteins, while E2F7 and E2F8 bind to DNA 
independent of DP proteins. An overview of E2F transcription family members is shown in Figure 5. 
 
 
 
Figure 5 E2F transcription factor family members. The DNA binding domain is indicated in 
green, the heptad repeat domain required for dimerization is shown in pink, interaction sites 
with cyclinA/cdk2 or Rb-family proteins are indicated in orange and blue, respectively 
(DeGregori, Johnson, 2006) 
 15
As with the previous members of transcription factor families, E2F family members can both activate 
or repress transcription of its target genes. The transcriptional activity of E2F1 through E2F5 is 
regulated through their association with RB or the related pocket proteins, p107 and p130. E2F1, 
E2F2, and E2F3a are so-called “activators” because they transcriptionally activate E2F target genes 
such as cyclin E. E2F3b, E2F4, and E2F5 are referred as "repressor" E2Fs because they repress E2F 
target genes. E2F regulates genes whose products are required for DNA synthesis and G1/S or G2/M 
phase progression, thus leading to stimulation or inhibition of cell proliferation. Additionally, E2Fs 
control the expression of genes involved in apoptosis, DNA repair, differentiation and development. 
 
3.5.3 The Myc transcription factor family 
 
Members of the Myc family share a carboxyl terminal basic region containing the helix-loop-helix 
(HLH) (Murreet al., 1989) and leucine zipper (LZ) (Landschulz et al., 1988) motif that mediates 
sequence-specific DNA binding and dimerization and a transactivation domain at the amino terminus. 
There are three mammalian myc genes, the c-myc, N-myc and L-myc. All members of the Myc family 
form a heterodimer with Max, a small, ubiquitously expressed protein that can bind to HLH-LZ protein, 
directly binds to the DNA (Baudino et al., 2001) and thus mediates the DNA binding of Myc. The 
transformation property of Myc family members is thought to be mediated through interaction between 
Myc and other cellular proteins. For example, N-myc can act as transcriptional activator when bound 
to the promoter region as N-myc/Max heterodimer, and transcriptional repressor when bound as a 
heterodimer with Mnt, Mxi or Mad (Grandori et al., 2000; Sakamuro et al., 1999). Some important 
interaction partners of Myc family members are shown in Figure 6. 
 
 
 
 
Figure 6 Localisation of binding sites on the Myc transactivation domain for interaction with 
protein cofactors (Cowling, Cole, 2006) 
 
The oncogenic potential of myc genes can be activated by chromosomal translocations, retroviral 
insertion or gene amplification which then results in deregulation of cell proliferation, cell cycle 
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regulation, apoptosis and genomic instability. Consequently, overexpression of Myc family members 
can also lead to neoplastic transformation (Facchini, Penn, 1998). Deregulation of different Myc family 
members has been shown to be clearly associated with different types of tumors; N-Myc is amplified in 
25% of neuroblastoma and is the best clinical prognostical marker for poor survival (Schwab, 2004). L-
Myc amplification is associated with approximately one fourth of primary small cell lung cancers 
(SCLC) (Makela et al., 1992) and c-Myc is associated with various human tumors.  The relative 
importance of Myc as transcriptional regulator mediating neoplastic transformation remains 
controversial. The main problem is the difficulty in clearly defining a true Myc target gene. There are 
various proteins targeting the so-called E-box, which is also the binding region of Myc/Max 
heterodimers. Therefore, it is difficult to identify specific promoter regions, which are regulated 
specifically by Myc. Furthermore, Myc has a relatively weak transactivation domain, thus again 
complicating the identification of target genes. For example, dozens of genes have been proposed to 
be target genes of c-Myc. Genes suggested to be activated by c-Myc, among them cad, cdc25a, odc, 
elF-4E and ISGF3γ  were proposed mainly using subtractive hybridization, differential display, or 
educated guessing. Nonetheless, the majority of these putative c-Myc target genes has been shown to 
remain unchanged in c-Myc null cells (Bush et al., 1998). Thus, it is likely that the interaction with other 
co-factors is essential for mediation of Myc’s oncogenic properties. 
The identification of transcription factor targets has made a big progress after decoding of the human 
genome, which provided a huge amount of sequence information, enabling genetic information 
analysis on a global scale. Therefore, a short historical overview of microarray technology and its 
application for target gene identification is given below. 
 
3.6 Microarray technology 
 
Microarray technology began to be used to study gene expression profiles in 1990s and to date, 
various DNA microarray and DNA chip devices and systems have been developed. The very first 
simple DNA arrays, so-called “dot-blots” have now progressed to the level of high-density microarrays 
(Southern, 2001).  
Nowadays, the term “microarray” most often describes chips or slides containing thousands of DNA 
elements that are used for simultaneous genome-wide measurement of mRNA levels in order to 
generate the so-called “gene expression profile”. 
There are different platforms of microarrays, one of them is the cDNA microarray. The spotted cDNA 
microarray consists of small aliquots of distinct cloned gene sequences. Each spot contains few 
hundred bases of a previously characterized sequence known from a cDNA library and represents one 
expressed gene. There are thousands of such spots on a glass slide. As the levels of mRNA in a 
particular cell reflect the metabolic activity of the related gene, the strength of the signal intensity 
measured by cDNA array reflects the amount of the presence of mRNA and thus the relative gene 
activity in the investigated sample. However, cDNA microarrays are limited by the problem of cross 
hybridization between mRNAs and other non-specific elements of the cDNA clone. 
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Another platform of microarrays are oligonuctleotide microarrays, where oligonucleotides (60-mers in 
Agilent arrays, 25-mers in Affymetrix arrays) are placed on a slide. Two types of oligonucleotides are 
used, those which match a target sequence exactly are called Perfect Match (PM) and those which 
have a single mismatch base in the middle of the sequence are called Mismatch (MM). The template, 
in case of Affymetrix labelled cRNA, binds to these probe pairs, usually 16-20 oligonucleotides with 
the sequences from different parts of each gene, which constitute the “probe set”. The intensity 
information from the values of each of the probes in a probe set is then combined to obtain an average 
expression value (Bolstad et al., 2003). 
Additionally, protein microarrays using antibodies or tissue microarrays consisting of dozens to 
hundreds of predefined microscopic elements of tissue arranged on a glass slide are used. 
Analysis of microarray data requires multiple steps, including data quantification, a step where 
translation of signal intensities obtained from microarrays into numerical values takes place. The next 
step is data normalization, a step to correct the untrue data resulting from differences in experimental 
procedures such as labelling, hybridisation and washes, diversities between chips and variation in 
detection procedures.  Finally, data mining and modelling are the most important steps to achieve 
accurate and significant biological conclusion from obtained data.  
Taken together, microarray data gives information on the expression level of each individual gene 
represented on the microarray. Therefore, microarrays have had a significant impact in our 
understanding of normal and abnormal cell biochemistry, an important aspect in oncology. Microarray 
approaches resulting in distinct expression profiles for each cancer type have been used for 
identification of molecularly distinct subtypes of cancers that were viewed previously as homogenous 
diagnostic categories. Thus, novel insights into molecular taxonomy of many cancers could be 
revealed. Moreover, a comprehensive investigation of whole pathways and interacting genes could be 
performed. As a result, gene expression signatures associated with activation of oncogenic pathways 
in tumors (Huang et al., 2003) or physiological targets of retinoblastoma protein pathway, deregulation 
of which is a hallmark of human cancer (Vernell et al., 2003) could now be identified using whole-
genome microarray analysis. Furthermore, targeted genetic manipulations (Lamb et al., 2003) or 
cellular responses to physiological stimuli in case of breast cancer (Chang et al., 2005) could be 
analysed using microarray technology. Microarray analysis of genome-wide expression pattern in 
tumors promises to improve the diagnostics, risk stratification and therapy outcome prediction for 
patients. Microarrays can be used to identify novel targets of oncogenic transcription factors, whose 
modulation might inhibit or reverse disease progression. By the use of tissue or cell microarrays also 
validation of the found targets can be performed. 
3.7 Identification of oncogenic transcription factor targets 
 
Identification of transcription factor targets is required to understand by which pathways the oncogenic 
property of many transcription factors are mediated. Target gene specificity is partly determined by the 
DNA binding domain of transcription factors, but also the promoter context, as for example the relation 
of the DNA binding site in relation to other promoter elements, contributes to the gene-specific control 
through transcription factors.  
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Different methods have been applied in order to determine regulatory DNA binding motifs, like 
monitoring of gene expression using Nothern blot or RNAse protection  assay, furthermore mutations 
of promoter sequences (promoter bashing), cDNA filter arrays and other “hit-or-miss” approaches 
were performed. These methods however were all limited to the study of previously identified genes 
and only quite a low number of genes can be monitored. 
Development of microarray technology has been a big progression for identification of transcription 
factor targets. Using the microarray approach, all genes which exhibit significant changes upon 
inactivation of a transcription factor can now be identified. Thus, all the genes present in the whole 
genome can be monitored by this method simultaneously. However, identification of genes which 
represent direct targets of a transcription factor is also dependent on the number and nature of indirect 
effects. Thus, the microarray expression profiling on its own is not sufficient for identification of direct 
transcription factor targets and additional methods are needed for verification of putative target genes. 
Commonly used methods for confirmation of microarray data are usually RT-PCR and 
immunohistochemistry. For identification of direct targets the combination of microarray technology 
with ChIP can be used. ChIP technique uses antibodies against specific transcription factors to isolate 
bound DNA sequences embedded in chromatin (Orlando et al., 1997). 
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4 Paediatric cancer 
 
In adults, genetic events leading to cancer are generally not inherited through the gametes; rather, 
they are changes in the DNA of somatic cells. For most solid human tumors, 15-20 years from 
carcinogen exposure to clinical detection of a tumor is needed. The major risk factors for cancer are 
tobacco, alcohol, diet, sexual and reproductive behavior, infectious agents, family history, occupation, 
environment and pollution. Whereas cancer has a very common incidence in adults (worldwide an 
estimated 11 million cancer cases were diagnosed in 2002, one quarter being in Europe), cancer is 
very rare event among children everywhere in the world. In industrialized countries, only about 0.5% of 
all cancers occur among children aged less than 15 years. Obviously, the mechanisms of cancer 
development must be different for children, indicated by age when cancer is detected and different 
types of cancer. 
Most cancer types occurring in children are already arising during embryonic development through 
acquired intrauterine genetic abnormality or an inherited genetic predisposition. Whereas most adult 
cancers are carcinomas, childhood cancers are histologically very diverse. The 12 major groups are 
leukaemias, lymphomas, brain and spinal tumors, sympathetic nervous system tumors, 
retinoblastoma, kidney tumors, liver tumors, bone tumors, soft-tissue sarcomas, gonadal and germ-
cell tumors, epithelial tumors, and other and unspecified malignant neoplasms. The following sections 
will be restricted to the subgroup of sarcomas.  
4.1 Sarcoma 
Malignant neoplasms that arise from cells of mesenchymal origin (for example, bone muscle, cartilage 
and other connective tissues) are called sarcomas. Sarcomas are a diverse group of relatively rare 
malignancies. Soft tissue sarcoma is a cancer type which occurs ten times more frequent in children 
than in adults.  Correct determination of histological subtype of sarcoma is very important for exact 
diagnosis of sarcoma and subsequent treatment. Development of new diagnostic techniques like 
quantitative real-time PCR or microarray analysis improved the accuracy and gave new insights into 
molecular properties of sarcomas. Genetically, sarcomas fall into two main categories. One group of 
sarcomas is characterized by a tumour-specific translocation that seems to be central to the 
pathogenesis of the tumour, and is used as diagnostic criteria. Another group of sarcomas are 
characterized not by a tumour-specific genetic alteration but by complex karyotypes that are 
characteristic of severe genetic and chromosomal instability. To date, a subset of sarcomas comprised 
of fourteen sarcoma types has been identified which is associated with specific translocations 
generating novel fusion oncoproteins (Xia, Barr, 2005). Some of these translocations are listed in 
Table 3.  
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Table 3. Chromosomal translocations in sarcomas. 
 
Sarcoma type Translocation Fusion product 
Alveolar rhabdomyosarma 
t(2;13)(q35;q14) 
t(1;13)(p36;q14) 
PAX3/FKHR 
PAX7/FKHR 
Ewing’s sarcoma 
t(11;22)(q24;q12) 
t(21;22)(q22;q12) 
EWS/FLI1 
EWS/ERG 
Clear-cell sarcoma t(12;22)(q13;q12) EWS/ATF1 
Desmoplastic small-round cell 
tumor 
t(11;22)(p13;q12) EWS/WT1 
Muxoid liposarcoma 
t(12;16)(q13;p11) 
t(12;22)(q13;q12) 
FUS/CHOP 
EWS/CHOP 
Table adapted from Xia, Barr, 2005 
 
The oncogenic character of these chimeric fusion proteins was shown in different studies, where 
transformation of primary cells was achieved by overexpression of EWS/FLI1 in immortalised mouse 
NIH3T3 cells (May et al., 1996), PAX3/FKHR in chicken embryo fibroblast (Scheidler et al., 1996; ), 
NIH3T3 cells (Lam et al., 1999) and in human embryonal RMS (eRMS) cell line (Anderson et al., 
2001) or FUS/CHOP in NIH3T3 cells (Schwarzbach et al., 2004). Tumorigenic function of these 
transcription factors was also further supported in vivo by the use of xenografts in mice for EWS/FLI1 
(Arvand et al., 2001), for FUS/CHOP (Perez-Mancera et al., 2002) and for PAX3/FKHR (Keller et al., 
2004). However, the tumor formation frequency was fairly low in these experiments and could be 
increased by combination with additional genetic alterations. Therefore, it is likely that expression of a 
fusion gene alone is not sufficient for tumor formation and that in most cases an additional 
collaborating genetic alterations are required. 
4.2 Transcription factors and their target genes 
 
Not only sarcomas are associated with specific translocations leading to formation of aberrant 
transcription factors. Therefore, three examples of chromosomal translocations leading to fusion of 
two genes encoding for transcription factors and their targets are summarized in this section. First, two 
members of Ets transcription factor family, AML1 and AML1- consisting fusion genes and EWS-Ets 
(see also Table 1) will be described. Second, the transcription factor associated with alveolar 
Rhabdomyosarcoma, PAX3/FKHR, will be shortly discussed. 
The TEL/AML1 fusion gene occurs in childhood B-cell acute lymphoblastic leukemia (ALL) as a result 
of the translocation of human chromosome 12;21. TEL is a member of Ets family, but in TEL/AML1 the 
N-terminal helix-loop-helix domain of TEL is fused to a nearly complete AML1 gene, thus leading to 
deregulation of AML1 target genes. Many of AML1 targets are mostly genes which are important for 
normal differentiation of hematopoietic progenitor cells and which regulate cell proliferation and 
survival. AML1 binds to the DNA sequence TGTGGT, the TEL/AML1 fusion leads to inhibition of basal 
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promoter activity, thus leading to repression of AML1 target genes. Some of AML1 and AML1-
containing fusion gene targets are listed in Table 4. 
 
Table 4. Target genes of AML1 and AML1- consisting fusion genes  
 
Gene Target Reference 
AML1 
GM-CSF 
IL-3 
M-CSF 
Myeloperoxidase 
Neutrophil elastase 
Granzyme B 
NP-3 
TCRβ 
TCRγ 
TCRδ 
Frank et al., 1995 
Uchida et al., 1999 
Zhang et al., 1996 
Britos-Bray and Friedman, 1997 
Nuchprayoon et al., 1994 
Babichuk and Bleackley, 1997 
Westendorf et al., 1998 
Prosser et al., 1992 
Hsiang et al., 1993 
Redondo et al., 1992 
TEL/AML1 
TCRβ 
IL3 
M-CSF 
Hiebert et al., 1996 
Uchida et al., 1999 
Fears et al., 1993 
AML1/ETO 
GM-CSF 
IL-3 
NP-3 
Frank et al., 1995 
Mao et al., 1999 
Westendorf et al., 1998 
 
 
EWS/FLI1 is a common fusion gene associated with Ewing’s sarcoma, consisting of the potent 
transactivation domain of EWS and the DNA-binding domain of FLI1, a member of Ets transcription 
family. Over the past several years numerous studies were published about the targets of EWS/FLI1 
transcriptional activation using representational difference analysis, microarray analysis or chromatin 
immunoprecipitation, thereby identifying plenty of putative EWS/ETS target genes. However, these 
target genes were mainly identified by transfection of fusion gene into different cell lines followed by 
various subtraction techniques mentioned above to isolate differentially expressed genes. The 
overexpression of EWS-ETS fusion protein in cell lines that don’t derive from Ewing tumors or the use 
of a very low number of Ewing cell lines led often to results which were then not statistically significant. 
Moreover, only few of the potential target genes identified in microarray screen have been validated by 
independent methods. Therefore, only some of the target genes confirmed as directly regulated by 
EWS-ETS fusion proteins in Ewings sarcoma are listed in Table 5. 
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Table 5. Target genes of EWS-Ets family 
 
Genes Targets Reference 
EWS-ETS: 
 
EWS-FLI1 
EWS-ERG        Group1 
EWS-FEV 
 
EWS- ETV1       
EWS-E1AF         
 
TGFBR2 
Phospholipase C-beta 
Uridine Phosphorylase 
c-myc 
ID-2 
PDGF-C 
PIM-3 
TNC 
NKX2.2 
CAV-1 
DAX-1 
Hahm et al., 1999 
Dohjima et al., 2000 
Deneen et al., 2003 
Nishimori et al., 2002 
May et al., 1997 
Zwerner and May, 2001 
Deneen et al., 2003 
Watanabe et a., 2003 
Owen and Lessnick, 2006 
Tirado et al., 2006 
Mendiola et al., 2006 
 
Group 2 
 
PAX3/FKHR is not a member of the ETS transcription factor family. However, also in this case, two 
transcription factors, PAX3 and FKHR are fused by a translocation leading to formation of a more 
potents transcription factor. PAX3/FKHR DNA–binding domain derives from PAX3 and contains a 
paired domain and additional octapeptide and homeodomain. PAX3/FKHR is - similar to EWS-ETS 
transcription factors - associated with a particular sarcoma type, namely alveolar rhabdomyosarcoma. 
The oncogenic potential of PAX3/FKHR is well documented; however, the pathways and downstream 
targets of PAX3/FKHR are still not completely characterized. The target genes of PAX3 and 
PAX3/FKHR can be divided in three groups: there are genes which are regulated by both Pax3/FKHR 
and Pax3, there are targets induced by Pax3/FKHR but not Pax3, such as PDGFαR and finally genes 
induced by Pax3/FKHR but repressed by Pax3. Some target genes are listed in Table 6. 
 
Table 6. Target genes of PAX3/FKHR 
 
Genes Targets References 
 
PAX3 
 
PAX3/FKHR 
NCAM 
MyoD 
c-met 
 
MYCN 
Bcl-xl 
CB1 
BMP4 
MBP 
Edelman et al., 1998 
Maroto et al., 1997 
Epstein et al., 1996; Ginsberg 
et al., 1998 
Khan et al., 1999 
Marque et al., 2000 
Begum et al., 2005 
Begum et al., 2005 
Kioussi et al., 1995 
PAX3/FKHR 
PDGFαR 
GLUT4 
Epstein et al., 1998 
Armoni et al., 2002 
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4.3 Rhabdomyosarcoma  
 
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, accounting for about 
8% of all cancers occurring in children (Pappo et al., 1999).  RMS often develops in the head and neck 
region of the body, but also other cases with the appearance of RMS at any site in the body are 
known, see also the indicated locations in the anatomical picture in Figure 7. 
 
∼22%
∼10% 
∼24%
∼19 %
∼9%
  
Figure 7 Anatomic localization sites of RMS. Common RMS sites are indicated in percentages 
(Pappo et al., 1995) 
 
Four histologically different subtypes of RMS are known, the embryonal, botroidal, alveolar and 
pleomorphic RMS with the common embryonal and alveolar subtypes accounting together for 
approximately 80% of all cases. 
 
Embryonal Rhabdomyosarcomas (eRMS) are the most common type of rhabdomyosarcoma, and it 
typically occurs in children at the age of less then 10 years. There is no specific genetic alteration 
observed in eRMS, but eRMS is often associated with loss of heterozygosity of 11p15. However, 
typically there are several alterations visible on a karyogramm derived from eRMS cells, as shown in 
Figure 7B. 
Botryoid Rhabdomyosarcoma often occurs in hollow organs, such as the bladder, vagina and uterus. 
It's often seen in infants and toddlers and accounts for about 6% of all RMS. 
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Alveolar Rhabdomyosarcomas (aRMS) typically affects older children and teenagers. Malignant cells 
normally affect large muscles forming hollow spaces (alveoli). Most of the cases of aRMS are 
associated with a specific translocation t(2;13) or (1;13). Genetic consequences of this event will be 
described more precisely in following section.  
Pleomorphic rhabdomyosarcoma can be found in extremities or the trunk. In contrast to other RMS 
subtypes it mostly occurs in adults and not in children. 
Typical cytogenetic changes of two main subtypes, embryonal and alveolar rhabdomyosarcoma, 
represented by respective karyogram are shown in Figure 8. Genetic alterations involved in 
tumorigenesis of these two subtypes will be discussed in more detail in following section. 
 
A              B      
  aRMS        eRMS 
 
Figure 8 Typical karyogram shown for aRMS (A) and eRMS (B). In aRMS, a typical translocation 
t(2;13) is indicated. In eRMS, a complex karyotype bearing different alterations are shown 
(www.htcl.cytspb.rssi.ru/tomors/RD) 
4.4 PAX genes 
 
The PAX gene family comprises nine family members, namely PAX1 to PAX9. All members of the 
PAX genes family contain an amino-terminal 128 amino-acid DNA-binding domain, termed the paired 
box domain. The paired box domain also gave the name for the family. Moreover, PAX3 and PAX7 
also contain a 60 amino-acid DNA-binding homeodomain and octapeptide motif. The homeodomain is 
also known to play important roles in developmental processes of many organisms. While certainly not 
the only developmental control genes, they have been shown to play crucial roles from the earliest 
steps in embryogenesis to the very latest steps in cell differentiation. The domain binds DNA through a 
helix-turn-helix (HTH) structure. The HTH motif is characterised by two alpha-helices, which make 
intimate contacts with the DNA and are joined by a short turn. The second helix binds to DNA via a 
number of hydrogen bonds and hydrophobic interactions, which occur between specific side chains 
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and the exposed bases and thymine methyl groups within the major groove of the DNA (Schofield, 
1987).  
PAX genes play a role in embryonic tissue development and cellular differentiation through promotion 
of cell proliferation, cell-lineage specification, migration and survival (Robson, He and Eccles, 2006). 
Due to this important role of PAX genes in development they also can contribute to cancer 
development if dysregulated. However, the precise role of PAX transcription factors in cancer is not 
known. Fife members of the PAX gene family - PAX2, PAX3, PAX5, PAX7 and PAX8 - are thought to 
have a tumour promoting function. Furthermore, PAX genes are often overexpressed in a wide range 
of cancer cell lines (Muratovska et al., 2003). The processes that are involved in tumorigenesis – 
limitless replicative potential, self-sufficiency in growth signals, resistance to apoptosis and gain of 
invasive and metastatic potential - can be misregulated by these genes in different manners, as 
summarized in Figure 9.  
 
 
 
 
Figure 9 Cancer contributing characteristics regulated by PAX genes that are favourable for 
tumor progression (Robson, He, Eccles, 2006) 
 
For development of RMS, PAX3 and PAX7 gene expression plays an important role. Tumor-
associated PAX3 expression has been detected in eRMS. Moreover, aRMS in most cases is 
associated with expression of an abberant transcription factor generated by fusion of two genes PAX3 
or PAX7 and FKHR, also known as FOXO1A (Galili et al., 1993). The formation of PAX3/FKHR is 
schematically shown in Figure 10.  
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Figure 10 Scheme of the generation of PAX3/FKHR fusion gene. The fusion protein PAX3/FKHR 
contains the two DNA-binding domains of PAX3 and the transactivation domain derived from 
FKHR (Xia, Barr, 2005) 
 
On the molecular level, PAX3/FKHR is a stronger transactivator compared to wild-type PAX3 
(Bennicelli et al., 1995; Fredericks et al., 1995). Therefore, the oncogenic properties of PAX3/FKHR 
are thought to base on dysregulation (i.e. up-, or downregulation) of PAX3 target genes. The 
identification of PAX3/FKHR target genes is one of the main goals of research approaches of this 
work. 
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5 Subject of investigation 
 
Taken together, studying endogenously expressed PAX3 in eRMS and PAX3/FKHR in aRMS cell 
lines provides the best opportunity to define the function of this fusion in tumor development. For the 
study of these genes a silencing approach using RNAi was applied. The role and mechanism by which 
PAX3/FKHR participates in aRMS development will be further analyzed in following studies, as many 
critical targets remain to be identified. The ultimate goal of these studies is to determine the full 
complement of PAX3/FKHR target genes, and to determine the mechanisms by which diverse target 
genes mediate aRMS development. We hope that this approach will identify new therapeutic targets 
that can be used to treat patients with this devastating disease. 
Finally, the approach we describe can be applied to any of a variety of tumor types associated with 
particular recurrent genetic abnormalities. These would include the translocation-associated 
sarcomas, such as Ewing’s sarcoma, synovial sarcoma, and myxoid liposarcoma, and translocation-
associated leukemias, including ALL containing TEL-AML1 rearrangements. By combining 
experimental approaches in appropriate cell types with validation against clinical samples, we 
anticipate that the data obtained using this approach will yield clinically-relevant datasets that can be 
used to identify new therapeutic targets in a variety of diseases. 
6 Results 
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Abstract 
 
The chromosomal translocation t(2;13), characteristic for the aggressive childhood cancer alveolar 
rhabdomyosarcoma (aRMS), generates the chimaeric transcription factor PAX3/FKHR with a well known 
oncogenic role. However, the molecular mechanisms mediating essential pathophysiological functions remain 
poorly defined. Here, we used comparative expression profiling of PAX3/FKHR silencing in vitro and 
PAX3/FKHR specific gene signatures in vivo to identify physiologically important target genes. Hereby, 51 
activated genes, both novel and known, were identified. We also found repression of skeletal muscle-specific 
genes suggesting that PAX3/FKHR blocks further differentiation of aRMS cells. Importantly, TFAP2B was 
validated as direct target gene mediating the anti-apoptotic function of PAX3/FKHR. Hence, we developed a 
pathophysiologically relevant transcriptional profile of PAX3/FKHR and identified a critical target gene for 
aRMS development.  
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Introduction 
 
Rhabdomyosarcoma (RMS) is a common childhood soft tissue sarcoma associated with the skeletal muscle 
lineage. Based on histology, two main subgroups of RMS, embryonal (eRMS) and alveolar (aRMS), are 
distinguished. The majority of cases of the more aggressive aRMS are associated with one of two reciprocal 
translocations t(2;13)(q35;q14) or t(1;13)(p36;q14), generating intronic fusions of PAX3 (or PAX7) and FKHR, 
also known as FOXO1A (Galili et al., 1993). The fusion proteins contain the two DNA-binding domains of 
PAX3 or PAX7, namely a paired– and a homeo-domain and the transactivation domain derived from FKHR.  
Earlier studies on PAX3/FKHR support an oncogenic role of this fusion protein in tumor initiation and 
maintenance. A tumor initiating effect has been evaluated in vitro where ectopic expression of PAX3/FKHR 
leads to transformation of chicken embryo fibroblast (Scheidler et al., 1996), NIH3T3 cells (Lam et al., 1999) 
and a human embryonal RMS (eRMS) cell line (Anderson et al., 2001). Furthermore, PAX3/FKHR induces 
murine aRMS postnatally in cooperation with other oncogenic events such as loss of Ink4A/ARF (Keller et al., 
2004). Involvement in tumor maintenance is reflected by the fact that downregulation of fusion protein activity 
by antisense oligonucleotides induces apoptosis (Bernasconi et al., 1996). Similarly, an inducible transcriptional 
repressor induced tumor regression in vivo via extensive apoptosis (Ayyanathan et al., 2000) suggesting that 
established RMS tumors are dependent on PAX3/FKHR expression. 
On the molecular level, PAX3/FKHR is a stronger transactivator compared to wild-type PAX3 (Bennicelli et al., 
1995; Fredericks et al., 1995). Therefore, the oncogenic properties of PAX3/FKHR are thought to base on 
dysregulation (i.e. up-, or downregulation) of PAX3 target genes. However, recent studies suggested that 
PAX3/FKHR might alter the expression of gene targets quantitatively and qualitatively distinct from PAX3 
(Begum et al., 2005; Epstein et al., 1998). Understanding the oncogenic function of PAX3/FKHR hence requires 
identification of the pathophysiologically relevant target genes. One difficulty in this search has been that most 
studies relied on heterologous cell systems to ectopically express PAX3/FKHR. Furthermore, most of these 
studies used clones stably expressing the fusion protein which precludes discrimination of direct from indirect 
regulatory events. Nevertheless, a number of potential target genes have been suggested by studies performed in 
heterologous systems such as c-met (Epstein et al., 1996; Ginsberg et al., 1998), MYCN (Khan et al., 1998), bcl-
xl (Margue et al., 2000), CNR1 and BMP4 (Begum et al., 2005) or CXCR4 (Tomescu et al., 2004). However, 
the pathophysiological role of these target genes regarding aRMS development or maintenance remains largely 
unclear.  
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Therefore, we developed a system to analyze PAX3/FKHR dependent gene expression in aRMS itself. This 
system consists of two different parts: first, endogenous PAX3/FKHR was downregulated by RNAi (Elbashir et 
al., 2001) in aRMS cells in culture followed by gene expression profiling. Second, expression signatures specific 
for PAX3(7)/FKHR-translocations were identified in aRMS tumor biopsies (Wachtel et al., 2004). Comparative 
expression analysis then was able to identify genes that are dysregulated by PAX3/FKHR both in vitro and in 
vivo. Functional studies furthermore revealed that one of these direct target genes, TFAP2B, acts as an essential 
mediator of PAX3/FKHR function in cell survival.  
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Results 
 
PAX3/FKHR promotes aRMS cell survival  
 
To characterize PAX3/FKHR target genes relevant for aRMS development and maintenance, we established a 
siRNA-mediated down-regulation strategy. Initially, nine different siRNA molecules against both the PAX3 part 
and the PAX3/FKHR breakpoint region were tested. siRNAs against the breakpoint region failed to efficiently 
down-regulate the message (data not shown). The remaining siRNA duplexes resulted in specific down-
regulation efficiencies up to 50% of the original mRNA levels as measured by qRT-PCR. Higher silencing 
efficiencies were subsequently achieved by different combinations, whereby two siRNAs led to the most 
effective specific inhibition of 70% in RD eRMS cells and by 80% in Rh4 aRMS cells (Figure 1A). On the 
protein level, a reduction to 50% of PAX3/FKHR in Rh4 cells and to 40% of PAX3 in RD cells was observed 
compared to control siRNAs (Figure 1B). No unspecific interferon response was observed (data not shown). 
Therefore, this combination of siRNAs was used in all silencing experiments. As in translocation-positive aRMS 
cells alleles for both PAX3 and PAX3/FKHR are present, siRNAs targeting the PAX3 part of the fusion protein 
could down-regulate both PAX3 and PAX3/FKHR. However, we found PAX3 >1000 fold less expressed than 
PAX3/FKHR in Rh4 cells suggesting that wild-type PAX3 expression can be neglected (data not shown).  
To characterize the physiological effects upon siRNA treatments, proliferation of RD and Rh4 cells after 24hrs, 
48hrs and 72h of PAX3 silencing was measured. Cell growth was found to be inhibited significantly in cells 
treated with PAX3 and PAX3/FKHR siRNA, but not in untreated or control treated cells (Figure 1 C, D). 
Furthermore, active caspase 3/7 showed an approximately 2-fold increase specifically in cells with silenced 
PAX3 and PAX3/FKHR expression (Figure 1 E, F). Thus, an anti-apoptotic function of PAX3 in eRMS and 
PAX3/FKHR in aRMS cell lines could clearly be demonstrated, as anticipated from earlier findings (Bernasconi 
et al., 1996). This validates our siRNA approach on the physiological level.  
 
Comparative microarray analysis reveals novel candidate PAX3/FKHR target genes 
 
Next, we sought to identify candidate target genes of PAX3/FKHR using gene expression profiling after 
treatment of aRMS cells with siRNA and corresponding controls for 24hrs, 48hrs and 72hrs. As a model system 
Rh4 cells were chosen based on previous expression profiling data indicating that Rh4 cells represent most 
closely in vivo biopsies (see supplementary material, Figure 1). The microarray data were analysed using the 
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GeneSpring 7.0 software (Figure 2 A). Genes downregulated after 24hrs of PAX3/FKHR silencing and therefore 
representing putative direct PAX3/FKHR targets, were selected. At the shortest time point of treatment (24 hrs) 
at which cellular apoptosis does not yet play a major role 1834 genes were specifically down-regulated (>1.5-
fold) when compared to scRNA treatment (see supplemental material S1). This list of genes identified in vitro 
was then compared to PAX3(7)/FKHR-translocation specific gene signature of 299 genes identified in aRMS 
tumor biopsies, representing putative in vivo PAX3/FKHR target genes (Wachtel et al., 2004). This comparison 
finally generated an overlapping list of 51 genes, which is statistically highly significant (p < 0.001) and not 
generated simply by chance (Figure 2B, C). These 51 genes therefore represent a transcriptional profile of in 
vivo PAX3/FKHR target genes. They were grouped into different functional classes as indicated in Figure 2D 
and Table 1. The largest set of genes including FGFR2 and CB1 (CNR1) appear to be involved in signal 
transduction (25%). Confirming our strategy, CB1 has been recently identified as a direct target of PAX3/FKHR 
(Begum et al., 2005). The second largest number of genes encode proteins with enzymatic activity (20%). 
Among them are ADAM10 and ADAM19 metalloproteinases which might be involved in the enhanced 
metastatic capability of aRMS cells. Finally, several genes are involved in transcriptional regulation and DNA-
binding such as the POU domain transcription factor POU4F1 and TFAP2B.  
Apart from down-regulated genes, we also found a group of genes upregulated 72hrs after PAX3/FKHR 
silencing suggesting that expression of these genes is normally repressed by PAX3/FKHR. This group was 
comprised of 260 genes (see supplemental material S2). Upregulation was specifically observed only starting at 
48hrs, suggesting an indirect effect of PAX3/FKHR (Figure 3A). Interestingly, genes with most prominent 
upregulation (up to 58-fold) are all related to normal myogenic differentiation. These included myosin light 
chain, troponin C, troponin I, crystalline alphaB and skeletal muscle myosin heavy chain. To confirm these 
findings, the expression values of two upregulated genes, TNNC2 (34.4-fold) and MYL1 (6.1-fold), were 
validated by qRT-PCR (Figure 3C). Interestingly, upregulation was specific for aRMS cells and not detected 
after downregulation of PAX3 in eRMS cells (Figure 3 B, D). Therefore, these experiments support the 
hypothesis that one of the oncogenic functions of PAX3/FKHR is to block terminal differentiation. Furthermore, 
they suggest that the cellular background has a profound effect on target genes bound and activated by PAX3 
and/or that the target gene spectra of PAX3 and PAX3/FKHR differs (Zhang and Wang, 2006) . 
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TFAP2B is a direct target gene of PAX3/FKHR  
 
One of the oncogenic functions of PAX3/FKHR is promotion of cell survival. Therefore, it was surprising that 
no classic apoptotic genes could be identified in our system. However, one of the potential target genes, 
TFAP2B, has previously been implicated in apoptosis in a mouse model (Moser et al., 1997). We therefore 
further characterized this potential target gene, first by verification of the microarray expression levels after 
siRNA treatment by qRT-PCR with CB1 as a control (Figure 4A). 
Next, we studied the impact of PAX3/FKHR on transcription of these genes in 293T cells, which normally 
express neither CB1 nor TFAP2B at substantial levels. As expected, after ectopical expression of PAX3/FKHR, 
transcription of both endogenous genes was induced ~5-fold (Figure 4B). To test whether direct DNA-binding is 
necessary, we used PAX3/FKHR mutants in which either the paired or the homeodomain DNA-binding domain 
contains inactivating point mutations (Xia & Barr, 2004). Interestingly, CB1 transcription was not induced by 
the mutant bearing a non-functional homeodomain, whereas TFAP2B transcription was not induced by the 
mutant with an impaired paired domain. We therefore conclude that activation of CB1 depends mainly on the 
PAX3 homeodomain, that of TFAP2B however on the paired domain (Figure 4B). Full transcriptional activation 
however, can only be reached using the intact PAX3/FKHR protein. 
To identify potential paired domain binding sites in the TFAP2B promoter, 3200 bp upstream of the 
transcriptional start site and deletion constructs thereof were cloned in front of a luciferase reporter and used in 
reporter assays in 293T cells. PAX3/FKHR induced a significant transactivation of up to 3-fold compared to 
control with the full-length as well as a shorter 1.5kb (deletion construct 1, TFAP2b_1) reporter construct 
(Figure 4C). Further deletion down to 0.8kb (deletion construct 2, TFAP2b_2) reduced transactivation 
significantly. Transactivation of the 1.5kb construct also was dependent on an intact paired domain as observed 
before (Figure 4D). Therefore, these experiments suggested a potential binding site for the PAX3/FKHR paired 
domain between -1592 bp and -806 bp. To verify these results we next performed a chromatin 
immunoprecipitation experiment to test for direct binding of PAX3/FKHR to this promoter region. Deletion 
constructs 1 and 2 were cotransfected with a his-tagged PAX3 construct into 293T cells and immunoprecipitated 
with either control anti-IgG or specific anti-his antibodies. We recovered a 2-fold higher amount of TFAP2B 
promoter DNA from the specific immunoprecipitation of deletion construct 1compared to the control but not of 
deletion construct 2. These experiments verify that PAX3/FKHR can bind to the TFAP2B promoter in the region 
-1592 to -806 (Figure 4E). In this region three potential PAX3/FKHR binding sites at positions -1461, -1252 and 
-1186 were identified (Figure 4F). Using site directed mutagenesis these sites were deleted individually and 
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tested in a reporter assay. Whereas promoter fragments with deletion of the site -1461 (deletion 1) could be 
activated >3-fold, deletion of the six nucleotides gttccg at position -1252bp (deletion 2) reduced the 
transactivation potential of PAX3/FKHR to background levels. As this motif has previously been described as 
binding motif for paired domains (Mayanil et al., 2001) it represents a likely binding site for the PAX3/FKHR 
paired domain. Deletion 3 at position -1186 also showed reduced activity (2-fold) suggesting that this site plays 
an assistant role.  
To confirm these data, an electrophoretic mobility shift assay was performed with double-stranded 
oligonucleotides corresponding to deletion sites 2 and 3. As expected, DNA-protein binding could be observed 
after ectopical expression of his-tagged PAX3 (Figure 4H) and was comparable when using PAX3/FKHR (data 
not shown). Furthermore, DNA-protein binding with the oligonucleotide specific for deletion site 3 was 
considerably weaker, consistent with the observation made with reporter deletion constructs (Figure 4G). 
We conclude from these experiments that TFAP2B is a novel direct target gene of PAX3/FKHR whose 
transactivation is dependent on two DNA-binding motifs recognized by the PAX3 paired domain at positions -
1252bp and -1186bp.  
 
TFAP2B mediates antiapoptotic function of PAX3/FKHR  
 
TFAP2B has been shown to suppress myc-induced programmed cell death in a range of cell lines (Moser et al., 
1997). Therefore, we hypothesized that the pro-survival function of PAX3/FKHR might depend on expression of 
TFAP2B as a PAX3/FKHR target gene. To test this hypothesis, we first investigated the effects of specific 
TFAP2B silencing on cell survival. siRNA mediated silencing of TFAP2B resulted in efficient down-regulation 
of TFAP2B expression on mRNA (80%) as well as on protein (50-60%) level (Figure 5A, B). Down-regulation 
of TFAP2B resulted in suppression of cell proliferation, not observed in control treated cells. Importantly, 
specific siRNA treatment also increased the rate of apoptosis as measured by an increase in caspase 3/7 activity 
by 1.7-fold (Figure 5D). The number of apoptotic cells significantly increased from 3% to 41% (Figure 5E), an 
increase very similar to the result observed after PAX3/FKHR silencing (3% to 36%). These experiments 
suggest that the anti-apoptotic function of PAX3/FKHR might be mediated, at least in part, by direct 
transcriptional activation of TFAP2B.  
To test this directly, Rh4 cells stably overexpressing TFAP2B from a heterologous promoter were generated. 
PAX3/FKHR was down-regulated by siRNA treatment and cell proliferation and apoptosis rate measured as 
before. In these cells proliferation was rescued to almost normal levels (Figure 6A) and the number of dead cells 
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increased only slightly (1.6-fold) whereas dead cells increased 5.1-fold in non-transfected and 3.5-fold in mock-
transfected Rh4 cells (Figure 6B).  We conclude from these experiments that TFAP2B acts downstream of 
PAX3/FKHR to mediate, at least part, of its anti-apoptotic function and therefore represents an essential target 
gene of PAX3/FKHR.  
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Discussion 
 
The identification of physiologically relevant PAX3/FKHR target genes is crucial for understanding the 
oncogenic function of this chimaeric transcription factor. Analysis of target genes has been hampered by the use 
of heterologous cell systems to study the fusion protein. Here, we used patient-derived aRMS cells to analyze 
PAX3/FKHR target genes using a loss-of-function silencing approach, in parallel to data acquired from tumor 
biopsies. This approach allowed the identification of a large set of bona fide PAX3/FKHR target genes. 
The choice of aRMS cells to be used as a model system was important and based on previous expression 
profiling data. These indicated that Rh4 cells most closely reflect in vivo biopsies and therefore are best suited to 
serve as model for aRMS tumors (Wachtel et al., 2004). Similar to other aRMS cells (Ayyanathan et al., 2000; 
Bernasconi et al., 1996) we found that ongoing expression of PAX3/FKHR is required for Rh4 cell survival, 
suggesting that aRMS cells are “addicted” to PAX3/FKHR expression. Measuring changes in the transcriptome 
at different time points after silencing of PAX3/FKHR revealed a set of genes whose expression is down-
regulated in parallel with PAX3/FKHR, and was therefore analyzed in more detail.  
Interestingly, at 24hrs after silencing only downregulated genes were identified which is in agreement with the 
observation that PAX3/FKHR mainly acts as transcriptional activator. Within the subset of potential 
PAX3/FKHR target genes, already known targets were present, like CB1 (Begum et al., 2005), MYCN (Khan et 
al., 1998) and NCAM (Edelman and Jones, 1995), thus confirming our strategy. To constrict the list to those 
genes relevant in vivo, the set was compared to a PAX3(7)/FKHR-translocation specific gene signature 
identified directly from aRMS tumor biopsies. From this comparison, we identified a subset of 51 overlapping 
genes which are likely to represent relevant PAX3/FKHR targets important for the oncogenic properties of the 
fusion protein. The comparative expression profiling therefore revealed a large amount of novel biological 
information. In a very recent study, Davicioni et al. measured the expression profiles after expression of 
PAX3/FKHR in the related embryonal RMS cell line RD and compared this gene set to data from tumor biopsies 
(Davicioni et al., 2006). Of the 61 potential target genes identified in their study, 9 are identical with genes 
identified in our study, namely ABAT, ADAM10, BMP5, IL4R, KIAA0555, MYCN, NELL1, NRCAM and 
POU4F1. In addition, another three genes (TFAP2B, CDH3 and CNR1) were excluded in their analysis only 
because transcriptional activation in RD cells was below the defined threshold level. This again underscores the 
validity of our approach.  
Performing ontology studies, six main groups of target genes were identified, such as genes encoding for 
receptors, among them FGFR2 or IL4R, which are obvious candidates as therapeutic targets. Moreover, genes 
 40
like NCAM, ADRA2A, POU4F1 or BMP5 could elucidate pathways involved in cell development and 
differentiation in aRMS. Other characteristics of aRMS tumors may be the result of other targets of 
PAX3/FKHR, such as ADAM 10 and ADAM 19 which could play a role in enhanced metastatic potential of 
aRMS cells, a crucial property of the alveolar subtype. 
Interestingly, 72hrs after siRNA treatment a set of genes upregulated in Rh4, but not in RD cells was identified, 
suggesting a specific repressing effect of PAX3/FKHR. This set included numerous genes related to muscle 
differentiation (see Table 2). There are different possible explanations for this observation: first, PAX3/FKHR 
could upregulate a transcriptional repressor, whereby repression would be an indirect effect, consistent with the 
time point (72hrs) at which expression changes were identified. Alternatively PAX3/FKHR is directly involved 
in repressing myogenic differentiation, which is consistent with the oncogenic role of this transcription factor. 
This differentiation-repressing activity of PAX3/FKHR is supported by recent studies, where PAX3 was shown 
to play a role in both initiation of the melanogenic cascade while preventing at the same time terminal 
differentiation in melanocyte stem cells (Lang et al., 2005). The precise mechanism how PAX3/FKHR 
accomplishes this differentiation barrier in aRMS is not clear. However, in our study expression levels of well 
known factors in the myogenic differentiation pathway downstream of PAX3 such as myogenin or MyoD were 
to low to be detected on our microarrays.  
Among the target genes identified which are interesting candidates to transduce the oncogenic effects of 
PAX3/FKHR was TFAP2B. It belongs to a transcription factor family consisting of four members, which are 
known to be coexpressed in early premigratory and migrating neural crest cells. Moreover, TFAP2B has been 
shown to play a role in apoptosis and survival of epithelial cells in collecting ducts and distal tubuli in mice 
embryonic tissue (Moser et al., 2003; Moser et al., 1997). Since PAX3/FKHR is also involved in regulation of 
cell survival, TFAP2B was confirmed on the molecular level as a direct target of PAX3/FKHR. The use of 
PAX3/FKHR mutants with impaired DNA-binding activity demonstrated paired domain dependency of TFAP2B 
expression, and promoter studies identified two paired domain binding sites in the TFAP2B promoter.  
Further supporting the notion that TFAP2B is a physiologically relevant in vivo target gene comes from the 
recent observation that TFAP2B is a highly specific and sensitive marker for translocation-positive aRMS in 
immunohistochemical analysis (Wachtel et al., 2006). This study directly confirms in vivo expression of the 
TFAP2B protein in a large number of tumor samples. Importantly, a similar behaviour was observed for CDH3 
(p-cadherin), and also this gene was identified in our study. Therefore it very likely represents an additional in 
vivo target gene of PAX3/FKHR.  
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The physiological relevance of TFAP2B for aRMS cell growth and survival was directly examined next. Our 
data show that downregulation of TFAP2B in aRMS cells induced apoptosis as efficiently as downregulation of 
PAX3/FKHR. Interestingly, induction of apoptosis by silencing of PAX3/FKHR could be prevented by TFAP2B 
overexpression. These results suggest that TFAP2B is directly involved in transduction of a PAX3/FKHR 
regulated oncogenic characteristic namely anti-apoptotic properties. Identification and analysis of the 
downstream apoptotic mechanisms is currently ongoing and may identify additional therapeutic target genes. In 
addition, these rescue experiments directly demonstrate that our target gene signature, is not due to any off-target 
effects of siRNA treatment. 
In conclusion, we identified a comprehensive signature of in vivo PAX3/FKHR target genes which are likely 
involved in mediating several oncogenic properties of the fusion protein such as migration, differentiation and 
survival. Indeed, TFAP2B mediates, at least in part, the survival function of PAX3/FKHR. Our approach of 
silencing fusion genes in its cellular context combined with in vivo expression data appears to be highly 
successful for identification of physiological targets to develop new therapeutics.  
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Material and methods 
 
Cell lines and plasmids 
Rh4 alveolar rhabdomyosarcoma (aRMS) cells were kindly provided by Peter Houghton (St. Jude Children's 
Research Hospital, Memphis, TN, USA). RD embryonal rhabdomyosarcoma (eRMS) and 293T human 
embryonic kidney cells were obtained from ATCC (LGC Promochem, Molsheim Cedex, France).  
The PAX3/FKHR construct consists of 3.7 kb insert cloned into pcDNA3 vector, PAX3/FKHR derived mutants 
have a single point mutation G48S or N269A located in the paired and homeodomain, respectively. 
For generation of Rh4 cells stably overexpressing murine TFAP2B, cells were transfected with the 
pcDNA3.1Neo plasmid containing a 1.8 kb TFAP2B insert. Mock-transfection with pcDNA3.1Neo was 
performed in parallel as control. Selection of stably transfected cells was preformed with 1 mg/ml G-418 Sulfate 
(Promega). 
 
siRNA-mediated silencing 
PAX3 and PAX3/FKHR knockdown was induced by RNA interference (RNAi) (Elbashir et al., 2001). A total of 
2x105 Rh4 or RD cells was plated and 24hrs later transfected with a combination of two chemically synthesized 
siRNAs (5’AAGAGAGAACCCGGGCAUG-dTdT, and 5’CAUGGAUUUUCCAGCUAUA-dTdT) both 
targeting the PAX3 part of the fusion gene (Qiagen, Hombrechtikon, Switzerland). For downregulation of 
TFAP2B, Rh4 cells were transfected with siRNA with the sequence 5’ACUUCGAAGUACAAAGUAA-dTdT 
(Qiagen, Catalog No. S100049259). As positive control siRNA targeting GAPDH (Catalog No. 4605, Ambion, 
Huntingdon, United Kingdom) was used, as negative control scrambled siRNA (scRNA) with the sequence 
5’UUCUUCGAACGUGUCACGU-dTdT (Qiagen, Catalog No. 1022076) with no known homology to 
mammalian genes. Transfection was done according to the manufacturer’s instructions using 7μl of GeneEraser 
(Stratagene, La Jolla, CA) and 20nM siRNA (final concentration).  
 
Quantitative RT-PCR 
Total RNA (1μg) was reverse-transcribed with Oligo(dT)15 Primer using the Omniscript Reverse Transcription 
Kit (Qiagen). Quantitative RT-PCR (qRT-PCR) detection of PAX3, TFAP2B and GAPDH was carried out with 
the commercially available assays-on-demand Hs00240950_m1, Hs00231468_m1 and Hs99999905_m1 
(Applied Biosystems, Rotkreuz, Switzerland), respectively. QRT-PCR detection of PAX3/FKHR was performed 
using PAX3 FOR (5’GCACTGTACACCAAAGCACG3’) and FKHR REV 
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(5’AACTGTGATCCAGGGCTGTC3’) primers applying the fluorescent SYBR green method (Applied 
Biosystems) on an Applied Biosystems 7900HT.  
 
Western Blot 
10µg of total nuclear protein was used for western blotting using NuPAGE electrophoresis system (Invitrogen, 
Basel, Switzerland). For PAX3 detection a goat-anti-PAX3 antibody (Santa Cruz Biotechnology, Heidelberg, 
Germany), for PAX3/FKHR detection a rabbit-anti-FKHR antibody (Cell Signaling Technology, Allschwil, 
Switzerland) and for detection of TFAP2B protein, a mouse-anti-TFAP2B antibody (Abcam, Cambridge, UK) 
were used.  
 
Gene expression analysis 
Global changes in gene expression were measured using Affymetrix HG-133A GeneChip arrays (Affymetrix 
Inc., Santa Clara, CA). cRNA target synthesis and experimental procedures for GeneChip hybridization and 
scanning were carried out according to the “GeneChip eukaryotic small sample target labeling technical note” 
(Affymetrix, Santa Clara, CA). Expression data of siRNA-, scRNA (control) – and non-treated cells was 
analyzed using  dChip2004(Li & Wong, 2001) and GeneSpring7.0 with default normalization and a cross-gene-
error model, resulting in 16221 genes. Representative data from two biological replicates is shown. 
 
Cell Proliferation assays 
Cell proliferation was measured using the MTT assay (Roche, Rotkreuz, Switzerland). Prior to MTT 
measurement, a standard curve for each cell line was generated using 500 to 1x 105 cells per well. A total of 
1x104 Rh4 or RD cells were plated per 96-well and transfected 24h later. The amount of converted MTT reagent 
was measured at different time points up to 72h later by a multi-detection microplate reader (Bio-Tek 
Instruments, Inc., Littau, Switzerland). 
 
Apoptosis assays 
One thousand cells from each experimental condition were assayed for caspase-3 activation using the Caspase-
Glo 3/7 Assay (Promega) according to the manufacturer’s instructions. Caspase activity was measured at an 
excitation wavelength of 485nm and an emission wavelength of 516nm. For the calculation of standard 
deviations, first the quotient of treated versus untreated cells was determined. The standard deviation of the 
quotient was then calculated as follows: for two numbers, A and B, with standard deviations, a and b, 
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(A±a) / (B±b) = (C±c) and c = A/B * sqrt ((a/A)2 + (b/B)2) where * indicates multiplication. 
For FACS analysis, Rh4 cells from one confluent 35mm dish were stained with 200µl of Propidium Iodide (PI) 
followed by cytometry analysis on a Cytomics FC500 Instrument (Beckman Coulter, Nyon, Switzerland). The 
flow cytometry data was then analysed by the FlowJo software. 
 
Cloning of the TFAP2B promoter and generation of deletion constructs 
TFAP2B promoter region from positions -3200 to +1 was amplified by PCR (primer FOR 
5’AAAGTACGAGTGTTAACTATCTGG3’; REV 5’GCAGCCTGGTCTCTAGGAGG3’) from 293T cell 
genomic DNA and cloned into the pGL3basic luciferase vector (Promega, Wallisellen, Switzerland). Deletion 
constructs were prepared using the Erase-a-base Kit (Promega), allowing progressive unidirectional deletions of 
approximately 200 bp at the 5’ end of the insert. 
 
Luciferase assay 
A total of 1x105 293T cells were plated per 35mm plate and cotransfected 24hrs later with 2 μg of TFAP2B-
promoter in pGL3basic plasmid plus 1 μg of either PAX3/FKHR or PAX3/FKHR derived mutants or pcDNA 
empty vector plus 100ng of pFIV-CMV-LacZ control plasmid (System Biosciences, Heidelberg, Germany) 
using the Ca2PO4 transfection method. 24h posttransfection, cells were lysed in reporter lysis buffer and assayed 
for luciferase as well as β-galactosidase activity using the corresponding assay systems (Promega). Luciferase 
activity values were normalized to the ß-galactosidase activity and expressed as relative luciferase units.  
 
Chromatin Immunoprecipitation (ChIP) assay 
ChIP was performed using a commercially avaible ChIP-IT enzymatic kit (Active Motif, Rixensart, Belgium) 
according to manufacturer’s instructions. 293T cells were cotransfected with two different deletion constructs, 
TFAP2b_1 or TFAP2b_2 containing 1592bp and 806bp of the TFAP2B upstream promoter region, respectively 
and a PAX3 construct encoding for His-tagged PAX3 protein. DNA-bound protein was immunoprecipitated 
using an anti-His (Quiagen) antibody or mouse IgG (Active Motif) as negative control. For quantification of 
coprecipitated DNA, amplification of a 470bp region of the TFAP2beta promoter with primer FOR 
5’GCGCAGAGATCCTCTTCTGG3’ and REV 5’AGCAACGTACGCACACGTTC3’ was measured by Sybr 
Green qRT-PCR. Signals of the anti-His precipitates were normalizes to the signals of the IgG precipitates. 
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Electrophoretic Mobility Schift Assays (EMSA) 
EMSA were performed using the Chemiluminescent Nucleic Acid Detection Module (Pierce, Rockford, USA) 
according to manufacturer’s instructions. Each protein-DNA binding reaction was carried out using 8µl of 
nuclear extracts from PAX3-His or PAX3/FKHR transiently transfected 293T cells and 20fmol of biotin labeled 
double stranded oligonucleotides corresponding to two possible PAX3 binding sites. Deletion site2 specific 
sequences Del2 (5’AGATCCTCTTCTGGGCGTCTGTTCCGGCTATGAGAAGCTCTCCGCA3’) and as 
control Del2Contr (5’AGATCCTCTTCTGGGCGTCTAAAAAAGCTATGAGAAGCTCTCCGCA3’) as well as 
deletion site3 specific sequences Del3 
(5’GGGGATGGGAAAGGGGGAACAGGGGAACAGATGAGTATTCATTTC3’) and the control Del3Contr 
(5’GGGGATGGGAAAGGGAAAAAAAGAAAAAAGATGAGTATTCATTTC3’) were synthesized as 5’ 
Biotin-labeled complementary oligonucleotide pairs (Microsynth, Balgach, Switzerland). 
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Figure legends 
 
Figure 1 Physiological effects of PAX3 and PAX3/FKHR silencing in RMS cells. 
(A) mRNA levels of PAX3 and PAX3/FKHR as measured by qRT-PCR analysis after RNAi mediated 
downregulation in eRMS (RD) and aRMS (Rh4) cells. The ratio of siRNA to scRNA (control) treatment is 
shown in %. (B) Protein levels as detected by Western blot in 10 µg of nuclear extract per lane. PAX3/FKHR 
levels were detected in Rh4 cells, PAX3 levels were detected in RD cells. Cells were treated as indicated with 
PAX3 specific siRNA (si) or control scRNA (sc). (C, D) Proliferation of RD and Rh4 cells as measured by MTT 
assay after 72h of treatment with either PAX3 specific siRNA, scRNA, siRNA targeting GAPDH, or transfection 
reagent alone (GeneEraser). The means ±standard deviations (error bars) from three independent triplica 
experiments are shown. (E, F) Induction of apoptosis in RD and Rh4 cells after the indicated time periods of 
treatment with either PAX3 specific siRNA, scRNA, siRNA targeting GAPDH or GeneEraser (transfection 
reagent) as measured by caspase-3/7 assay. Fold change values of caspase activity of treated vs. non-treated cells 
from two independent triplica experiments are shown. 
 
Figure 2 Changes in gene expression after PAX3/FKHR silencing and identification of PAX3/FKHR target 
genes in aRMS cells. 
(A) Diagram depicting normalized expression values (log10 scale) of 16221 filtered genes as measured in Rh4 
cells after 0, 24, 48 and 72hrs of treatment with PAX3-specific siRNA. Each line represents the expression of 
one gene. (B) Diagram depicting the overlap between a PAX3(7)/FKHR-specific gene signature derived from 
aRMS biopsies and genes downregulated by PAX3-specific siRNA treatment in Rh4 cells: 51 genes are present 
in both signatures. 
(C) Temporal changes of expression levels of the 51 genes identified in B in Rh4 cells after 0, 24, 48 and 72hrs 
of treatment with PAX3-specific siRNA or scRNA. (D) Graphic representation depicting the ontology of the 51 
potential PAX3/FKHR target genes identified in B. A complete list of the functions as well as downregulation 
levels of the 51 genes is shown in Tab. 1.  
 
Figure 3 Upregulated genes after silencing of PAX3 and PAX3/FKHR in RMS cells. 
(A) Diagram depicting expression values (fold change scale) of 260 genes upregulated more than 2-fold in Rh4 
cells after 72h of PAX3-specific siRNA treatment. (B) Expression levels of the same set of genes as in A in RD 
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cells. Expression values were calculated in relation to scRNA treatment, levels of upregulation are listed in 
supplementary Tab. 2. 
(C) Diagram depicting the expression values (fold change scale) of 52 genes (represented by 67 probe sets) 
involved in muscle development, which are upregulated in Rh4 cells after silencing of PAX3/FKHR for 72hrs. 
Levels of upregulation are listed in Tab.2 (D) Diagram depicting the expression values of the same 52 genes as 
in C in RD cells after 72hrs of PAX3 silencing. E, F: Verification of the expression changes of two genes, 
TNNC2 and MYL1, by qRT-PCR analysis. Fold change values in siRNA - compared to scRNA-treated cells is 
shown. 
 
Figure 4 Targeting of the TFAP2b promoter by PAX3/FKHR.  
(A) mRNA levels of  TFAP2b and CB1 were measured by qRT-PCR in Rh4 cells at indicated time points after 
RNAi mediated PAX3/FKHR downregulation. The ratio of siRNA to scRNA treatment is shown in %. (B) 
mRNA levels of TFAP2b and CB1 in 293T cells, either untransfected or transfected with the indicated 
PAX3/FKHR construct, as measured by qRT-PCR. PAX3hd and PAX3pd are homeodomain- and paired 
domain-specific mutants of PAX3/FKHR. (C) Deletion analysis of the TFAP2B promoter. A luciferase reporter 
construct containing the 3200 bp upstream of the TFAP2B transcriptional start site (TFAP2b_full) or deletion 
constructs thereof, containing remaining parts of 1592bp (TFAP2b_1) or 806bp (TFAP2b_2), respectively, are 
shown schematically in the upper panel. Transactivation of PAX3/FKHR on the different constructs as measured 
by luciferase assays is shown in the lower panel. The means ±standard deviations (error bars) from two 
independent duplicate experiments are shown ([RLU], relative light units). (D) Transactivation of the indicated 
PAX3/FKHR constructs on deletion construct TFAP2b_1 as measured by luciferase assay. (E) Sequences of 
three potential PAX3/FKHR binding sites within the TFAP2B promoter region. Commonly described motifs for 
paired domain binding are indicated by bold cursive type. Sequences for the design of oligonucleotides used for 
EMSA are underlined. (F) Binding of PAX3 to the promoter regions of the TFAP2b_1 and TFAP2b_2 deletion 
constructs as detected by chromatin immunoprecipitation. His-tagged PAX3 protein/DNA complexes were 
immunoprecipitated with αHis antibody or unspecific mouse αIgG. QRT-PCR quantification of precipitated 
DNA of each experiment (n=3) was performed in triplicates and values from the anti-His immunoprecipitation 
were normalized with the values from the control immunoprecipitation with IgG. (G) Schematic representation 
of single deletions of possible binding sites of PAX3/FKHR in TFAP2b_1 as introduced by site-directed 
mutagenesis is shown in the upper panel. Luciferase activity of the indicated deletion constructs as measured 
after cotransfection with PAX3/FKHR in 293T cells. Each bar represents means ±standard deviations from three 
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independent duplicate experiments. (H) EMSA used for measurement of DNA binding properties of PAX3 
against the deletion site 2 in the promoter region of TFAP2B. The assay was performed with 8 µl of nuclear 
protein extracted after transfection of PAX3-His in 293T cells. As control, mock-transfected 293T cells and 
mismatch oligonucleotides were used.  
 
Figure 5 Physiological effects of TFAP2B silencing in aRMS cells. 
(A) mRNA level of TFAP2B after RNAi mediated downregulation in Rh4 cells as measured by qRT-PCR 
analysis. The ratio of siRNA to scRNA (control) treatment is shown in %. (B) Protein levels of TFAP2B as 
determined by Western Blot with 10 µg of nuclear protein from TFAP2B specific - (si) and control siRNA (sc) 
treated cells extracted 24h and 48h after transfection. In the positive control lane, mTFAP2B transiently 
overexpressed in 293T cells is shown as size control. FKHR protein levels were used as loading control. (C) Cell 
proliferation as measured by MTT assay after different time periods of treatment with TFAP2B specific siRNA, 
scRNA and transfection reagent alone (GeneEraser). The means ±standard deviations (error bars) from three 
independent triplicates experiments are shown. (D) Apoptosis rate in Rh4 cells transfected with the indicated 
siRNA as detected by a caspase-3/7 assay at the indicated time points. Mean values of one representative 
experiment performed in triplicates are shown. (E) Histogram plots of FACS results of cells stained with PI 24h 
after treatment with indicated the siRNA. Percentages of PI-positive cells are depicted above the horizontal bars. 
 
Figure 6 Physiological link between PAX3/FKHR and TFAP2B. 
(A) Cell proliferation of mock-transfected Rh4 cells and cells stably overexpressing mTFAP2B as measured by 
MTT assay at indicated time points after PAX3/FKHR silencing. Treatment with siRNA specific for 
PAX3/FKHR was compared to scRNA, siRNA targeting GAPDH and GeneEraser alone. (B) Comparison of 
apoptosis rates in parental Rh4 cells, Rh4 cells stably overexpressing TFAP2B and mock-transfected Rh4 cells 
as measured by FACS of PI-stained cells 24h after downregulation of PAX3/FKHR.  
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Figure 2 
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 Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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I. Table1 Ontology and downregulation levels of 51 potential PAX3/FKHR target genes 
 
Gene Name Common Description 
Downre
gulation 
24h 
(fold) 
Function 
Signal transduction 
207232_s_at DZIP3 zinc finger DAZ interacting protein 3 
6.1 
 
ligase activity, protein 
ubiquitination, RNA binding,  zinc 
ion binding 
220197_at ATP6V0A4 ATPase, H+ transporting, lysosomal V0 subunit a isoform 4 5.7 
ion transport,  proton transport ,  
regulation of pH 
204882_at ARHGAP25 Rho GTPase activating protein 25 4.2 GTPase activator activity 
203638_s_at 
 
FGFR2 
 
fibroblast growth factor receptor 2 
(bacteria-expressed kinase, 
keratinocyte growth factor receptor, 
craniofacial dysostosis 1, Crouzon 
syndrome, Pfeiffer syndrome, 
Jackson-Weiss syndrome) 
3.2 
 
cell growth, protein amino acid 
phosphorylation 
 
 
206723_s_at 
 
 
EDG4 
 
endothelial differentiation, 
lysophosphatidic acid G-protein-
coupled receptor, 4 
2.9 
G-protein coupled receptor protein 
signaling pathway, lysosphingolipid 
and lysophosphatidic acid receptor 
activity, lipid binding 
 
212915_at 
 
 
SEMACAP3 
 
Likely ortholog of mouse semaF 
cytoplasmic domain associated 
protein 3 
 
2.7 
 
metal ion binding, protein 
ubiquitination, ubiquitin-protein 
ligase activity 
203233_at IL4R interleukin 4 receptor 2.6  
immune response,receptor signaling 
protein activity 
209869_at ADRA2A adrenergic, alpha-2A-, receptor 2.5 
activation of MAPK activity, Ras 
protein signal transduction, positive 
regulation of cell proliferation 
 
213436_at 
 
CNR1; CB1; 
CB-R; CB1A; 
CANN6; 
CB1K5 
cannabinoid receptor 1 (brain) 
 
 
2.3 
 
cannabinoid receptor activity, G-
protein signaling, coupled to cyclic 
nucleotide second messenger 
205068_s_at GRAF GTPase regulator associated with focal adhesion kinase pp125(FAK) 1.9 
nervous system development,  Rho 
GTPase activator activity 
221578_at RASSF4 Ras association (RalGDS/AF-6) domain family 4 1.8 oxidoreductase activity 
200972_at TM4SF8 transmembrane 4 superfamily member 8 1.7 cell motility, cell proliferation 
218373_at FTS fused toes homolog (mouse) 1.6 apoptosis,  ubiquitin-like activating enzyme activity 
DNA binding 
 
202320_at 
 
 
GTF3C1 
 
 
general transcription factor IIIC, 
polypeptide 1, alpha 220kDa 
 
 
9.6 
 
DNA binding, RNA polymerase III 
transcription factor activity,  
rRNA transcription, tRNA 
transcription 
 
205935_at 
 
 
FOXF1 
 
 
forkhead box F1 
 
 
2.8 
 
regulation of transcription, DNA-
dependent; regulation of 
transcription from Pol II promoter 
 
209757_s_at 
 
 
MYCN 
 
v-myc myelocytomatosis viral 
related oncogene, neuroblastoma 
derived (avian) 
2.8 
transcription factor activity, protein 
binding, regulation of transcription, 
DNA-dependent 
 
206940_s_at 
 
POU4F1 POU domain, class 4, transcription factor 1 2.7 
development,  transcription factor 
activity, regulation of transcription 
from Pol II promoter 
218445_at H2AFY2 H2A histone family, member Y2 2.6 dosage compensation 
 
214451_at 
 
 
TFAP2B 
 
transcription factor AP-2 beta 
(activating enhancer binding protein 
2 beta) 
 
2.6 
 
nervous system development, 
transcription factor activity, 
transcription coactivator activity 
 
211341_at 
 
 
POU4F1 
 
POU domain, class 4, transcription 
factor 1 
 
2.4 
 
development,  transcription factor 
activity, regulation of transcription 
from Pol II promoter 
Enzymes 
212989_at MOB mob protein 3.4 kinase activity, lipid metabolism, transferase activity 
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214961_at KIAA0774 KIAA0774 3.1 catalytic activity 
 
221605_s_at 
 
 
PIPOX 
 
 
pipecolic acid oxidase 
 
 
3.0 
 
electron transport, oxidoreductase 
activity, tetrahydrofolate 
metabolism 
206447_at ELA1 elastase 1, pancreatic 3.0 trypsin activity, pancreatic elastase activity, hydrolase activity 
209460_at ABAT 4-aminobutyrate aminotransferase 2.9 transferase activity, neurotransmitter catabolism 
 
209765_at 
 
 
ADAM19 
 
a disintegrin and metalloproteinase 
domain 19 (meltrin beta) 
 
2.5 
 
hydrolase activity; 
metalloendopeptidase activity, 
proteolysis 
 
212006_at 
 
 
UBXD2 
 
 
UBX domain containing 2 
 
 
2.3 
 
regulation of transcription, DNA-
dependent , transcription factor 
activity 
 
204074_s_at 
 
 
KIAA0562 
 
glycine-, glutamate-, 
thienylcyclohexylpiperidine-binding 
protein 
 
2.2 
 
 
binding, hydrolase activity 
 
205811_at 
 
POLG2 
 
polymerase (DNA directed), gamma 
2, accessory subunit 
 
1.9 
 
DNA repair, DNA-dependent DNA 
replication, protein biosynthesis, 
metallopeptidase activity 
202603_at 
 
ADAM10 
 
a disintegrin and metalloproteinase 
domain 10 
1.9 
 
hydrolase activity, protein amino 
acid phosphorylation, 
metalloendopeptidase activity 
Cell growth and/or maintenance 
 
205430_at 
 
 
BMP5 
 
Human DNA sequence from clone 
RP1-181C24 on chromosome 
6p11.1-12.2 Contains the 3' end of 
the BM 
 
6.2 
 
 
cell differentiation, cytokine 
activity, growth, growth factor 
activity, skeletal development 
 
209814_at ZNF330 zinc finger protein 330 2.9 metal ion binding, protein binding , zinc ion binding 
203651_at 
 
ZFYVE16 
 
zinc finger, FYVE domain 
containing 16 
 
1.9 
 
endosome transport , metal ion 
binding, protein targeting to 
lysosome, regulation of endocytosis, 
vesicle organization and biogenesis 
Structural molecules 
221854_at PKP1 plakophilin 1 (ectodermal dysplasia/skin fragility syndrome) 8.0 cell-cell signaling, cell adhesion 
203256_at CDH3 cadherin 3, type 1, P-cadherin (placental) 6.0 cell adhesion,  calcium ion binding, 
203072_at 
 
MYO1E 
 
myosin IE 
 
2.1 
 
actin binding, ATP binding, ATPase 
activity, actin filament-based 
movement 
211059_s_at GOLGA2 golgi autoantigen, golgin subfamily a, 2 1.7 protein binding 
Neuronal 
206089_at NELL1 NEL-like 1 (chicken) 4.7 nervous system development, cell adhesion 
 
204105_s_at 
 
 
NRCAM 
 
 
neuronal cell adhesion molecule 
 
 
3.5 
 
ankyrin binding, cell-cell adhesion, 
neuron migration, positive 
regulation of neuron differentiation, 
protein binding,synaptogenesis 
Unknown 
210102_at LOH11CR2A loss of heterozygosity, 11, chromosomal region 2, gene A 2.7 unknown 
221185_s_at 
 
DKFZp434B2
27 
synonyms: FLJ11667, FLJ23571; 
Homo sapiens hypothetical protein 
DKFZp434B227 (DKFZp434B227), 
mRNA. 
2.6 
 
unknown 
 
205888_s_at KIAA0555 KIAA0555 gene product 2.5 unknown 
213179_at 
  
602381329F1 NIH_MGC_93 Homo 
sapiens cDNA clone 
IMAGE:4499023 5', mRNA 
sequence. 
2.4 
 
unknown 
 
209693_at ASTN2 astrotactin 2 2.4 unknown 
219438_at FLJ12650 hypothetical protein FLJ12650 2.3 unknown 
220610_s_at LRRFIP2 leucine rich repeat (in FLII) interacting protein 2 2.3 unknown 
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207759_s_at FLJ41105 hypothetical gene supported by AK123100 2.2 unknown 
49111_at  MRNA; cDNA DKFZp762M127 (from clone DKFZp762M127) 2.2 unknown 
43511_s_at  MRNA; cDNA DKFZp762M127 (from clone DKFZp762M127) 1.9 unknown 
212736_at BC008967 hypothetical gene BC008967 1.8 unknown 
219225_at PGBD5 piggyBac transposable element derived 5 1.6 unknown 
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II Table 2 Upregulation levels of 52 muscle development related genes represented by 67    probe sets 
 
Gene Name Common Description 
Rh4 fold change 
upregulation si vs 
sc 
RD fold change 
upregulation si 
vs sc 
209904_at TNNC1 troponin C, slow 58.2 0.8 
205163_at HUMMLC2B  myosin light chain 2 37.1 0.9 
205388_at TNNC2 troponin C2, fast 34.4 1.0 
206304_at MYBPH myosin binding protein H 22.4 1.0 
205940_at MYH3 myosin, heavy polypeptide 3, skeletal muscle, embryonic 21.6 0.6 
206393_at TNNI2 troponin I, skeletal, fast 18.4 0.8 
221994_at PDLIM5 LIM protein (similar to rat protein kinase C-binding enigma) 15.1 0.9 
214122_at PDLIM7 PDZ and LIM domain 7 (enigma) 14.2 1.2 
210329_s_at SGCD sarcoglycan, delta (35kDa dystrophin-associated glycoprotein) 12.6 1.3 
209283_at CRYAB crystallin, alpha B 9.6 1.0 
205951_at MYH1 myosin, heavy polypeptide 1, skeletal muscle, adult 9.5 5.1 
219772_s_at SMPX small muscle protein, X-linked 8.6 1.1 
205730_s_at ABLIM3 Homo sapiens actin binding LIM protein family, member 3 (ABLIM3), mRNA. 8.3 0.9 
206394_at MYBPC2 myosin binding protein C, fast type 7.7 3.9 
34471_at MYH8 myosin, heavy polypeptide 8, skeletal muscle, perinatal 7.4 1.5 
213023_at UTRN utrophin (homologous to dystrophin) 7.2 1.3 
205610_at MYOM1 myomesin 1 (skelemin) 185kDa 6.3 1.0 
206116_s_at TPM1 tropomyosin 1 (alpha) 6.2 0.7 
209888_s_at MYL1 myosin, light polypeptide 1, alkali; skeletal, fast 6.1 1.0 
200974_at ACTA2 actin, alpha 2, smooth muscle, aorta 5.9 0.8 
218736_s_at PALMD palmdelphin 5.9 1.1 
201438_at COL6A3 collagen, type VI, alpha 3 5.8 1.2 
206538_at MRAS muscle RAS oncogene homolog 5.6 3.5 
210298_x_at FHL1 four and a half LIM domains 1 5.3 1.0 
210395_x_at MYL4 myosin, light polypeptide 4, alkali; atrial, embryonic 5.3 0.6 
216054_x_at 
MYL4; GT1; 
ALC1; AMLC; 
PRO1957 
Human MLC1emb gene for embryonic 
myosin alkaline light chain, promoter and 
exon 1. 
5.2 0.5 
205693_at TNNT3 troponin T3, skeletal, fast 5.1 0.7 
210088_x_at MYL4 myosin, light polypeptide 4, alkali; atrial, embryonic 5.1 0.5 
210330_at SGCD sarcoglycan, delta (35kDa dystrophin-associated glycoprotein) 5.0 2.1 
206717_at MYH8 myosin, heavy polypeptide 8, skeletal muscle, perinatal 5.0 1.4 
217585_at NEBL nebulette 4.8 1.0 
210202_s_at BIN1 bridging integrator 1 4.6 0.8 
205547_s_at TAGLN transgelin 4.5 0.8 
203037_s_at MTSS1 metastasis suppressor 1 4.2 1.0 
207317_s_at CASQ2 calsequestrin 2 (cardiac muscle) 4.1 1.1 
213371_at LDB3 LIM domain binding 3 4.1 0.7 
203821_at DTR 
diphtheria toxin receptor (heparin-
binding epidermal growth factor-like 
growth factor) 
4.0 0.5 
214087_s_at MYBPC1 myosin binding protein C, slow type 4.0 1.0 
203243_s_at PDLIM5 LIM protein (similar to rat protein kinase C-binding enigma) 4.0 1.0 
205177_at TNNI1 troponin I, skeletal, slow 3.9 0.7 
207302_at SGCG sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) 3.9 1.1 
204173_at MLC1SA myosin light chain 1 slow a 3.8 0.9 
206117_at TPM1 tropomyosin 1 (alpha) 3.5 0.7 
201976_s_at MYO10 myosin X 3.4 1.0 
202931_x_at BIN1 bridging integrator 1 3.3 0.9 
214492_at SGCD sarcoglycan, delta (35kDa dystrophin- 3.1 1.3 
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associated glycoprotein) 
219829_at ITGB1BP2 integrin beta 1 binding protein (melusin) 2 3.1 0.3 
217274_x_at 
MYL4; GT1; 
ALC1; AMLC; 
PRO1957 
skeletal embryonic form; H.sapiens 
skeletal embryonic myosin light chain 1 
(MLC1) mRNA 
2.8 0.7 
215279_at SVIL supervillin 2.7 1.1 
213717_at LDB3 LIM domain binding 3 2.6 1.0 
204533_at CXCL10 chemokine (C-X-C motif) ligand 10 2.5 1.2 
213022_s_at UTRN utrophin (homologous to dystrophin) 2.5 1.4 
214643_x_at BIN1 bridging integrator 1 2.5 1.1 
201079_at SYNGR2 synaptogyrin 2 2.5 0.7 
222022_at DTX3 deltex 3 homolog (Drosophila) 2.5 1.2 
215222_x_at  microtubule-actin crosslinking factor 1 2.4 0.8 
210201_x_at BIN1 bridging integrator 1 2.3 0.9 
207968_s_at MEF2C 
MADS box transcription enhancer factor 
2, polypeptide C (myocyte enhancer 
factor 2C) 
2.3 1.0 
209926_at MEF2B 
MADS box transcription enhancer factor 
2, polypeptide B (myocyte enhancer 
factor 2B) 
2.2 1.1 
209200_at MEF2C 
MADS box transcription enhancer factor 
2, polypeptide C (myocyte enhancer 
factor 2C) 
2.2 1.0 
219107_at BCAN brevican 2.2 1.1 
216887_s_at LDB3 LIM domain binding 3 2.2 1.0 
210360_s_at MTSS1 metastasis suppressor 1 2.1 0.7 
206813_at CTF1 cardiotrophin 1 2.1 0.8 
202222_s_at DES desmin 2.1 0.7 
203004_s_at MEF2D 
MADS box transcription enhancer factor 
2, polypeptide D (myocyte enhancer 
factor 2D) 
2.1 0.8 
201792_at AEBP1 AE binding protein 1 2.0 0.9 
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Abstract 
 
PAX3 is a transcription factor whose expression is associated with ebryonal rhbdomyosarcoma 
(eRMS). However, the molecular mechanisms mediating essential pathophysiological functions of 
PAX3 remain poorly defined. Here, we compared expression profiling of PAX3 silencing in eRMS cells 
with microarray data avaible from overexpression experiments in different cell lines to identify a 
minimal set of physiologically important target genes irrespectively of cellular background. 
Surprisingly, we identified only a single gene to be regulated by PAX3 under all conditions analyzed. 
This gene, PRKAR2B, was not recognized as PAX3 target before and implicates PKA signalling in 
mediating PAX3 function. Furthermore our data suggests the involvement of TRAIL-induced apoptosis 
in eRMS. 
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Introduction 
 
PAX3 belongs to a family of genes encoding transcription factors. To date, nine members (PAX1-
PAX9) have been described (Dahl et al., 1997; Stuart and Gruss, 1996) which are involved in 
regulation of tissue development and cellular differentiation in embryos. PAX3 plays a pivotal role 
during neural tube closure (Stuart and Gruss, 1996) and PAX3 expression is required during 
embryogenesis for the proper migration and specification of myogenic progenitor cells (Relaix et al., 
2004). Different PAX family members have been assigned with a wide range of cancers (Muratovska 
et al., 2003). The precise role of PAX transcription factors in cancer is not known, but it has been 
shown that PAX genes are preventing terminal differentiation and maintaining progenitor cell state 
(Tremblay et al., 1996). Two members of the PAX gene family, PAX3, and PAX7, show tumor-
associated expression in different cancer types, among them neuroblastomas (Harris et al., 2002) and 
squamos cell lung carcinomas (Racz et al., 2000). Furthermore, PAX3 has been shown to contribute 
to melanoma tumor development (Scholl et al., 2001). In melanoma, the function of PAX3 at a nodal 
point in adult melanocyte stem cell differentiation has been described, where PAX3 simultaneously 
initiates melanogenic cascade while preventing terminal differentiation (Lang et al., 2005). Also in 
different sarcoma types such as rhabdomyosarcoma and Ewing’s sarcoma constitutive PAX3 and 
PAX7 expression has been reported (Barr et al., 1999). 
There are two major subtypes of rhabdomyosarcoma, the alveolar (aRMS) and embryonal 
rhabdomyosarcoma (eRMS). In both subtypes, PAX3 and PAX7 are thought to be involved in 
tumorigenesis. In 80% of the aRMS subtype an abberant transcription factor is generated by the 
reciprocal translocation t(2;13)(q35;q14) or t(1;13)(p36;q14), which leads to the fusion of PAX3 or 
PAX7 to FKHR, also known as FOXO1A (Davis et al., 1995; Galili et al., 1993). In PAX3(7)/FKHR, the 
two DNA binding domains, namely paired and homeodomain, derive from PAX3(7) and the stronger 
transactivation domain from FKHR. As PAX3(7) derived DNA binding domain is identical in PAX3(7) 
and PAX3(7)/FKHR encoded proteins, this leads to the assumption that these transcription factors 
would target similar genes and that PAX3(7)/FKHR acts as stronger transactivator than the wild-type 
PAX3(7), leading to upregulation of PAX3(7) target genes. This conclusion was supported by recent 
microarrays studies describing translocation-dependent gene signature (Davicioni et al., 2006; 
Wachtel et al., 2004). Moreover, TFAP2beta, one of the best discriminating genes between eRMS and 
aRMS detected by microarray analysis, was recently revealed as a downstream-target of PAX3/FKHR 
and is involved in PAX3/FKHR mediated tumor-maintenance (submitted manuscript). Furthermore, in 
vivo data support the hypothesis of common genes targeted by wild-type and fusion protein, as the 
phenotype of PAX3-mutant mice could be rescued by introducing of a PAX3/FKHR gene (Relaix et al., 
2003).  
ERMS is not associated with specific translocation, however, PAX3 is implicated in the invasive and 
metastatic potential of eRMS. Recent findings show that it might do so by maintenance of a progenitor 
cell state and promoting cell survival. This finding was supported by several studies demonstrating the 
“oncogene –addiction” of eRMS tumors, as silencing of PAX3 gene by siRNA or oligonucleotides 
results in induction of apoptosis (submitted manuscript)(Bernasconi et al., 1996; Elbashir et al., 2001). 
On the other hand, there are data suggesting that PAX3 and PAX3/FKHR have slightly different 
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binding properties and thus are promoting the expression of different target genes, depending on 
cellular background and differentiation status of cells (Begum et al., 2005; Linardic et al., 2005). To 
date several target genes of PAX3 and PAX3/FKHR which can activate the myogenic transcription 
program have been reported (Khan et al., 1999). Several PAX3/FKHR targets, among them MYCN 
(Khan et al., 1999) or bcl-xl have been identified (Margue et al., 2000). The best characterized gene is 
c-met (Relaix et al., 2003), whose PAX3-dependent expression in muscle precursor cells is essential 
for proper migration. Recent findings however suggest that precursor cell may be different in eRMS 
and aRMS (Linardic et al., 2005); while the specificity of PAX3/FKHR fusion gene for aRMS suggests 
that the cell context is critical for oncogenesis, the parental alveolar rhabdomyosarcoma cell of origin 
remains unknown. Consistent with this finding, recent microarray analysis could reveal that 
PAX3/FKHR alters the expression of gene targets in a cell-type specific manner quantitatively and 
qualitatively distinct from PAX3 (Begum et al., 2005). As anticipated, a PAX3/FKHR specific gene 
signature could not be detected in eRMS.  
Numerous publications recently performed microarray approaches in order to identify novel 
PAX3/FKHR and PAX3 target genes. A PAX3/FKHR specific gene signature which defines a group of 
potential PAX3/FKHR target genes was revealed using biopsy samples (Davicioni et al., 2006; 
Wachtel et al., 2004). For identification of PAX3 targets, overexpression studies have been performed 
in medulloblastoma and osteosarcoma cells and subsequently combined with microarray analysis 
(Begum et al., 2005; Mayanil et al., 2001). Furthermore, similar approaches have been used with 
PAX3/FKHR which was overexpressed in RD (Davicioni et al., 2006), NIH3T3 (Khan et al., 1999) and 
osteosarcoma cells (Begum et al., 2005) and the resulting changes detected by microarray analysis 
have been described. Moreover, a similar approach was also performed with the murine RMS cells 76-
9 (Nabarro et al., 2005).  
However, since the results obtained in these studies are not consistent, we hypothesized that 
overexpression in different cellular backgrounds contributes to broad variation in data. To avoid 
complications by cell background, we choose a complementary approach for identification of PAX3 
target genes and combined siRNA-mediated down-regulation strategy in eRMS cells with microarray 
analysis, thus identifying endogenous putative PAX3 targets in eRMS itself. Thereafter, we integrate 
all available literature data to identify a minimal set of target genes depending on PAX3 irrespective of 
cellular background. 
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Material and Methods 
 
Cell lines 
 
Rh4 alveolar rhabdomyosarcoma (aRMS) cells, originating from acites fluid of a St Jude patient at 
autopsy in 1982, was provided by Peter Houghton (St. Jude Children's Research Hospital, Memphis, 
TN, USA). RD embryonal rhabdomyosarcoma (eRMS) and 293T human embryonic kidney cell lines 
were obtained from ATCC (LGC Promochem, Molsheim Cedex, France).  
Cells were maintained under proliferating conditions in Dulbecco modified Eagle medium 
supplemented with 10% fetal bovine serum and grown in 95% air, 5% CO2 at 37oC. 
 
 
siRNA-mediated silencing 
 
PAX3 and PAX3/FKHR knockdown was performed with the RNA interference (RNAi) technique 
(Elbashir et al., 2001). A total of 2x105  rhabdomyosarcoma or melanoma cells was plated and 24h 
later transfected with a combination of two chemically synthesized siRNAs 
(5’AAGAGAGAACCCGGGCAUG-dTdT and 5’CAUGGAUUUUCCAGCUAUA-dTdT) both targeting the 
PAX3 part of the fusion gene (Qiagen, Hombrechtikon, Switzerland). Transfection was performed 
according to manufacture’s instructions using 7μl of GeneEraser (Stratagene, La Jolla, CA) and 20nM 
siRNA (final concentration).  
 
Quantitative RT-PCR 
 
Total RNA samples (1μg) were reverse-transcribed with Oligo(dT)15 Primer using the Omniscript 
Reverse Transcription Kit (Qiagen). Quantitative RT-PCR detection of PAX3 and GAPDH was 
performed with commercially avaible assays-on-demand Hs00240950_m1, and Hs99999905_m1 
(Applied Biosystems, Rotkreuz, Switzerland), respectively. Furthermore, genes involved in apoptotic 
TRAIL pathway, bcl-2 and one of receptors of TRAIL, TRAILR4, were analysed using commercially 
avaible assays-on-demand (Hs00236329_m1 and Hs00174664_m1, respectively). TaqMan analysis 
was carried out according to the manufacturer’s instructions on an Applied Biosystems 7900HT 
Sequence Detector. Expression levels of the gene of interest were normalized with GAPDH 
expression levels. Experiments were performed in triplicate and standard deviations were calculated 
based on the results of three biological replicates. 
 
Western Blot 
For Western Blot analysis of siRNA mediated effects on protein level, 1x107 cells per treatment were 
harvested at each indicated time point and nuclear extract was prepared. Protein concentration was 
measured with the Bradford method using Protein Assay Dye Reagent Concentrate (Bio-Rad, Reinach, 
Switzerland). 10µg of total protein was then used for western blotting. For PAX3 detection a goat-anti-
PAX3(7) antibody (Sigma, Switzerland) was used, mouse-anti-PCNA (Bioscience) was used as control 
antibody.  
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Cell Proliferation assays 
Cell proliferation was measured using the MTT assay system (Roche, Rotkreuz, Switzerland). A total 
of 1x104 RD cells were plated per 96-well and transfected 24h later. The amount of converted MTT 
reagent was measured at different time points up to 72h later by a multi-detection microplate reader 
(Bio-Tek Instruments, Inc.) at wavelength 595 nm. 
 
Apoptosis assays 
One thousand cells from each experimental condition were assayed for caspase-3 activation using the 
Caspase-Glo 3/7 Assay (Promega) according to the manufacturer’s instructions. Caspase activity was 
measured at an excitation wavelength of 485nm and an emission wavelength of 516nm by a multi-
detection microplate reader (Bio-Tek Instruments, Inc.). Experiments were performed in triplicates. 
 
Gene expression analysis 
Global changes in gene expression of RD upon knock down of PAX3 by RNAi were measured using 
Affymetrix HG-133A GeneChip arrays (Affymetrix Inc., Santa Clara, CA). cRNA target synthesis and 
experimental procedures for GeneChip hybridization and scanning were carried out according to the 
“GeneChip eukaryotic small sample target labeling technical note” (Affymetrix, Santa Clara, CA). 
Expression data of siRNA - or scRNA (control) treated and nontreated cells was analyzed using 
dChip2004 and GeneSpring7.0 software programs. The identified sets of downregulated genes were 
compared with published microarray data from other studies. 
 
Pathway analysis  
The PANTHER (https://panther.appliedbiosystems.com/) classification system was applied to classify 
proteins (and their genes) according to families, molecular functions and pathways.  
The analysis was performed with the set of genes involved in apoptosis, identified by dchip2004 gene 
expression analysis program to be up – or down regulated upon siRNA treatment at time points 24hrs, 
48hrs and 72hrs. Genes involved in the TRAIL pathway were identified and subsequently analyzed 
using real-time PCR.  
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Results 
 
1. PAX3 promotes RD cell survival 
 
To characterize PAX3 target genes relevant for eRMS development and maintenance, we first 
established a siRNA-mediated down-regulation strategy. Therefore, a combination of two chemically 
synthezised siRNAs, which led to the strongest specific inhibition of PAX3 expression, was used for 
silencing of PAX3 in the eRMS cell line RD. PAX3 expression was suppressed in RD already after 24h 
of treatment by nearly 70% on mRNA level. PAX3 protein levels were also reduced, although delayed, 
to 40% compared to control-treated samples 48h after treatment (Figure 1A).  
To characterize the physiological effects occurring upon siRNA treatments, we next measured 
proliferation of RD after treatment with PAX3 specific and control siRNAs for 24hrs, 48hrs and 72hrs. 
Cell growth was found to be inhibited significantly in cells treated with siRNA targeting PAX3, whereas 
normal proliferation rates were observed in untreated or control (scRNA, anti-GAPDH siRNA, 
transfection reagent alone) cells (Figure 1 B). Furthermore, assessment of apoptotic activities by 
measuring active caspase 3/7 showed an approximately 1.7-fold increase in enzymatic activity in cells 
with silenced PAX3 expression compared to control treated cells (Figure 1 C). Thus, an anti-apoptotic 
function of PAX3 in eRMS cell lines could clearly be demonstrated. These results are in accordance 
with earlier findings, demonstrating an anti-apoptotic function of PAX3 in eRMS cells treated with 
specific antisense oligonucleotides (Bernasconi et al., 1996) and therefore validate our siRNA 
approach also on the physiological level.  
 
2. Comparison between genes downregulated in Rh4 cells and RD cells after PAX3/FKHR and 
PAX3 downregulation, respectively 
 
First, we identified genes, specifically downregulated in RD cells upon PAX3 silencing. Towards this 
end, RD cells were treated with siRNA, RNA isolated at time points 0 hrs, 24hrs, 48hrs and 72hrs 
followed by determination of their expression profile at each time point. To eliminate unspecific effects 
caused by the treatment procedure, the expression profiles of cells treated with scRNA (control) and 
non-treated cells were also determined. The microarray data was analysed using GeneSpring 7.0 
software (see Methods). First, gene expression values were normalized per chip and per gene (default 
normalization) and filtered based on a cross-gene-error-model. Genes downregulated more than 1.5 
fold in siRNA treated samples and not affected by control treatment, were filtered and the ratio 
between siRNA and scRNA treatment was calculated. 338 genes represented by 340 probe sets could 
be identified in this analysis (for entire list see supplementary data). 
To identify those genes which are potentially regulated by both, PAX3 and PAX3/FKHR, a direct 
comparison between genes downregulated in Rh4 cells and RD cells after 24hrs was performed. First, 
the “present” and “absent” calls had to be modified for further calculation because genes that are 
highly expressed in Rh4 cells were expressed at low levels in RD cells. This resulted in “absent” calls 
in treated, but not in untreated cells. We therefore decided to include all genes even if they were 
“absent”. The analysis was performed at the shortest time point of treatment (24 hrs) assuming that 
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direct targets are the first genes downregulated. In Rh4 cells, 1834 genes were identified to be 
specifically down-regulated (>1.5 fold) by siRNA-treatment at time point 24hrs when compared to 
scRNA treatment. Therefore, a large number of 1834 probe sets specifically downregulated in Rh4 
cells were searched for possible target genes of PAX3 in RD cells. All expression values were 
corrected with the scRNA control levels. Interestingly, only 98 genes out of 1834 were specifically 
downregulated in same manner in RD cells (>1.5 fold downregulation when compared to control 
treatment), meaning that almost one third (29%) of PAX3 dependent genes are also regulated in the 
same manner by PAX3/FKHR, but only 5% of PAX3/FKHR regulated genes are equally regulated by 
PAX3 (Figure 2). This difference could depend on the characteristic of PAX3/FKHR which is a stronger 
transactivator than PAX3, therefore more changes of regulated genes can be detected at the same 
cut-off level. To further constrict relevant PAX3 and PAX3/FKHR target genes, we next performed 
gene ontology studies. The largest number of genes are involved in signal transduction (32%) among 
them protein kinases and phosphatases like PRKAR2B (protein kinase, cAMP-dependent, regulatory, 
type II, beta) or PPP4R2 (protein phosphatase 4, regulatory subunit 2). The second largest number of 
genes encode for enzymes (18%) and finally, numerous genes (16%) are involved in transcriptional 
regulation and DNA or protein binding, respective gene names and downregulation levels are 
indicated in Table 1. These data lead to the conclusion that distinct genes are regulated by PAX3 and 
PAX3/FKHR, however, also a large overlap could be found between these genes. 
 
3. Comparison with PAX3 targets from PAX3 overexpressing cells 
 
We next sought to compare our list of target genes with the set of previously published putative PAX3 
targets. Gene lists from two studies performed to identify PAX3 target genes were compared with our 
data set. Of the 28 genes identified in osteosarcoma cell line, SaOs (Begum et al., 2005) two genes, 
PRKAR2B and SEMA3 and, could be identified by the comparison with RD (338) specific genes and 
one of them, PRKAR2B, was also in common with RD and Rh4 (98) specific genes (Figure 3).  Exact 
gene names are given in Table 2 and Table 3. However, genes encoding for the same family of 
proteins, like metalloproteinases and zink-finger proteins, could be found to be regulated in both cell 
types, induced after overexpression in osteosarcoma cells and downregulated by low PAX3 levels in 
eRMS cells. 
The second study revealed 102 genes induced by PAX3 after overexpression in medulloblastoma 
cells (Mayanil et al., 2001). However, the comparison of this gene list with our data set did not result in 
an overlap of any genes, suggesting that PAX3 regulated genes are entirely different in 
medulloblastoma and eRMS cells. 
 
4. Comparison with PAX3 targets from PAX3/FKHR overexpressing cells 
 
PAX3/FKHR has been shown to be a stronger transactivator than PAX3 (Fredericks et al., 1995), 
therefore several studies have been performed introducing PAX3/FKHR in several cell types and 
analyzing the resultant gene expression changes, thus expecting more pronounced activation of PAX3 
targets by PAX3/FKHR. We therefore hypothesised that genes, upregulated in cells upon ectopic 
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PAX3(7)/FKHR expression might be common with those which are downregulated upon PAX3 
silencing. Three studies performed with NIH3T3, osteosarcoma and RD cells identified different 
putative target genes induced by PAX3(7)/FKHR overexpresion.  
In the first study, PAX3/FKHR was introduced into NIH3T3 cells and a set of 11 genes has been 
identified by cDNA microarray analysis to be induced specifically by PAX3/FKHR (Khan et al., 1999). 
However, no overlap could be found with our data set, probably also due to different array techniques.  
In a second study, eRMS cell line RD was analysed upon ectopic expression of PAX3/FKHR or 
PAX7/FKHR and subsequent microarray analysis of PAX3/FKHR, PAX7/FKHR or vector transduced 
RD population was performed (Davicioni et al., 2006). Thus, 389 genes could be identified as 
differentially expressed. Comparison with our data sets revealed 9 genes regulated equally by 
PAX3(7)/FKHR overexpression or PAX3 silencing in RD cells and 4 genes when compared to the 
smaller set of 98 genes  (Figure 4A).  
In the third study, PAX3/FKHR overexpression in osteosarcoma cells specifically induced 65 genes 
(Begum et al., 2005). Comparison of the 65 genes with our data set revealed an overlap of 4 genes 
when compared to our data (Figure 4B). Interestingly, one gene, PRKAR2B (protein kinase, cAMP-
dependent, regulatory, type II, beta), appears to be regulated by PAX3 and PAX3/FKHR in all the 
studies. All gene names and probe numbers are summarized in Tables 2 and 3. 
 
 
5. Comparison between genes downregulated in RD cells after PAX3 downregulation and in-
vivo data (biopsies) 
Next we asked whether any of the 98 genes, regulated by both PAX3 and PAX3/FKHR, might be 
associated with PAX3 downregulation in vivo. Therefore a comparison between genes, downregulated 
in RD cells after PAX3 silencing and in vivo data obtained by expression analysis of biopsy samples 
was performed. To date, there are two main gene signatures discriminating between translocation-
positive aRMS and translocation-negative aRMS and eRMS published (Davicioni et al., 2006; Wachtel 
et al., 2004). 
First, the signature list consisting of 417 genes (Wachtel et al., 2004) was compared to the set of 338 
genes, downregualted in RD cells and to the set of 98 genes, downregulated in RD and Rh4 cells and 
resulted in an overlap of 12 and 5 genes, respectively (Figure 5, Table 2 and 3).  
In the second study also a gene signature consisting of 534 genes was identified, in this approach a 
larger data set of 139 biopsies was used (Davicioni et al., 2006). A comparison with our 98 gene set 
revealed overlap of nine genes (Figure 5). With our 338 gene set, 19 genes were in common. The 
complete list of overlapping genes is summarized in Table 2 and 3. 
Moreover, a subset of 51 direct PAX3/FKHR in vivo target genes identified in Rh4 cells was identified 
in our previous study (manuscript submitted). Three genes, TFAP2beta, DZIP3 and FGFR2 were 
downregulated in both sets in RD and Rh4 cells (data not shown).  
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6. PAX3-dependent pathways 
 
Ontology studies of genes affected by PAX3 downregulation showed different groups of genes 
according to their function. In the preceding analysis, we searched for direct target genes of PAX3 24 
hrs after transfection. Assuming that genes up or downregulated after longer period of time are not 
direct target genes of PAX3 but probably regulated indirectly, we now also examined gene expression 
pattern at later time points. Therefore, genes specifically up- or downregulated upon PAX3 silencing 
were examined at time points 24h, 48h and 72h post-transfection. Unlike in Rh4 cells, no induction of 
muscle development related genes was observed in RD cells.  
A group of apoptosis-related genes regulated indirectly could be identified. Pathway analysis revealed 
four genes which showed altered expression upon PAX3 silencing, TRAIL-R, Bcl-2, Apaf-1 and 
caspase 7 were involved in TNF-related apoptosis-inducing ligand (TRAIL) pathway (Figure 6A), which 
is sufficient to be considered as statistically significant. Therefore, one possible way how apoptosis is 
mediated in RD cells, could be via TRAIL pathway. Interestingly, one of the genes involved in this 
pathway, bcl-xl, has already been shown to be transcriptionally activated by PAX3 and PAX3/FKHR 
(Margue et al., 2000), indicating at least one mechanism of the anti-apoptotic effect of PAX3. For 
validation of the microarray data, two genes, tumor necrosis factor receptor superfamily, member 10d 
(TRAIL-R) and blc-2 were also analysed using qRT-PCR (data not shown). Indeed, mRNA expression 
values of TRAIL-R increased 2.7 fold 24h after PAX3 downregulation as compared to non-silencing 
scRNA treatment.  
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Discussion 
 
Understanding of the oncogenic properties of PAX3 requires identification of the relevant downstream 
targets. We demonstrated previously that a large set of PAX3/FKHR target genes could be identified 
by comparative expression analysis of a silencing approach with subsequent microarray analysis and 
a gene signature identified in tumor biopsies (manuscript submitted). Performing a similar approach, a 
set of possible target genes was identified using microarray analysis of RD cells after silencing of 
PAX3.  
Using this approach, 98 genes could be found downregulated equally in eRMS and aRMS subtypes 
by silencing of PAX3 and PAX3/FKHR, respectively. There are different explanations for this result; 
first, eRMS and aRMS represent two different histological subtypes of RMS with distinct molecular 
profiles, histology and clinical outcome. While the aRMS subtype is in most cases associated with a 
specific translocation, no consistent chromosomal rearrangements have been identified in eRMS so 
far. However, gains and losses of whole chromosomes have been described in eRMS (Bridge et al., 
2000; Weber-Hall et al., 1996) and frequently loss of heterozygocity at the 11p15 locus could be 
detected.  Moreover, alterations of genomic imprinting in this locus could be identified (Scrable et al., 
1989). The frequent loss of heterozygocity and involvement of genomic imprinting suggest that 
inactivation of a tumour suppressor gene located in this region could contribute to eRMS 
tumourgenesis, as both copies of a gene could be inactivated sequentially. 
Secondly, PAX3 on its own is a less potent transactivator then PAX3/FKHR; therefore the expression 
levels of its target genes don’t necessarily have to be altered in a prominent way as can be observed 
in translocation-positive aRMS. Indeed, PAX3/FKHR dependent gene signatures could be identified by 
overexpression studies in heterologues systems  such as osteosarcoma cell line, SaOS-2 (Begum et 
al, 2005)  and cell lines remodelling eRMS, RD (Begum et al, 2005; Davicioni et al, 2006). Such an 
approach of ectopically expressed PAX3 in medulloblastoma cell line, DAOY,  revealed set of genes, 
altered in their expression by stronger PAX3 expression as compared to endogenous levels (Mayanil 
et al., 2006). However, in this approach no difference between direct target genes and genes 
regulated indirectly could be determined. Moreover, not all published microarray data could be 
compared with our data set, as data obtained with different array techniques (Khan et al., 1999) and 
data from mouse cell line (Nabarro et al., 2005) could not be incorporated into the comparison. 
Third, although RMS is thought to originate from myogenic precursor cells, the precise cell type from 
which the RMS subtypes originate is still a matter of debate. Recent findings support the hypothesis  
that the cell of origin in eRMS and aRMS might be different, as introduction of same panel of genetic 
changes leading to rhabdomyosarcoma in more or less differentiated human skeletal muscle cell of 
origin gave rise to different tumor morphologies (Linardic et al., 2005). In relation to that, differentiation 
status might be different in eRMS and aRMS cell of origin, as no induction of differentiation-associated 
genes could be detected in RD cells, but in Rh4 cells. Consistent with these findings, cell-type-specific 
regulation of target genes by PAX3 and PAX3/FKHR is possible and was supported by findings of 
Begum et al., revealing a distinct but overlapping set of genes targeted by PAX3/FKHR and PAX3 in a 
cell-type specific manner. 
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For our analytical set up to identify relevant PAX3 target genes, in vivo data is crucial; therefore a 
gene signature specifically associated with PAX3 expression in eRMS biopsy samples woeld be 
desirable. To our knowledge, no gene signature from eRMS biopsy samples which depends 
exclusively on PAX3 expression has been published so far. Taking into account that PAX3 expression 
is required for cancer cell survival in eRMS (Bernasconi et al, 1996) and - suggested by our results 
and confirmed in previous studies - in melanoma cells (Scholl et al, 2001; Muratovska et al, 2003), and 
most eRMS cell line show increased PAX3 expression (Bernasconi et al, 1996; Barr et al, 1999) it can 
be assumed that the PAX3 expression plays a significant role in oncogenic processes in eRMS.  
One gene identified by our comparison approach appears to be regulated in osteosarcoma cells, RD 
cells and RMS biopsy samples by both, PAX3 and PAX3/FKHR is PRKAR2B, a cAMP dependent 
protein. This was an unexpected result, as no other known target of PAX3 or PAX3/FKHR appeared to 
be regulated in cell independent manner. Moreover, no implication of PRKAR2B in eRMS 
development has been described so far. As shown recently, protein kinase A targets the transcription 
factor CREB and plays a role in the induction of myogenic determination genes such as PAX3, MyoD 
and Myf5 via Wnt signaling (Chen et al., 2005). However, direct activation of PAX3 by CREB is 
possible, as core CRE sites are present in the promoter region of PAX3. Thus, physiologic interaction 
between PAX3 and PRKAR2B could contribute to signal transduction impeding myogenic 
differentiation and thus contribute to tumorigenesis in eRMS. However, although microarray data from 
several independent studies suggest PAX3 dependent regulation of PRKAR2B in different cell types 
and its contribution to cancer formation as a signal molecule is likely, no further studies of PRKAP2B 
role in eRMS are available to date. We therefore aim to reveal the role of PRKAR2B in our eRMS cell 
models, which is the subject of ongoing work. 
It has been shown in different studies including this one, that PAX3 plays a role in apoptosis and cell 
survival. Although the anti-apoptotic protein bcl-xl has been described to be regulated by PAX3 
(Margue et al., 2000), little is known about pathways mediating the anti-apoptotic properties of PAX3. 
One possible pathway how apoptosis is mediated in RD could be determined with our microarray 
study, namely the TNF-related apoptosis-inducing ligand (TRAIL) pathway. TRAIL induced apoptosis 
could be an important aspect in clinical treatment since there are numerous studies describing TRAIL 
resistance in different sarcoma types (Komdeur et al., 2004). Indeed, TRAIL-sensitive cell lines of both 
embryonal and alveolar histology have been described (Petak et al., 2000). RD cells were found to be 
highly sensitive to TRAIL pathway in this study, thus supporting our findings. Nevertheless, no 
involvement of TRAIL pathway in Rh4 cells could be detected by microarray analysis in our approach. 
Thus, the physiological relevance of our microarray data remains to be proven. However, this 
approach may be important for development of new therapeutic approaches for the treatment of RMS.  
Our approach of combination of RNAi mediated silencing of PAX3 transcription factor with subsequent 
microarray analysis revealed one possibility for the search of new pathways for better therapeutically 
relevant targets and treatments. Moreover, our data complies with previous findings supporting the 
theory that eRMS and aRMS represent distinct entities with likely different origins where besides 
altered expression of PAX3 or PAX3/FKHR additional molecular alterations contribute to 
tumorgenesis.  
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Figure legends  
 
Figure 1 Physiological effects of PAX3 silencing in RD cells 
(A) mRNA and protein levels of PAX3 as measured by qRT-PCR analysis and Western blot after RNAi 
mediated downregulation in eRMS cell RD. For mRNA levels, the ratio of siRNA to scRNA (control) 
treatment is shown in %.  In the densiometric analysis of protein amount the  siRNA and scRNA 
(control) treated samples were normalized with PCNA levels and the ratio calculated (B) Proliferation 
of RD cells as measured by MTT assay after 72h of treatment with either PAX3 specific siRNA, 
scRNA, siRNA targeting GAPDH, or transfection reagent alone (GeneEraser). The means ±standard 
deviations (error bars) from three independent triplica experiments are shown. (C) ) Induction of 
apoptosis in RD cells after the indicated time periods of treatment with either PAX3 specific siRNA, 
scRNA, siRNA targeting GAPDH or GeneEraser (transfection reagent) as measured by caspase-3/7 
assay. Fold change values of caspase activity of treated vs. non-treated cells from two independent 
triplica experiments are shown. 
 
 
Figure 2 Changes in gene expression after PAX3 and PAX3/FKHR silencing in eRMS and aRMS cells 
 (A) Diagram depicting normalized expression values (log10 scale) of 1834 specifically downregulated 
genes as measured in Rh4 cells 24h after PAX3/FKHR silencing.  Global expression changes were 
measured in Rh4 cells after 0, 24, 48 and 72hrs of treatment with PAX3-specific siRNA. Each line 
represents the expression of one gene. (B) Blot depicting the sam set of genes of control-treated Rh4 
cells (scRNA). (C) Diagram depicting normalized expression values (log10 scale) of 340 specifically 
downregulated genes as measured in RD cells 0, 24h, 48 and 72hrs after PAX3 silencing. (D) 
Expression pattern of control-treated Rh4 cells (scRNA) as in C. (E) Diagram depicting the overlap 
between PAX3/FKHR-specific downregulated genes identified in Rh4 cells and genes downregulated 
after PAX3-specific siRNA treatment. 98 genes are present in both sets of genes. (F) Graphic 
representation depicting the ontology of the 98 potential PAX3 and PAX3/FKHR target genes 
identified in E. A complete list of the functions as well as downregulation levels of the 98 genes in RD 
and Rh4 cells is shown in Tab. 1.  
 
Figure 3 Comparison of genes downregulated in RD after PAX3 silencing and induced by PAX3 
overexpression in osteosarcoma cells 
Venn diagram representing the overlap between 338 genes specifically downregulated in RD cells, 98 
genes specifically downregulated in RD and Rh4 cells and published set of 28 genes induced by 
overexpression of PAX3 in osteosarcoma cells (Begum et al., 2005). All gene names identified by the 
overlap are listed in Table 2 and 3. 
 
Figure 4 Comparison of genes downregulated in RD after PAX3 silencing and induced by PAX3/FKHR 
overexpression in osteosarcoma and RD cells 
(A) Venn diagram representing the overlap between 338 genes specifically downregulated in RD cells, 
98 genes specifically downregulated in RD and Rh4 cells and published set of 389 genes induced by 
overexpression of PAX3/FKHR in RD cells (Davicioni et al., 2006). All gene names identified by the 
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overlap are listed in Table 2 and 3.  (B) Venn diagram representing the overlap between 338 genes 
specifically downregulated in RD cells, 98 genes specifically downregulated in RD and Rh4 cells and 
published set of 65 genes induced by overexpression of PAX3/FKHR in osteosarcoma cells (Begum et 
al., 2005). All gene names identified by the overlap are listed in Table 2 and 3. 
 
Figure 5 Comparison of RD cells gene expression changes and biopsy data  
(A) Venn diagram depicting the overlap between a PAX3(7)/FKHR-specific gene signature consisting 
of 417 genes resp. 534 genes derived from RMS biopsies and 98 genes downregulated by PAX3-
specific siRNA treatment in both, RD and Rh4 cells (B) Venn diagram depicting the overlap between a 
PAX3(7)/FKHR-specific gene signature consisting of 417 genes resp. 534 genes derived from RMS 
biopsies and 338 genes downregulated by PAX3-specific siRNA treatment in RD cells 
 
Figure 6 TRAIL pathway involved in PAX3 mediated apoptosis  
(A) Scheme of TRAIL pathway is shown, apoptosis-related genes identified by microrray analysis are 
highlighted in red.  
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Figure 2 
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 Figure 3 
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Figure 4 
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Figure 5 
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  KIAA0669 KIAA0669 gene product 
  NEU3  sialidase 3 (membrane sialidase) 
  NUDT4 nudix (nucleoside diphosphate linked 
moiety  X)-type motif 4 
A B 
98 genes  
eRMS and  
aRMS
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Figure 6 
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Tab. 1 Ontology and downregulation levels of 98 PAX3 and PAX3/FKHR regulated genes 
 
Gene Name Common Description 
RD 
fold 
down 
Rh4 
fold 
down 
Signal transduction 
204966_at BAI2 brain-specific angiogenesis inhibitor 2 1.5 2.1 
209236_at SLC23A1 Contains the 3' end of the SLC23A1 gene encoding solute carrier family 23 (nucleobase transporters) member 1 1.5 3.9 
207990_x_at ACRV1 acrosomal vesicle protein 1 1.5 4 
209392_at ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin) 1.6 3.6 
213305_s_at PPP2R5C protein phosphatase 2, regulatory subunit B (B56), gamma isoform 1.6 6.4 
219744_at FN3K fructosamine-3-kinase 1.6 3 
204037_at EDG2 endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 2 1.7 3.6 
201602_s_at PPP1R12A protein phosphatase 1, regulatory (inhibitor) subunit 12A 1.7 8.7 
221372_s_at P2RX2 purinergic receptor P2X, ligand-gated ion channel, 2 1.8 2.9 
208376_at 
CCR4; 
CKR4; k5-5; 
CMKBR4; 
ChemR13; 
CC-CKR-4 
chemokine (C-C) receptor 4; Homo sapiens chemokine (C-
C motif) receptor 4 (CCR4), mRNA 1.9 4 
203126_at IMPA2 inositol(myo)-1(or 4)-monophosphatase 2 1.9 1.5 
206084_at PTPRR protein tyrosine phosphatase, receptor type, R 2.0 2 
215524_x_at Hs.495215 T-cell antigen receptor alpha (TCRA) 2.1 7.5 
218180_s_at EPS8L2 EPS8-like 2 3.1 5.1 
203680_at PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta 3.9 3.8 
220764_at PPP4R2 protein phosphatase 4, regulatory subunit 2 3.9 3.7 
206249_at MAP3K13 mitogen-activated protein kinase kinase kinase 13 4.0 6.1 
212977_at CMKOR1 chemokine orphan receptor 1 7.3 3.1 
209697_at PPP3CC protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform (calcineurin A gamma) 9.1 2.8 
209795_at CD69 CD69 antigen (p60, early T-cell activation antigen) 10.4 3.6 
DNA and/or protein binding 
220748_s_at ZNF580 zinc finger protein 580 1.5 1.6 
207605_x_at H-plk Krueppel-related zinc finger protein 1.6 7.7 
213473_at BRAP BRCA1 associated protein 1.6 2.3 
220292_at ZNF434 synonyms: MGC4179, FLJ20417, FLJ31901; Homo sapiens zinc finger protein 434 (ZNF434), mRNA 1.7 9.1 
202600_s_at NRIP1 nuclear receptor interacting protein 1 1.7 1.9 
208003_s_at NFAT5 nuclear factor of activated T-cells 5, tonicity-responsive 1.8 1.6 
210954_s_at TSC22D2 TSC22 domain family 2 1.9 19.7 
214774_x_at TNRC9 trinucleotide repeat containing 9 2.6 5.2 
222026_at RBM3 RNA binding motif (RNP1, RRM) protein 3 2.7 2.7 
202617_s_at MECP2 methyl CpG binding protein 2 (Rett syndrome) 2.9 3.1 
214447_at ETS1 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) 3.4 3.6 
209870_s_at APBA2 amyloid beta (A4) precursor protein-binding, family A, member 2 (X11-like) 3.5 2.3 
213068_at DPT dermatopontin 4.2 3.1 
214451_at TFAP2B transcription factor AP-2 beta (activating enhancer binding protein 2 beta) 8.9 2.6 
209243_s_at PEG3 paternally expressed 3 11.9 2.9 
204907_s_at BCL3 B-cell CLL/lymphoma 3 15.7 2.7 
Structural molecules 
206835_at STATH statherin 1.5 2.2 
203045_at NINJ1 ninjurin 1 1.6 2 
208623_s_at VIL2 villin 2 (ezrin) 1.6 3.5 
207146_at KRTHA2 keratin, hair, acidic, 2 1.9 2.5 
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206509_at PIP prolactin-induced protein 2.3 3.8 
203352_at ORC4L origin recognition complex, subunit 4-like (yeast) 3.3 2.8 
Enzymes 
215867_x_at CA12 carbonic anhydrase XII 1.5 3.4 
213540_at HSD17B8 hydroxysteroid (17-beta) dehydrogenase 8 1.5 3.7 
220641_at NOX5 NADPH oxidase, EF hand calcium-binding domain 5 1.5 2.6 
213991_s_at HS3ST1 heparan sulfate (glucosamine) 3-O-sulfotransferase 1 1.5 4.6 
219113_x_at DHRS10 dehydrogenase/reductase (SDR family) member 10 1.5 6.7 
207751_at DPYS dihydropyrimidinase 1.6 3.1 
205369_x_at DBT dihydrolipoamide branched chain transacylase  1.9 2.4 
205778_at KLK7 kallikrein 7 (chymotryptic, stratum corneum) 1.9 2.1 
206867_at GCKR glucokinase (hexokinase 4) regulatory protein 2.2 2.2 
219028_at HIPK2 homeodomain interacting protein kinase 2 2.3 2 
207316_at HAS1 hyaluronan synthase 1 2.3 3.1 
214627_at EPX eosinophil peroxidase 2.4 2.5 
213536_s_at UBE2I ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast) 2.6 3.1 
205652_s_at TTLL1 tubulin tyrosine ligase-like family, member 1 3.0 3.2 
213952_s_at ALOX5 arachidonate 5-lipoxygenase 3.5 3.1 
205158_at RNASE4 ribonuclease, RNase A family, 4 3.9 4.1 
209993_at ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 4.0 2.2 
201815_s_at TBC1D5; KIAA0210 
Homo sapiens TBC1 domain family, member 5 (TBC1D5), 
mRNA 4.9 9.3 
Metabolism 
215085_x_at DLEC1 deleted in lung and esophageal cancer 1 1.5 1.7 
217556_at CLCN4 chloride channel 4 1.5 4.4 
200866_s_at PSAP prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy) 1.6 2.6 
204984_at GPC4 glypican 4 1.6 5.8 
219911_s_at SLCO4A1 solute carrier organic anion transporter family, member 4A1 1.7 12.5 
210440_s_at CDC14A CDC14 cell division cycle 14 homolog A (S. cerevisiae) 1.8 3.6 
205738_s_at FABP3  fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor) 1.8 5.9 
210164_at GZMB granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) 2.0 2 
204454_at LDOC1 leucine zipper, down-regulated in cancer 1 2.5 2.8 
214287_s_at CDC2L5 cell division cycle 2-like 5 (cholinesterase-related cell division controller) 5.6 4 
210240_s_at CDKN2D cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) 8.4 2.1 
215047_at TRIM58 tripartite motif-containing 58 12.8 14.6 
Others 
212483_at IDN3 IDN3 protein 1.5 1.5 
221031_s_at DKFZP434F0318 hypothetical protein DKFZp434F0318 1.5 11.4 
219252_s_at FLJ20514 hypothetical protein FLJ20514 1.6 3.5 
214204_at PACRG PARK2 co-regulated 2.1 5.1 
218591_s_at FLJ14075 hypothetical protein FLJ14075 2.5 5.6 
222325_at NCRMS non-coding RNA in rhabdomyosarcoma (RMS) 2.6 3.1 
216562_at SRMP1; dJ1057D4.1 
spermidine synthase (SPDSY) pseudogene match: 
proteins: Sw:O82147 Sw:Q12074 Sw:Q09741 Sw:Q64674;  2.8 4.4 
212289_at ANKRD12 ankyrin repeat domain 12 2.9 3.6 
216063_at HBBP1 hemoglobin, beta pseudogene 1 2.9 2 
217252_at OSIL;A170; p62B oxidative stress induced like 3.0 2.3 
217239_x_at 
 VH gene family III; VDJ rearrangement; Homo sapiens 
lymphocyte-predominant Hodgkin's disease case #4 
immunoglobulin heavy chain gene, variable region, partial 
cds 
3.0 4.9 
221273_s_at DKFZP761H1710 hypothetical protein DKFZp761H1710 3.5 1.5 
217362_x_at HLA-DRB3 major histocompatibility complex, class II, DR beta 3 3.6 2.8 
216163_at HBLD2 HESB like domain containing 2 4.5 3.8 
204047_s_at C6orf56 chromosome 6 open reading frame 56 4.9 6 
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Table 2. Comparison of 98 genes, specifically downregulated in RD and Rh4 cells with published data 
 
 
Gene name Description 
1. Genes upregulated by PAX3 in osteosarcoma cells (Begum et al., 2006) 
PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta 
2. Genes upregulated by PAX3/FKHR in osteosarcoma cells (Begum et al., 2006) 
PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta 
3. Genes upregulated in RD upon ectopic expression of PAX3(7)/FKHR (Supplementary Table 
S3) 
CMKOR1 chemokine orphan receptor 1 
STATH statherin 
LDOC1 
 leucine zipper, down-regulated in cancer 
PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta 
4. in-vivo data obtained from biopsies (Wachtel et. al., 2004) 
 
TFAP2B 
 
transcription factor AP-2 beta (activating enhancer  binding protein 2 
beta) from Pol II promoter 
DZIP3 zinc finger DAZ interacting protein 3 
LDOC1 leucine zipper, down-regulated in cancer 
EDG2 
 
endothelial differentiation, lysophosphatidic acid G-protein-coupled 
receptor, 2 
FGFR2 
fibroblast growth factor receptor 2 (bacteria-expressed kinase, 
keratinocyte growth factor receptor, craniofacial dysostosis 1, Crouzon 
syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome) 
5. Signature identified by Triche (Supplementary Table S2) 534 genes 
TFAP2B 
 
transcription factor AP-2 beta (activating enhancer  binding protein 2 
beta) from Pol II promoter 
PRKAR2B 
 protein kinase, cAMP-dependent, regulatory, type II, beta 
EDG2 endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 2 
GPC4 glypican 4 
PEG3 paternally expressed 3 
DZIP3 zinc finger DAZ interacting protein 3 
FGFR2 
fibroblast growth factor receptor 2 (bacteria-expressed kinase, 
keratinocyte growth factor receptor, craniofacial dysostosis 1, Crouzon 
syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome) 
TNRC9 trinucleotide repeat containing 9 
TSC22D2 TSC22 domain family 2 
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Tab 3. Comparison of 338 genes, specifically downregulated in RD cells with published data 
 
Gene name Description 
1. Genes upregulated by PAX3 in osteosarcoma cells (Begum et al., 2006) 
SEMA3 sema domain, secreted, (semaphorin) 3C 
PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta 
2. Genes upregulated by PAX3/FKHR in osteosarcoma cells (Begum et al., 2006) 
PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta 
CALCRL calcitonin receptor-like 
SCAMP1 secretory carrier membrane protein 1 
SEMA3C sema domain, secreted, (semaphorin) 3C 
3. Genes upregulated in RD upon ectopic expression of PAX3(7)/FKHR (Supplementary Table 
S3) 
PAX5 paired box gene 5 (B-cell lineage specific activator protein) 
MAGEL2 MAGE-like 2 
SCN3A sodium channel, voltage-gated, type III, alpha 
LRP5 low density lipoprotein receptor-related protein 5 
LDOC1 leucine zipper, down-regulated in cancer 1 
PRKAR2B Protein kinase, cAMP-dependent, regulatory, type II, beta 
CMKOR1 chemokine orphan receptor 1 
SATB1 special AT-rich sequence binding protein 1 (binds to nuclear matrix/scaffold-associating DNA's) 
STATH statherin 
4. in-vivo data obtained from biopsies (Wachtel et. al., 2004) 
UBE2G2 ubiquitin-conjugating enzyme E2G 2 (UBC7 homolog, yeast) 
TU3A TU3A protein 
LDOC1 leucine zipper, down-regulated in cancer 1 
EDG2 endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 2 
KIAA0523 KIAA0523 protein 
 
TFAP2B 
 
transcription factor AP-2 beta (activating enhancer  binding protein 2 
beta) from Pol II promoter 
DZIP3 zinc finger DAZ interacting protein 3 
FGFR2 
fibroblast growth factor receptor 2 (bacteria-expressed kinase, 
keratinocyte growth factor receptor, craniofacial dysostosis 1, Crouzon 
syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome) 
KIAA0669 KIAA0669 gene product 
NEU3 sialidase 3 (membrane sialidase) 
NUDT4 nudix (nucleoside diphosphate linked moiety X)-type motif 4 
TBCD tubulin-specific chaperone d 
5. Signature identified by Triche (Supplementary Table S2) 534 genes 
PAX5 paired box gene 5 (B-cell lineage specific activator protein) 
MAGEL2 MAGE-like 2 
KIAA0657 KIAA0657 protein 
KIAA0523 KIAA0523 protein 
SC65 synaptonemal complex protein SC65 
PRKX protein kinase, X-linked 
PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta 
 
TFAP2B 
 
transcription factor AP-2 beta (activating enhancer  binding protein 2 
beta) from Pol II promoter 
DZIP3 zinc finger DAZ interacting protein 3 
EDG2 endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 2 
FGFR2 
fibroblast growth factor receptor 2 (bacteria-expressed kinase, 
keratinocyte growth factor receptor, craniofacial dysostosis 1, Crouzon 
syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome) 
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GPC4 glypican 4 
HBLD2 HESB like domain containing 2 
PEG3 paternally expressed 3 
PTP4A3 protein tyrosine phosphatase type IVA, member 3 
RRBP1 ribosome binding protein 1 homolog 180kDa (dog) 
SCAMP1 secretory carrier membrane protein 1 
TBCD tubulin-specific chaperone d 
TNRC9 trinucleotide repeat containing 9 
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Abstract 
Constitutive active signaling pathways are a characteristic phenomenon for many tumor types and tumor 
cells are often addicted to continuous signaling. Specific inhibition of such pathways has been 
demonstrated to be an effective therapeutic approach in different tumors. So far, mainly upstream 
components of these pathways have been used as molecular targets, such as growth factor receptors, 
which contain drugable enzymatic activities. However, in many tumors more downstream components of 
signaling pathways are mutationally activated, such as in alveolar rhabdomyosarcoma (aRMS), in which 
specific translocations lead to the formation of the chimaeric transcription factor PAX3/FKHR. Here, we 
present evidence for a mechanism allowing regulation of PAX3-FKHR activity by the kinase inhibitor 
PKC412 (N-benzoyl-staurosporine). The drug influences the phosphorylation status of PAX3-FKHR and 
hence its transcriptional activity. Furthermore, we demonstrate a potent antitumorigenic potential of 
PKC412 for aRMS in vitro and in vivo. Our study suggests that targeting of kinases controlling the activity 
of oncogenic transcription factors by small molecule inhibitors is a promising therapeutic strategy against 
cancer.   
 
 
Introduction 
Most tumors show molecular aberrations in signal transduction pathways controlling proliferation, 
apoptosis, angiogenesis and metastasis. In principle, such aberrations can occur at any site of the signal 
transduction cascade, including transmembrane growth factor receptors at the beginning of a cascade 
(e.g., EGF-R, VEGF-R, FLT-3), more downstream located cytoplasmic signal transduction kinases (e.g., 
mTOR, PKC, AKT/PKB) {Blume-Jensen, 2001 #369} {Gschwind, 2004 #370} {Bianco, 2006 #371} or 
transcription factors (TF) at the end of a cascade directly leading to disregulated gene expression.  
Importantly, in many tumor types, tumors cells have been shown to acquire a dependency on these 
constitutive active signaling cascades. Hence, inhibition of the aberrant constitutive signaling inhibits 
tumor growth and since the success of Gleevec as a targeted therapy for chronic myeloid leukemia (CML), 
the principle of specific targeting of aberrant signal transduction pathways by small molecule inhibitors is 
thought to be a promising method to fight cancer {Manley, 2002 #372} {Levitzki, 2002 #373} which has 
been expanded to many other tumor types. This approach seems especially suitable for tumors with 
aberrations in upstream components of signaling cascades, cell surface receptors, or cytoplasmic signal 
transduction kinases, as the involved proteins are easily accessible for inhibiting antibodies or often 
contain drugable enzymatic activities. So far, it has not been applied to tumors containing aberrations 
located at the end of signaling cascades, such as TF, for which fewer, if any, specific small molecule 
inhibitors are available. However, as TF represent the second most frequently mutated class of proteins in 
tumors {Futreal, 2004 #307}, the availability of specific inhibitory compounds against this class of proteins 
would broaden the principle of targeted therapy to many additional tumor types.   
Rhabdomyosarcoma (RMS) accounts for 5 – 8 % of all pediatric malignancies and is the most common 
soft tissue sarcoma diagnosed in children {Merlino, 1999 #374}, and no targeted drug therapy  is available 
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so far. Histopathologically, RMS can be classified into various subtypes with two major forms, alveolar 
RMS (aRMS) and embryonal RMS (eRMS). 80% of the aRMS are characterised by specific translocations 
that are absent in eRMS. These translocations always include the N-terminal part of PAX3 or PAX7 which 
in the majority of cases are fused to the C-terminal part of FKHR generating the chimaeric transcription 
factors PAX3/FKHR (t(2;13)(q35;q14)) or PAX7/FKHR (t(1;13)(p36;q14)). Furthermore, in single cases 
NCOA1 {Wachtel, 2004 #257} and AFX {Barr, 2002 #43} have been found as PAX3(7) fusion partners. 
Overexpression of these translocation products, especially of PAX3-FKHR, is associated with a poor 
prognosis {Sorensen, 2002 #107}. Hence, the 5-year survival rate of aRMS patients is much lower (30 %) 
compared to the one of eRMS patients (60 %) {Raney, 2001 #375}, and once metastasizing, aRMS 
become resistant to conventional chemo- and radiotherapy. Therefore, new therapeutic agents are 
urgently needed to increase the survival rate of aRMS patients. 
Importantly, tumor cell survival of translocation-positive aRMS is dependent on continuous expression of 
the fusion proteins. Downregulation of PAX3/FKHR by antisense oligonucleotide treatment induces 
apoptotic cell death in aRMS cell lines {Bernasconi, 1996 #333}. Furthermore, inhibition of PAX3 target 
genes using a KRAB-PAX3 repressor leads to tumor growth inhibition and apoptosis in vivo {Ayyanathan, 
2000 #376}. However, the technical complexity of their application in vivo prevents a clinical 
implementation of antisense nucleic acids in the near future. Therefore, the identification of other, clinically 
applicable, mechanisms for PAX3-FKHR inhibition would be of great interest.  
In this study, we present evidence for a mechanism allowing regulation of PAX3/FKHR activity by the 
kinase inhibitor PKC412 {Fabbro, 2000 #327}. PKC412 is known as a potent inhibitor of several kinases 
including PKC, Akt/PKB, c-Kit, FLT3, and FGFR, and was evaluated in phase II clinical trials for AML 
patients {Tenzer, 2001 #365} {Schmidt-Arras, 2004 #377} {Chen, 2005 #354} {Stone, 2005 #337}. As we 
show here, the drug can influence the phosphorylation status of PAX3/FKHR and hence its transcriptional 
activity. Furthermore, we demonstrate a potent antitumorigenic potential of PKC412 for aRMS in vitro and 
in vivo. These studies suggest that targeting kinases controlling activity of oncogenic transcription factors 
by small molecule inhibitors is a promising therapeutic strategy against cancer.   
 
 
Material and Methods  
 
Cell lines and pharmacological inhibitors 
Two human aRMS cell lines (Rh4, Rh30) and two eRMS cell lines (RD, Ruch-2) were used. The Rh4 cell 
line was obtained from the St. Jude Children’s Hospital, Memphis, USA. The Rh30 and RD cell lines were 
purchased from ATCC (Rockville, MD, USA). The RUCH-2 cell line was established in our laboratories 
{Scholl, 2000 #368}. For ectopic expression studies of PAX3/FKHR, the human embryonal kidney cell line 
293T was used (ATCC). All cell lines were grown in Dulbecco’s modified Eagle’s medium supplemented 
with 2 mM L-glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin and 10 % FCS (Invitrogen, Basel, 
Switzerland) at 37°C, 5 % CO2. 
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The following compounds were used: PKI166 (EGFR/ErbB2 inhibitor), CGP59326 (EGFR inhibitor), NVP-
ABG424-NX-4 (c-met inhibitor), PKC412 (N-benzoyl-staurosporine; inhibitor of different kinases, among 
them PKC, FGFR2/4, Flt3) and rapamycin (mTOR inhibitor). Rapamycin was purchased from Sigma 
(Buchs, Switzerland), all other inhibitors were provided by Novartis (Basel, Switzerland). Concentrations 
used in this study were chosen on the basis of preliminary dose-response experiments. 
 
MTT Assay: 
24 hours after seeding in 96-well plates (10’000 cells / well) cells were treated with pharmacological 
inhibitors in a volume of 100 µl medium including 10% serum for 96 hours. MTT assays (Roche, Rotkreuz, 
Switzerland) were then performed according to the manufacturer’s protocol to measure cell numbers.  
For IC50 determination, cells were exposed to PKC412 concentrations ranging from 0 - 10 µM. After 96 
hours, cell viability was detected by MTT. IC50 values were calculated by nonlinear regression analysis 
using the GraphPad Prism software (GraphPad Software Inc., USA). 
 
Trypan Blue Exclusion assay: 
For determining cell viability, 106 cells were seeded in a 10 cm dish. 24 hours later, the pharmacological 
inhibitors were added to the medium. After 96 hours incubation, floating and adherent cells were pooled, 
spun down and resuspended in a defined volume of medium. After diluting the cells 1:1 with 0.4 % of 
trypan blue solution (Sigma, Buchs, Switzerland), alive and dead cells were counted in a Neubauer 
chamber. 
 
Caspase-3 assay: 
To evaluate induction of apoptosis, active caspase-3 was detected by using the CaspGLOW red active 
caspase-3 staining kit (Biovision, USA) according to the instructions given by the manufacturer. Briefly, 3 x 
105 cells per 6-well were treated with 0.5 µM PKC412 for 24 - 72 hours. At each time point, floating and 
trypsinized cells were pooled, spun down, and incubated with Red-DEVD-FMK caspase-3 inhibitor for 45 
min at 37°C. Cells positive for active caspase-3 were scored by fluorescence microscopy.  
  
Immunoblotting: 
Cells were washed once with icecold PBS and harvested by scraping in lysis buffer (20 mM Tris-Cl pH 
7.5, 150 mM NaCl, 1 mM EDTA, 1 % NP-40, 10 % glycerol) containing 1x complete protease inhibitor 
cocktail (Roche, Rotkreuz, Switzerland). After incubation for 15 min on ice, lysates were centrifuged at 
13’000 g for 5 min and supernatants were frozen at -80°C until use. Lysates (30 µg/lane) were resolved by 
SDS-PAGE and transferred to nitrocellulose membranes (Protean; Schleicher & Schuell, Kassel, 
Germany). Membranes, blocked with 5 % BSA in TBS and Tween-20 (0.1 % w/v), were then probed with 
primary and HRP-coupled secondary antibodies using standard protocols. Primary antibodies used were 
rabbit polyclonal anti-PARP (1:XXX; Cell Signaling Technology, Danvers, USA) and mouse anti-tetra His 
(1:1000; Qiagen). Visualization of the antibodies was performed by using the enhanced ECL system 
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(Amersham, Buckinghamshire, UK). 
 
Immunofluorescence 
Cells plated on gelatine-coated glass coverslips were washed once with DPBS, fixed with 3% 
paraformaldehyd in PBS for 15 min, washed with DPBS and incubated with 0.1 M glycine in PBS for 5 
minutes. After washing, the cells were permeabilized with 0.2% Triton X-100 in PBS for 15 minutes and 
washed with DPBS. The cells were then incubated with the primary antibody (anti-tetra-His, 1:200; 
Qiagen) in PBS containing 3% BSA for 1 hour at room temperature. After washing three times for 5 
minutes with DPBS the cells were incubated with a 1:200 dilution of Alexa488-labeled secondary antibody 
(1:200; XXX) in PBS containing 3% BSA for 1 hour at room temperature. After washing three times for 5 
minutes with DPBS, the coverslips were drained and mounted in XXX solution (). The coverslips were 
sealed with nail polish and examined by fluorescence microscopy. 
 
Purification of the PAX3 DNA-binding domain protein 
The PAX3 part represented in the translocation product PAX3/FKHR (AA1-391 of PAX3), including both 
the PAX3 paired- and homeodomain, was HIS-tagged (PAX3His) in pcDNA3 vector and transiently 
expressed in 293T cells. 48 hours after transfection the cells were lysed for 30 min on ice in a buffer 
containing 50 mM NaH2PO4 (pH 8.0), 1% Triton X-100, 300 mM NaCl, 10 mM imidazole, 40 mM NaF, 10 
mM β-glycerolphosphate, 1 mM Na3VO4, 1mM EGTA, and 1x complete protease inhibitor mix including 1 
mM EDTA (Roche, Rotkreuz, Switzerland). After centrifugation of the extract at 10’000 g for 10 min, the 
supernatant was incubated with 8 μl/ml 50% Ni-NTA agarose slurry (Qiagen) for 2 hours at 4°C under 
constant rotation. The Ni-NTA agarose was then washed 4 times with a buffer containing 50 mM NaH2PO4 
(pH 8.0), 300 mM NaCl, and 20 mM imidazole, and 2 times with a similar washing buffer containing 50 
mM imidazole. The protein was then eluted with a buffer containing 50 mM NaH2PO4 (pH 8.0), 300 mM 
NaCl and 250 mM imidazole. 
Protein purity and concentrations were determined on a bioanalyzer using protein 200 assay chips 
(Agilent Technologies, Waldbronn, Germany) 
 
Desalting of the purified PAX3 protein 
200 μl of the purified PAX3 solution was desalted on a C8 reversed-phase HPLC column (Brownlee 
Aquapore RP-300, 2.1 x 100 mm, PerkinElmer, Shelton, USA). The protein was eluted with the following 
HPLC program: (i) isocratic flow 0 % solvent B (v/v) for 10 min; (ii) linear gradient from 0 to 75 % B in 13 
min; (iii) linear gradient from 75 to 100 % B in 5 min; and (iv) isocratic flow 100 % B for 10 min. Solvents A 
and B were 0.1 % trifluoroacetic acid (TFA) and 0.07 % TFA in 80 % acetonitrile, respectively.  
 
2D-SDS-PAGE 
100 μl of the desalted protein solution was dried in a vacuum centrifuge. Isoelectric focusing was 
performed on an IPGphor electrophoresis unit(Amersham Pharmacia Biotech, Uppsala, Sweden) 
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according to standard protocols (Gorg et al., 2000). Immobiline IPG strips with a non linear pH gradient of 
3-10 (Amersham) were used and the samples were applied on the strips by in-gel rehydration. SDS-PAGE 
was carried out on a Protean II xi system (Bio-Rad, Hercules, CA, USA). Gels consisted of 13 % w/v 
acrylamide with 2.7 % piperazine diacrylamide  (PDA) as crosslinker. Gel dimensions were 20 x 16 x 0.15 
cm and running conditions were 40 mA/gel at 15 °C. Proteins were visualized by a long silver nitrate 
staining (Rabilloud, 2000).  
 
Enzymatic digestion and LC-MALDI-TOF-MS analysis of the peptides 
200 μl of the desalted protein solution was dried in a vacuum centrifuge. The protein was redissolved in 10 
μl of a solution containing 150 mM Tris, 6 M urea, and 6 mM EDTA (pH = 8), and incubated for 2 h at 
37°C. 5 μl of a solution containing 0.5 μg of endoproteinase Lys C (Roche Diagnostics, Mannheim, 
Germany) and 45 μl H2O were added and incubated overnight at 37°C.  
6 μl of the peptide solution was loaded on a reversed-phase capillary HPLC column (PepMap C18, 0.3 x 
150 mm, LC Packings, Amsterdam, Netherlands). The peptides were separated with the following HPLC 
programm: (i) isocratic flow 5 % solvent B (v/v) for 5 min; (ii) linear gradient from 5 to 20 % B in 5 min;  (iii) 
linear gradient from 20 to 60 % B in 20 min; (iv) linear gradient from 50 to 100 % B in 5 min; (v) isocratic 
flow 100 % B for 10 min. Solvents A and B were 0.1 % TFA and 0.07 % TFA in 80 % acetonitrile, 
respectively. The flow rate was 4 μl /min. Peptides eluting from the HPLC column were collected onto a 
600 μm AnchorChipTM  target (Bruker Daltonics, Leipzig, Germany), using a Probot microfraction collector 
(LC Packings), and fractions were collected in 15 s intervals. 1.5 μl of matrix solution was added to each 
fraction. A 1:10 dilution of saturated HCCA (α-cyano-4-hydroxycinnamic acid in 33 % CH3CN, 0.1 % TFA) 
in Ethanol/Aceton 2:1 was used as matrix solution. Mass mapping was performed with an autoflex® 
MALDI-TOF-MS (Bruker Daltonik). Phosphorylated peptides were analyzed in the positive-ion mode with 
delayed extraction (60 ns) and the following voltages were applied; source 20 kV, extraction 18.80 kV, 
lens 7.85 kV. 
 
In vivo labeling with [32P]orthophosphate  
293T cells grown in 10 cm petridishes were transfected with PAX3His or empty vector. 36 hours after 
transfection, cells were washed two times with phosphate-free MEM, and then incubated for 6 hours in 
phosphate-free MEM supplemented with 80 μCi/ml [32P]orthophosphate (Phosphorous-32; GE Healthcare, 
Amersham, Buckinghamshire, UK). Thereafter, PAX3His was purified with the help of Ni-NTA agarose as 
described above. Purified proteins were then separated by SDS-PAGE and blotted onto nitrocellulose 
membrane, followed by detection of 32P with a phosphorimager (Molecular Dynamics, Sunnyvale, CA, 
USA). 
 
Transactivation assay 
pcDNA3-PAX3/FKHR together with a reporter plasmid containing the luciferase gene downstream of 
PAX3 paired- or homeodomain DNA-binding sites (6xCD19 DNA-binding sites {Czerny, 1993 #346} or P3 
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binding site {Xia, 2004 #235}) and a plasmid containing the lacZ gene was transfected into 293T cells or 
electroporated into Rh4 cells using the AMAXA system (Program O17, buffer R) in ratios ensuring 
measurement in the linear range of the assay. Similarly, pcDNA3-FKHR together with a reporter plasmid 
containing the luciferase gene downstream of the bim promoter {Motta, 2004 #217} and a plasmid 
containing the lacZ gene was transfected into 293T cells in a ratio of 1:1:0.01. 
16 hours later the cells were incubated with PKC412 or DMSO vehicle for 24h, followed by lysis in reporter 
lysis buffer (Promega, Madison, WI, USA). ß-Galactosidase and luciferase activities were determined with 
the corresponding assay systems (Promega). Luciferase activity values were normalized with the ß-
galactosidase activity values. 
 
Mutagenesis 
PAX3/FKHR mutants were generated using the “GeneTailor site-directed mutagenesis system” 
(Invitrogen) according to the manufactorer´s instructions. All constructs were sequenced for verification. 
 
Silencing of PAX3/FKHR 
SiRNA mediated silencing of PAX3/FKHR was performed as described previously (Ebauer et al.). 
 
Real time PCR 
1 µg RNA was used for cDNA synthesis with oligo-dT primers using the Omniscript kit (Qiagen) including 
DNAse treatment. Then, 5 to 10 ng cDNA was used as template for the PCR reaction under universal 
cycling parameters on an ABI7900 instrument using commercially available target probes ("Assay-On-
Demand") for the indicated genes and Mastermix (all from Applied Biosystems, Applera Europe BV, 
Rotkreuz, Switzerland). Detection of PAX3/FKHR was achieved using PAX3 forward 
(5’GCACTGTACACCAAAGCACG3’) and FKHR reverse (5’AACTGTGATCCAGGGCTGTC3’) primers 
applying the fluorescent SYBR green method (Applied Biosystems). Cycle threshold (CT) values were 
normalized to GAPDH. Relative expression levels of the target genes among the different samples were 
calculated using the CT method. 
 
RMS xenograft studies: 
107 Rh4 or Rh30 cells in 100 µl of PBS were injected into the right flank of athymic CD1 nude (nu/nu) mice 
(Charles River, Germany). When tumors reached a volume of 130 - 200 mm3, oral treatment with PKC412 
(100 mg/kg/day) or placebo for 15 days was started. Tumor diameters (d1, d2) were measured 2 -3 times a 
week using a digital calliper. Tumor volumes were calculated by using the following formula: V = (4/3) π r3, 
where r = ((d1 + d2)/4). At the end of the treatment period, mice were sacrificed, tumors were isolated and 
fixed in 4 % paraformaldehyde in PBS. Paraffin-embedded tumor sections were subjected to hematoxylin 
and eosin (H&E) stainings. Cell proliferation was assessed by Ki-67 stainings using a monoclonal rabbit 
Ki-67 antibody (1:XXX; clone SP6; NeoMarkers, Fremont, USA) and a biotinylated anti-rabbit IgG antibody 
(1:XXX; Jackson ImmunoResearch, West Grove, USA), respectively. Immunostaining was performed 
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using a standardized automated procedure on a Ventana Benchmark system (Ventana Medical Systems, 
Tucson, USA). Furthermore, apoptosis was detected by terminal deoxynucleotidyl transferase (Tdt)-
mediated nick end labeling (TUNEL) according to the instructions of the manufacturer (in situ cell death 
detection kit, Fluorescin, Roche, Rotkreuz, Switzerland). Ki-67 or TUNEL positive cells were scored in 5 - 
10 randomly selected visual fields at x200 (Ki-67) or x160 (TUNEL) magnification.  
 
 
Results 
  
Influence of kinase inhibitors on growth of RMS cells 
Recent gene expression studies of RMS biopsies {Davicioni, 2006 #335} {Wachtel, 2004 #257} identified 
a series of receptor tyrosine kinases (RTKs) with potential oncogenic capabilities highly expressed in 
embryonal and/or alveolar RMS. Among these are EGFR (ErbB1), which is highly expressed in eRMS, 
and HGFR (c-met) and FGFR2/4, which show high expression levels in aRMS. Therefore, as these RTKs 
represent interesting putative targets for RMS treatment, we tested a series of small molecule inhibitors 
targeting them in comparison to rapamycin as mTOR inhibitor {Hosoi, 1999 #332} for potential growth 
inhibitory effects on two aRMS (Rh4, Rh30) and two eRMS (RD, Ruch-2) cell lines. Expression of the 
relevant target genes in these cell lines was verified in gene expression data acquired from these cells 
and corresponded to the expected pattern (data not shown). The experiments were carried out according 
to the same general outline. Inhibitors were tested for antiproliferative effects in dose response 
experiments as assessed by MTT assay (Fig.1A). Then,  induction of cell death by the different inhibitors 
was measured by trypan blue exclusion assays (Fig.1B). For the individual drugs, we made the following 
observations: 
Rapamycin, the inhibitor of mTOR, is known to induce apoptosis in Rh30 cells when cultured in serum-
free medium. In the presence of serum, rapamycin induces cell cycle arrest {Hosoi, 1999 #332}. In our 
experiments, which were all carried out under serum-containing conditions, we could confirm the growth 
inhibitory effects of rapamycin in RMS. Both, aRMS and eRMS cells showed a reduced metabolic activity 
in the MTT assays (Fig.1A). However, no significant loss of cell viability was observed (Fig.1B). 
PKI166 and CGP59326 are known to block the activity of either both EGFR (ErbB1) and ErbB2, or only 
EGFR, respectively. In RMS cell lines, CGP59326 affected neither cell growth nor viability (Fig.1A,B). IN 
contrast, PKI166 inhibits growth of aRMS cells, more efficiently than eRMS (Fig.1A), but without significant 
induction of cell death (Fig. 1B), indicating rather inhibition of proliferation than induction of cell death in 
aRMS cell lines.   
The c-met inhibitor NVP-ABG424-NX-4 showed in all RMS cell lines only a moderate influence on cell 
growth except for RD cells (Fig. 1A). RD cells also exhibited a dramatic induction of cell death, suggesting 
that they are the only RMS cells tested which are sensitive to this drug.  
Finally, PKC412 which is known to inhibit FGFR (but also various other kinases such as PKC, PKB/Akt, 
Flt-3 and c-kit), inhibited proliferation of Rh4 and Rh30 much more effective than that of RD cells (Fig. 1A). 
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Also RUCH-2 cells showed a reduced proliferative activity. However, cell death is significantly induced 
only in the two aRMS and not in eRMS cells (Fig. 1B).  
Taken together, among the inhibitors tested, PKC412 demonstrates the most efficient anti-proliferative 
and cell death inducing effect specifically for aRMS cells. The current lack of alternative drugs for 
treatment of metastasized aRMS makes this finding especially interesting. Therefore, PKC412 was further 
characterized. 
 
PKC412 induces apoptosis in aRMS cells 
Therapeutically significant IC50 levels for PKC412 were only achieved in aRMS, but not in eRMS cells 
(Fig.2A). To investigate whether cell death is due to apoptosis, we used an activated caspase-3 assay. As 
shown in Fig. 2B, induction of caspase-3-dependent apoptosis dramatically increases in aRMS cells when 
treated with 0.5 μM PKC412 for 24-72 hours. In contrast, apoptosis is only slightly induced in eRMS cells. 
This finding was confirmed by examining cleavage of the caspase-3 substrate PARP (Fig.2C), indicative 
for active caspase-3 and therefore ongoing apoptosis, as early as 4 hours after start of incubation with 0.5 
μM PKC (Fig. 2B). Therefore, PKC412 selectively induces caspase-3 dependent apoptosis in alveolar but 
not in embryonal RMS cells. 
 
PKC412 influences the transcriptional activity of PAX3/FKHR 
As first demonstrated a decade ago, aRMS cells undergo apoptosis upon silencing of PAX3/FKHR by 
oligonucleotides {Bernasconi, 1996 #333} {Margue, 2000 #64} or siRNA (manuscript submitted), 
demonstrating that aRMS cells are strongly addicted to active PAX3/FKHR.  
Hence, we argued that PKC412 might have an influence on PAX3/FKHR activity. In the absence of 
PKC412 ectopic expression of PAX3/FKHR in HEK 293T cells induces transcription of the PAX3/FKHR-
target gene CB1 from undetectable levels in a dose dependent manner, as detected by qRT-PCR 
(Fig.3A). A point mutation (N269A) within the homeodomain of PAX3, specifically inactivating its 
homeodomain-DNA binding {Xia, 2004 #235}, prevents this induction of CB1 transcription (Fig.3A), but not 
of the paired domain dependent target gene AP2β (data not shown). This strongly suggests that induction 
of CB1 transcription in 293T cells is a direct effect of PAX3/FKHR on the promoter of this gene and not 
indirect via other proteins, confirming the results of other studies {Begum, 2005 #256}. Furthermore, also 
in Rh4 cells, the bulk part of the CB1 expression measured is PAX3/FKHR dependent, as specific 
silencing of PAX3/FKHR by siRNA reduced CB1 expression to less than 20 percent compared to 
scrambled control (Fig.3B). The transcription level of this gene was therefore used as an indicator for 
PAX3/FKHR activity in further experiments. In presence of PKC412, PAX3/FKHR-induced transcription of 
CB1 in 293T cells is inhibited in a dose-dependent manner, whereas expression of housekeeping genes 
used for normalization such as GAPDH was uninfluenced (Fig.3C). Similarly, endogenous mRNA levels of 
CB1 were reduced in Rh4 cells upon PKC412 treatment (Fig.3C). This inhibitory effect of PKC412 was 
further validated by conventional transactivation assays using luciferase reporter plasmids containing 
specific promoters for the paired domain (6xCD19) or the homeodomain (P3) of PAX3. Again in these 
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assays PKC412 strongly reduces PAX3/FKHR induced expression of the reporter in both 293T cells and 
Rh4 cells (Fig.3D).  
To exclude that PKC412 mediates these effects via downregulation of PAX3/FKHR expression, mRNA as 
well as protein levels of PAX3/FKHR were measured. Interestingly and contrary, incubation of 
PAX3/FKHR-transfected 293T cells with PKC412 led to an increase of PAX3/FKHR on the mRNA level as 
measured by qRT-PCR (Fig.3E) as well as on the protein level as determined by Western blot analysis 
(Fig.3F). Taken together, these results suggest that PKC412 modulates PAX3/FKHR activity and that 
these effects are rather under- than overestimated.  
To evaluate whether the PAX3- or the FKHR-part of the fusion protein are targets of the PKC412 
mediated effect, we measured the influence of PKC412 on the transactivation activity of the alternative 
translocation product PAX3/NCOA1 {Wachtel, 2004 #257} and on FKHR alone. This approach 
demonstrated that PKC412 inhibits transcriptional induction of CB1 by PAX3/NCOA1 very similar to 
PAX3/FKHR (Fig.3G). In contrast, the transactivation potency of FKHR on a luciferase reporter plasmid 
driven by the promoter of the FKHR-target gene bim {Motta, 2004 #363} was unchanged or slightly 
stimulated by PKC412 in a dose dependent manner (Fig.3H). Taken together, these data suggest that it is 
rather the PAX3 part than the FKHR domain of the fusion protein that is influenced by PKC412.  
 
The PAX3 part of PAX3/FKHR is phosphorylated at multiple sites 
As broad spectrum kinase inhibitor, we hypothesized that PKC412 might affect phosphorylation(s) status 
as a mechanism to reduce the activity of PAX3/FKHR. Up to date, several phosphorylation sites targeted 
by PKB/Akt, p38 and Erk have been described in the FKHR part of the fusion protein {Rena, 1999 #334; 
Rena, 2002 #21; Brunet, 1999 #234; Asada, 2006 #364}. However, at least the sites targeted by PKB/Akt, 
which is known to be inhibited by PKC412 {Tenzer, 2001 #365}, mainly regulate FKHR subcellular 
localization and are thought to have no function in the context of the permanently nuclear localized 
PAX3/FKHR fusion protein {Del Peso, 1999 #20}. Therefore, and since PAX3/FKHR and PAX3/NCOA1 
behave similarly, we examined the phosphorylation state of the PAX3 part of PAX3/FKHR directly using a 
His-tagged form (PAX3His). Immunohistochemistry of transfected 393T cells with an anti-His-tag antibody 
proved that PAX3His is localized in the nucleus of the cells, as known for full lenght PAX3/FKHR (Fig.4A). 
Furthermore, incubation with 10 μM PKC412 for 24h did not change the localization of the protein. 
PAX3His was then purified from 32P-labeled 293T cells and tested for potential phosphorylation. As 
demonstrated in Fig.4B, a strong 32P-signal was detected in the PAX3His protein, directly suggesting that 
PAX3 is a phosphoprotein. Analysis with 2D-gel electrophoresis further supported this conclusion, as the 
purified PAX3-His protein revealed to be a mixture of several species with different pIs, reminiscent of 
multiple phosphorylation sites in a protein (Fig.4C). Finally, LC-MALDI-TOF mass spectrometric analysis 
of LysC-digested PAX3-His protein directly revealed 4-5 phosphates in the peptide 186-216 (m/z of 4-fold 
phosphorylated peptide is 3602, m/z of 5-fold phosphorylated peptide is 3683) (Fig.4D). This peptide 
includes the so called octapeptide of PAX3 and contains six Ser residues (S187, S193, S197, S201, 
S205, S209) as potential phosphorylation sites (Fig. 4E). Four out of these six Ser (S187, S201, S205, 
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S209) are conserved among the PAX3 proteins from different species suggesting irreplaceablity for proper 
function of PAX3 (Fig.4F). Interestingly, in silico analysis of the probability for phosphorylation using the 
DISPHOS1.3 web resource (http://core.ist.temple.edu/pred/), which uses disorder information to predict 
phosphorylation, revealed that these six Ser residues and the two flanking S180 and S222 have the 
highest probability for being phosphorylated among all potential phosphorylation sites in PAX3 (data not 
shown).  
 
Phosphorylation influences activity of PAX3/FKHR 
To test whether PKC412 influences the phosphorylation status of PAX3His, protein purified from PKC412- 
and control-treated 293T cells was compared by 2D-gel electrophoresis. As shown in Fig. 5A, PKC412 
induces a clear shift of the PAX3His species towards more basic pIs. Furthermore, electrospray ionization 
(Fig.5B) as well as MALDI-TOF (data not shown) mass spectrometric analysis of the same proteins 
revealed a PKC412-treatment induced shift towards smaller protein species. These results suggest that 
PKC412 affects the post-translational modification of PAX3.  
To test whether these phosphorylation sites are directly affecting PAX3/FKHR activity, we mutated the six 
Ser in the phosphorylated peptide individually into Asp, to mimic phosphorylation and potentially prevent 
PKC412 mediated inhibition. However, these single mutations did not affect sensitivity of PAX3/FKHR 
towards PKC412 (data not shown). Instead, mutation of all six Ser altogether into Asp partially rescues 
transcriptional activity of PAX3/FKHR (Fig.5C), suggesting involvement of more than one of these sites in 
regulation of PAX3/FKHR activity. Additional mutation of S180 into Asp did not lead to a significant further 
increase in rescue (Fig.5C), whereas mutation of S222 led to complete loss of transactivation activity (data 
not shown). Therefore, activating mutations can be inhibited by PKC412 to a lesser extant than the wild 
type protein. Furthermore, loss-of-function mutation of the six Ser into Ala led to a loss of transactivation 
activity as measured in transactivation assays using the 6xCD19 reporter plasmid by about 50% (Fig.5D). 
We conclude that indeed phosphorylation plays a role in regulation of PAX3/FKHR activity and can be 
influenced by PKC412 treatment. 
 
Inhibition of in vivo tumor growth of aRMS xenografts by PKC412 
Kinase inhibitors are interesting molecules for potential treatment of aRMS, especially when they are able 
to affect activities of key oncogenes such as PAX3/FKHR. Therefore, we further investigated the effects of 
PKC412 on tumor growth in vivo. Towards this end, Rh4 and Rh30 xenograft mice were treated daily by 
oral administration of PKC412 (100 mg kg-1). Treatment was maintained for 15 days and tumor size 
measured every 2 - 3 days. In both xenograft models tumor growth was significantly inhibited by PKC412 
treatment (Fig. 6A). In Rh4 xenografts a complete suppression of tumor growth was observed, whereas in 
Rh30 xenografts tumor growth was strongly decreased by PKC412. 
To further characterize the effect of PKC412 on xenograft tumors, mice were sacrificed at the end of the 
treatment period, tumors isolated, and stained by immunohistochemistry. Tumor morphology was 
determined by H&E stainings. Placebo-treated Rh4 (Fig. 6B, upper line) and Rh30 (Fig. 6C, upper line) 
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xenograft sections both showed a high density of actively growing tumor cells. In contrast, PKC412 treated 
tumors (Fig. 6B, lower line) showed a dramatic increase in connective tissue.  
In order to quantify the influence of PKC412 on tumor cell proliferation in vivo, tumor sections were 
immunohistochemically stained for the proliferation marker Ki-67 and apoptotic cells were detected by 
TUNEL staining. As shown in Fig. 6B, the number of Ki-67 positive cells is decreased in both Rh4 and 
Rh30 xenografts after treatment, whereas the number of apoptotic tumor cells dramatically increased by 4 
- 5 fold in tumors isolated from both Rh4 and Rh30 xenograft mice treated with PKC412. 
In summary, PKC412 significantly inhibited tumor growth, reduced numbers of actively dividing tumor cells 
while simultaneously increasing number of apoptotic cells. 
 
 
Discussion 
Aberrant constitutive activation of signaling cascades involved in regulation of differentiation, cell division 
and apoptosis is characteristic for many tumors and is thought to be a fundamental cause for 
tumorigenesis, promoting both tumor development and progression. Importantly, in many tumor types, 
tumors cells have been shown to acquire a dependency on such constitutive signaling and are growth 
inhibited or undergo apoptosis upon inhibition of these cascades, a phenomenon named oncogene 
addiction {Weinstein, 2002 #361; Weinstein, 2006 #362}. Therefore, components of these aberrant 
signaling pathways represent potential ´Achilles` heels` of the tumors and are postulated to be promising 
targets for tumor treatment. Especially upstream components of these cascades such as growth factor 
receptor kinases or cytoplasmic signal transduction kinases have been proposed as targets due to their 
good accessability for inhibitory antibodies or drugable enzymatic activities. In some cases the use of 
inhibitors against particular aberrant kinases has already made the way to the clinics as supplemental or 
even monotherapeutic alternative approach to conventional tumor therapies. Up to date, eight kinase-
targeted oncology drugs have received regulatory approval (for a review see {Sebolt-Leopold, 2006 
#348}), most prominently in case of the bcr-abl kinase inhibitor Gleevec (Imatinib) for CML treatment 
{Cohen, 2002 #378} or the EGFR inhibitors Gefitinib (Iressa) {Cohen, 2004 #379}, and Erlotinib (Tarceva) 
{Johnson, 2005 #380} for treatment of non small cell lung cancer. More than 100 additional agents are 
currently undergoing clinical evaluation. 
In case of RMS, the current treatment is still based on conventional treatment regimens (surgery, 
chemotherapy and radiotherapy), which in the case of metastasized aRMS often fail. Alternative treatment 
agents are therefore highly desired.  
In an approach to find targetable pathways in RMS, we therefore analyzed our recent gene expression 
data of RMS biopsies {Wachtel, 2004 #257} for the expression of kinases with a known tumor-relation and 
tested a series of kinase inhibitors against three selected kinases (EGFR, HGFR, FGFR), in comparison 
with mTOR which has been characterized as target in RMS in vitro {Hosoi, 1999 #347}, for their ability to 
reduce the growth of different aRMS and eRMS cell lines.  
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From all substances tested, PKC412 (N-benzoylstaurosporine; midostaurin; CGP41251) was found to 
have the most promising anti-growth effect. This compound induces very efficiently apoptosis in aRMS cell 
lines and also in aRMS xenografts in nude mice in submicromolar concentrations. This is well below the 
steady-state plasma levels of 2-7 μM, which were achieved in phase I clinical trials with this substance 
{Propper, 2001 #357}. As these concentrations were well tolerated by patients, our in vitro data provide a 
potential preclinical rationale for clinical studies of aRMS treatment.  
PKC412 is a derivative of staurosporine and was developed as PKC inhibitor. Although being less 
unspecific when compared to staurosporine, which is known to bind to a bulk of the whole kinome {Fabian, 
2005 #271}, also PKC412 was subsequently found to inhibit a wide range of other kinases such as 
cdk1/cycB, PKA, c-src, KDR (VEGFR2) and others in submicromolar concentrations {Fabbro, 1999 #336}. 
Based on these characteristics, PKC412 has been successfully applyed as inhibitor of different  oncogenic 
kinases in a range of tumors in vitro, e.g. as FGFR inhibitor in myeloproliferative disorder or multiple 
myeloma {Chen, 2004 #355; Chen, 2005 #354}, as kit inhibitor in mast cell leukemia {Gotlib, 2005 #356; 
Gleixner, 2006 #359} or as Akt inhibitor in myeloma {Bahlis, 2005 #360}. Its potential clinical use is most 
advanced as Flt3 inhibitor for the treatment of AML, for which PKC412 is used in a phase II clinical study 
{Stone, 2005 #337}.  
In this study, an inhibitory effect of PKC412 on transcriptional activity of PAX3/FKHR, an important 
potential therapeutic target in RMS, was detected. This effect of PKC412 is reflected e.g. by its ability to 
inhibit the induction of target gene transcription upon ectopic expression in the non-RMS cell line 293T. In 
the aRMS cell line Rh4 the endogenous transcription of these target genes is also affected by PKC412, 
albeit less pronounced. However, while 293T cells do well tolerate even 10 μM PKC412, aRMS cells 
rapidly undergo apoptosis upon PKC412 treatment, potentially interfering with determination of target 
gene levels. In contrast, when using reporter-plasmid based transactivation systems to measure 
PAX3/FKHR activity, the effects of PKC412 in 293T and Rh4 cells were comparable, suggesting effective 
inhibition of PAX3/FKHR activity by PKC412 also in Rh4 cells.  
We found that the inhibitory effect of PKC412 on PAX3/FKHR activity is at least partially based on 
modulation of phosphorylation sites in the PAX3 part of the fusion protein. While phosphorylation of PAX2 
{Cai, 2002 #341}, PAX6 {Mikkola, 1999 #343} {Kim, 2006 #342} and PAX8 {Poleev, 1997 #338} {Van 
Renterghem, 1996 #339} has been reported, phosphorylation sites in PAX3 have not been published so 
far. However, an influence of PKC on the transcriptional activity of PAX3 in presomitic mesoderm has 
been suggested in a recent work {Brunelli, 2007 #381}. Interestingly, while the phosphorylation sites in 
PAX2,6,8 have either not been elucidated or are located in the transactivation part of the protein, in the 
highly homologous DNA binding part of the PAX proteins no phosphorylation has been reported up to 
date. The region encompassing phosphorylation sites in PAX3 is located in the DNA binding part between 
the two DNA binding domains of PAX3 in the so called octapeptide region of PAX3. The octapeptide is a 
conserved region found in 7 out of 9 PAX family members, and in the case of PAX5 it has been shown to 
be involved in protein-protein interaction with the corepressor groucho-4 thereby influencing its 
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transcriptional activity {Eberhard, 2000 #301}. The fact that also PAX3 interacts with groucho-4 {Lang, 
2005 #344} suggests that a similar mechanism might operate in PAX3.  
MALDI-TOF analysis revealed that at least 4 out of 6 Ser residues are phosphorylated in the peptide 186-
216 of PAX3. Interestingly only multiple but not single mutations of these sites into Asp did reduce the 
sensitivity of the protein towards PKC412, suggesting that a combination of several phosphorylated sites 
is necessary for full transcriptional activity of PAX3/FKHR. As multisite phosphorylation is in many cases a 
cooperative and coordinate event, mutation of one phosphorylation site might not reveal the true function 
of that site (for review see {Holmberg, 2002 #278}). Whether all or a combination of some of these sites is 
involved in PKC412-sensitivity is under current investigation. Furthermore, the fact that exchange of all the 
six Ser by Asp did not completely protect from PKC412-mediated inhibition of PAX3/FKHR suggests that 
beside modulation of these phosphorylation sites also other mechanisms regulating PAX3/FKHR activity 
are affected by PKC412. 
Translocation-positive aRMS cells have been shown to highly depend on the presence of active fusion 
proteins, as silencing of PAX3/FKHR by oligonucleotides {Bernasconi, 1996 #333} {Margue, 2000 #64} or 
siRNA (manuscript submitted) very efficiently induces apoptosis in these cells. This suggests that 
reduction of PAX3/FKHR activity by PKC412 in aRMS cells may be, at least in part, the responsible 
mechanism for the detected induction of apoptosis. As tumors have many, and often overlapping, 
biological pathways they can use to grow and resist death, the current opinion is that inhibition of different 
signal transduction pathways in parallel may be more effective when compared to therapies targeting 
specifically one single pathway (for review see {Faivre, 2006 #350}). In this context, the diverse inhibitory 
effects of PKC412 could be advantageous. Furthermore, such multitarget therapy is thought to have an 
increased likelihood of sustained effectiveness due to the reduced probability for appearance of resistant 
clones.  
About one third of the known cellular oncogenes are transcription factors {Karamouzis, 2002 #349} 
{Futreal, 2004 #307} therefore these factors are highly interesting targets for potential therapeutic 
interventions. Unfortunately, the absence of a directly targetable enzymatic activity complicates the 
targeting of these factors. Experimental approaches to inhibit transcription factors, such as antisense 
nucleic acid approaches have been shown to be very useful in vitro, also in the case of aRMS 
{Bernasconi, 1996 #333}, but the technical complexity of an application in vivo prevents routine clinical 
implementation for the moment. The use of small molecule inhibitors influencing transcription factor 
activity could be an alternative. As demonstrated in our study, they may not target transcription factors 
directly, but kinases that regulate their activity. This approach would have the advantage that small 
molecule inhibiting a well characterized class of enzymes (kinases) could be used. Furthermore, as most 
of the approximate 1000 human transcription factors are thought to be regulated by phosphorylation 
{Gardner, 2005 #280}, the principles shown here may be worthwhile to explore for additional tumors 
addicted to oncogenic transcription factors such as e.g. Ewing’s sarcoma. 
In summary, our data reveal PKC412 as an interesting potential agent for the treatment of aRMS and 
provide a preclinical rationale for clinical studies with this inhibitor in aRMS patients. 
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Figure Legends 
 
Fig.1. Screening of small molecule inhibitors for inhibitory effects on growth of aRMS (Rh4, Rh30) and 
eRMS (RD, Ruch-2) cell lines. (A) Changes in proliferative activity as measured by MTT assays. Small 
molecule inhibitors presumably targeting EGFR/ErbB2 (PKI166), EGFR (CGP59326), c-met (NVP-
ABG424-NX-4), FGFR (PKC412), and mTOR (Rapamycin) were applied for 96 hours. Each inhibitor was 
tested at three concentrations (indicated in µM). Columns, mean of three independent experiments 
performed in triplicate; bars, SD. (B) Cell death was assessed using trypan blue exclusion. RMS cells 
were treated with a moderate concentration of the inhibitors described in (A) for 96 hours. Columns, mean 
of three independent experiments; bars, SD.  
 
Fig.2. PKC412 induces apoptosis in aRMS but not in eRMS cell lines. (A) IC50 values of PKC412 as 
determined by MTT assays of RMS cells treated with graded concentrations of PKC412 (0 - 10 µM) for 96 
hours. Note: the IC50 value for RD cells was not determinable (n. d.) because a 50 % inhibition of 
proliferative activity could not be achieved by using the corresponding PKC412 concentrations. Columns, 
mean of three independent experiments performed in triplicate; bars, SD.  (B) Evaluation of apoptotic cells 
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by an activated caspase-3 assay after treatment with 0.5 µM PKC412 (X) or DMSO ( ) for 24 – 72 hours. 
Points, mean of three independent experiments; bars, SD. (C) Western blot analysis of PARP cleavage 
performed on lysates (15 µg/lane) of RMS cells after treatment with 0.5 µM PKC412 or DMSO for 2, 4, 8 
and 16 hours.   
 
Fig.3. PKC412 inhibits the transcriptional activity of PAX3/FKHR. (A) Induction of transcription of the 
PAX3/FKHR target gene CB1 in 293T cells upon ectopic expression of the indicated PAX3/FKHR 
constructs as measured by qRT-PCR. Results of one representative experiment are shown. (B) Effect of 
siRNA-mediated silencing of PAX3/FKHR on the transcription level of CB1 in Rh4 cells as measured by 
qRT-PCR at the indicated time points. (C) Effect of PKC412 on ectopic PAX3/FKHR-induced CB1 
transcription in 293T cells and on endogenous CB1 transcription in Rh4 cells as measured by qRT-PCR. 
Cells were incubated with the indicated concentration range of PKC412 for 16h. Mean and SD of three 
independent experiments are shown. (D) Effect of PKC412 on the transactivation potency of PAX3/FKHR 
on two luciferase reporter plasmids containing specific promoters for the paired domain (6xCD19) or the 
homeodomain (P3) of PAX3. Rh4 or 293T cells transfected with PAX3/FKHR together with the indicated 
reporter plasmid were incubated with the indicated concentration of PKC412 for 16h. Mean and SD of 
three independent experiments are shown. (E) Effect of PKC412 on the level of PAX3/FKHR transcript in 
PAX3/FKHR transfected 293T cells as measured by qRT-PCR. Cells were treated as described in B. (F) 
Effect of PKC412 on the level of PAX3/FKHR protein in PAX3/FKHR transfected 293T cells as measured 
by Western blot detection with an anti-PAX3 antibody. Cells were treated as described in B. (G) 
Comparison of the effects of PKC412 on the transcriptional activation of CB1 by PAX3/FKHR and 
PAX3/NCOA1. 293T cells were transfected with the indicated PAX3-fusion protein construct and 
incubated with PKC412 for 16h. (H) Effect of PKC412 on the transactivation potency of FKHR on a 
luciferase reporter plasmid driven by the promoter of the FKHR-target gene bim. 293T cells transfected 
with FKHR and the bim reporter plasmids were incubated with the indicated concentration range of 
PKC412 for 16h. Mean and SD of three independent experiments are shown. 
 
Fig.4. The PAX3 part of PAX3/FKHR is phosphoylated in vivo. (A) Immunofluorescent detection of the His-
tagged PAX3-part from PAX3/FKHR (PAX3His) with an α-tetra-His antibody in transfected 293T cells 
cultivated in presence or absence of 10 μM PKC412 for 24h. (B) Phosphoimager detection of 32P (left 
panel) and α-tetra-His immunodetection (right panel) of Western blotted PAX3His protein purified from 32P 
labeled 293T cells. (C) Silver stained 2D-gel of PAX3His protein purified from 293T cells (lower panel) and 
α−tetra-His immunodetection of a blotted 2D gel of the same protein (upper panel). (D) MALDI-TOF mass 
spectrum of the peptide aa186-216 of PAX3. PAX3His was purified from PAX3His-transfected 293T cells 
and digested by LysC. Resulting peptides were isolated by chromatography and investigated for 
phosphorylation by MALDI-TOF-MS. (E) Schematic representation of the domain structure of PAX3 
depicting the localization of the identified phosphorylation sites in PAX3. (F) Alignment of the PAX3 protein 
sequences from the indicated species including the region with the identified phosphorylation sites. 
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Phosphorylation sites conserved among all four species (S187, S201, S205, S209) are indicated by 
arrows. 
 
Fig.5. Partial rescue from inhibition by PKC412 by phosphate mimicking mutations in PAX3/FKHR. (A) 
Silver stained 2D-gel of PAX3His protein purified from transfected 293T cells incubated in absence (upper 
panel) or presence (lower panel) of 10 μM PKC412 for 16h. (B) ESI-MS analysis of the same proteins as 
in A. (C) Effect of PKC412 on induction of CB1 transcription in 293T cells upon ectopic expression of 
wildtype PAX3/FKHR or PAX3/FKHR with Ser-Asp exchanges of the indicated amino acids as measured 
by qRT-PCR. Mean and SD of three independent experiments are shown. (D) Relative transactivation 
potencies of wildtype PAX3/FKHR or PAX3/FKHR with the indicated Ser-Ala mutations on the 6xCD19 
reporter plasmid as measured by luciferase assays. Mean and SD of three independent experiments are 
shown. Asterisks represent P<0.05 vs. wt.  
 
Fig.6. In vivo anti-tumor effects of PKC412 in two different aRMS xenograft models. (A) Growth inhibition 
of Rh4 and Rh30 xenografts in female CD-1 athymic nude mice (nu/nu) treated with a daily dose of 100 
mg/kg PKC412 for up to 15 days. (B) Evaluation of proliferation and apoptosis in PKC412-treated 
xenografts by immunohistochemistry and TUNEL staining. After treatment, tumors were excised, fixed and 
paraffin-embedded. Sections were stained for Ki-67 (upper row) or TUNEL-stained (lower row). 
Proliferation and apoptosis were quantified by counting Ki-67- and TUNEL-positive cells. Columns, means 
for each treatment group (n = 3 - 6); bars, SD. (C) Haematoxylin and eosin (H&E) stainings of Rh4 (A - D) 
and Rh30 (E - H) xenograft sections. Upper row, placebo-treated tumors; lower row, PKC412-treated 
tumors. Cells within the square in left panels are shown in right panels at higher magnification (Bar 200 
µm (left panels) and 100 µm (right panels). 
 
Figure S1. Effects of PKC412 on phosphorylation of signal transduction proteins. Western blot analysis of 
p-AKT, p-FGFR1-4, p-4E-BP1, p-p70/85 S6 kinase, p-p44/42 and p-IGFR-I were performed in cell lysates 
(30 µg/lane) from Rh4 cells after treatment with indicated concentrations of PKC412 for 10 minutes. Blots 
were stripped and reprobed with anti-ß-catenin as a loading control.  
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PAX3 role in melanoma cell survival 
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Introduction 
 
PAX3 belongs to the group of (paired box) genes that encode a set of transcription factors. To date, nine 
members (PAX1-PAX9) have been described (Dahl et al., 1997; Stuart and Gruss, 1996) involved in 
regulation of tissue development and cellular differentiation in embryos. Apart from its role in embryonal 
development, different PAX family members have been assigned with a wide range of cancers 
(Muratovska et al., 2003). The precise role of PAX transcription factors in cancer is not known, but it has 
been shown that PAX genes are preventing terminal differentiation and maintaining progenitor cell state 
(Tremblay et al., 1996). Two members of PAX gene family, PAX3, and PAX7, show tumor-associated 
expression in different cancer types, among them neuroblastomas (Harris et al., 2002), squamos cell lung 
carcinomas (Racz et al., 2000) and rhabdomyosarcoma (Frascella et al., 1998). In rhabdomyosarcoma, 
PAX3 is implicated in the invasive and metastatic potential of cancer cells, as it plays a role in 
maintenance of a progenitor cell state and promotes cell survival. Similarly, the function of PAX3 at a 
nodal point in adult melanocyte stem cell differentiation has been described, where PAX3 simultaneously 
initiates melanogenic cascade while preventing terminal differentiation (Lang et al., 2005). This finding 
was supported by several studies demonstrating the “oncogene –addiction” of eRMS and melanoma 
tumor cells, as inhibition of PAX3 expression in either ERMS or melanoma cell lines using siRNA or 
antisense PAX3 oligonucleotides results in induction of apoptosis (submitted manuscript)(Bernasconi et 
al., 1996; Elbashir et al., 2001; Frascella et al., 1998; Scholl et al., 2001). 
In our work, we aim to establish an RNAi based approach to reveal the role of PAX3 in the melanoma cell 
viability. Moreover, we examined the effect of PKC412, a kinase inhibitor, on melanoma cell survival to get 
insights into regulation of PAX3 activity. 
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Material and Methods 
 
Cell lines 
 
Mel15 and A365 melanoma cell lines were provided by Dr. R. Drummer (University Hospital Zürich, 
Switzerland). Cells were maintained under proliferating conditions in Dulbecco modified Eagle medium 
supplemented with 10% fetal bovine serum and grown in 95% air, 5% CO2 at 37oC. 
 
 
siRNA-mediated silencing 
 
PAX3 knockdown was performed by use of the RNA interference (RNAi) technique (Elbashir et al., 2001). 
A total of 2x105  melanoma cells was plated and 24h later transfected with a combination of two chemically 
synthesized siRNAs (5’AAGAGAGAACCCGGGCAUG-dTdT and 5’CAUGGAUUUUCCAGCUAUA-dTdT) 
both targeting the PAX3 gene (Qiagen, Hombrechtikon, Switzerland). Transfection was performed 
according to manufacture’s instructions using 3μl of Lipofectamine (Invitrogen, Basel, Switzerland) and 
20nM siRNA (final concentration).  
 
Quantitative RT-PCR 
 
Total RNA samples (1μg) were reverse-transcribed with Oligo(dT)15 Primer using the Omniscript Reverse 
Transcription Kit (Qiagen). Quatitative RT-PCR detection of PAX3 and GAPDH was performed with 
commercially avaible assays-on-demand Hs00240950_m1, and Hs99999905_m1 (Applied Biosystems, 
Rotkreuz, Switzerland), respectively. TaqMan analysis was carried out according to the manufacturer’s 
instructions on an Applied Biosystems 7900HT Sequence Detector. Expression levels of the gene of 
interest were normalized with GAPDH expression levels. Experiments were performed in triplicate and 
standard deviations were calculated based on the results of three biological replicates. 
 
Cell Proliferation assays 
 
Cell proliferation was measured using the MTT assay system (Roche, Rotkreuz, Switzerland). A total of 
1x104 Mel15 or A365 cells were plated per 96-well and transfected 24h later. The amount of converted 
MTT reagent was measured at different time points up to 72h later by a multi-detection microplate reader 
(Bio-Tek Instruments, Inc., Littau, Switzerland) at wavelength 595 nm. 
For the measurement of cell proliferation upon treatment with kinases inhibitor, the compound PKC412 
was used (kindly provided by Novartis, Basel, Switzerland). A total of 1x104 Mel15 or A365 cells were 
plated per 96-well and treated 24h later with PKC412 in a final volume of 100 µl medium including 10% 
serum for 72 hrs. 
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Results 
 
1. PAX3 promotes cell survival of melanoma cells  
 
The cell survival promoting role of PAX3 in eRMS and PAX3/FKHR in aRMS is well characterized. 
However, wide range of different cancer cell types also show high expression of PAX3, among them cells 
from brain, melanoma, breast and colon cancer (Muratovska et al., 2003). Previously, the role of 
PAX3/FKHR and PAX3 in aRMS and eRMS development and maintenance was shown using a siRNA-
mediated down-regulation strategy (manuscript submitted). As this approach has yet not been used in 
melanoma cells, we sought to characterize the role of PAX3 in melanoma cell lines by siRNA-mediated 
down-regulation. We used the melanoma cell line Mel15 which expresses PAX3 at high levels and A365 
cells, which do not express PAX3.  
The combination of two published siRNAs used for PAX3 and PAX3/FKHR silencing was also applied in 
this approach. The treatment with specific siRNA suppressed the PAX3 mRNA level in Mel15 melanoma 
cells by nearly 70% (Figure 1A). In the control cell line, GAPDH mRNA level was suppressed by treatment 
with siRNA specific for GAPDH by approximately 50% (Figure 1B).   
To characterize the physiological effects occurring upon siRNA treatments, we next measured 
proliferation of Mel15 and A365 cells after treatment with PAX3 specific and control siRNAs for 24hrs, 
48hrs and 72hrs. Cell growth was found to be inhibited in Mel15 cells treated with siRNA targeting PAX3, 
whereas only unspecific inhibition of proliferation rates was observed in A365 cells (Figure 1 C, D). Thus, 
an anti-apoptotic function of PAX3 in Mel15 could be demonstrated. These results are in accordance with 
earlier findings, demonstrating an anti-apoptotic function of PAX3 melanoma cells treated with specific 
antisense oligonucleotides (Scholl et al., 2001) and therefore validate our siRNA approach also on the 
physiological level.  
 
2. PKC412 treatment leads to proliferation stop of melanoma cells 
 
It has been shown in different tumors types that a constitutive active signaling cascade is contributing to 
tumorigenesis. For example, in alveolar rhabdomyosarcoma, PKC412 has been shown to regulate 
PAX3/FKHR activity by altering its phosphorylation status. Moreover, an antitumorigenic potential of 
PKC412 for aRMS has been shown in vitro and in vivo (Wachtel, Amstutz et al., manuscript in 
preparation). We assumed that similar regulation of PAX3 transcription factor by kinases could occur in 
melanoma cells. To investigate that, we measured the effect of PKC412 treatment of melanoma cells 
Mel15 and A365. Indeed, PKC412 treatment of Mel15 inhibited the proliferation rate in dose-dependent 
manner (Figure 2A), whereas A365 cells did not show any PKC412 specific effect (Figure 2B). Thus, the 
regulation of PAX3 activity by protein kinases seems to play a role in the survival of the two examined 
melanoma cells. 
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Discussion 
 
PAX3 is a transcription factor which activates different tissue-specific targets and appears to play an 
essential role in the development of both, melanogenic and myogenic cell lineages. The oncogenic 
properties of PAX3 include the capability of promoting cell viability, migration and self-sufficiency in growth 
signals. For the understanding how these oncogenic characteristics are mediates, identification of the 
relevant PAX3 downstream targets and signalling pathways involved in tumor development are required.  
However, the set of PAX3 target genes, which are involved in these properties remains, with the exception 
of some single gene as c-met (Relaix et al., 2003) and some signalling pathways involving HGF/SF 
(Saitoh et al., 1994) and IGF-1R receptors (Furlanetto et al., 1993) are largely unknown.  
The RNAi strategy revealed the promoting role of PAX3 in cell survival of melanoma cells. PAX3-
expressing melanoma cell line was susceptible to siRNA treatment and showed reduced cell proliferation 
compared with control PAX3-negative melanoma cells. Similar results were achieved in the previous work 
performed with RMS cell lines (submitted manuscript), suggesting an antiapoptotic function of PAX3 in 
both, melanoma and rhabdomyosarcoma. The antiproliferative effect of PKC412 in melanoma cells 
suggests that the activity of PAX3 might be regulated via pathways involving protein kinases. However, 
these preliminary results need to be verified by further studies.  
Taken together, the silencing of PAX3 by siRNA or inhibition of PAX3 transcription factor activity by broad 
spectrum kinase inhibitors such as PKC412 might represent a possible novel therapeutic strategy for 
treatment of melanoma. 
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Figure 1 
 
 
0
20
40
60
80
100
120
0h 24h 48h 72h
%
 P
A
X3
 m
RN
A 
ex
pr
es
si
on
0
20
40
60
80
100
120
0h 24h 48h
%
 G
A
PD
H
 m
R
N
A
 e
xp
re
ss
io
siRNA vs scRNA
siRNA vs scRNA
A B
Mel15 A365 
siRNA siRNA
C D 
0
2
4
6
8
10
24h 48h 72h
M
el
15
 c
el
l n
um
be
r x
 1
0
4
0
2
4
6
8
10
12
14
24h 48h 72h
A
36
5 
ce
ll 
nu
m
be
r x
 1
04
scRNA scRNA
GAPDH GAPDH
Lipofectamine Lipofectamine
Mel15 A365 
 
 127
Figure 2 
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8 Discussion 
8.1 RNAi technique  
 
RNA interference (RNAi) is a process of sequence specific post-transcriptional gene silencing. The 
mechanism of RNAi has been first recognized by Andrew Fire et al. in 1998 and already in 2002 the 
phenomenon or RNAi was termed as the “Breakthrough of the Year” by the journal Science. RNAi is 
initiated by the enzyme called DICER, which processes double-stranded RNA (dsRNA) into small pieces 
of 21-25 nucleotide small interfering RNA (siRNA) (Bernstein et al., 2001). The siRNAs are incorporated 
into the RNA-induced silencing protein complex (RISC), a multicomponent nuclease, and guide this 
complex to the target mRNA which is then recognized and cleaved. This guidance of RISC to target 
mRNA is highly sequence specific and, thus, target specific. RNAi regulation of endogenous genes in 
mammalian cells occurs via short dsRNA molecules termed as microRNA (miRNA). MiRNAs are a class 
of non-coding RNAs of approximately 22 nucleotides. MiRNA can not only inhibit gene expression by 
mRNA degradation, but also inhibit the translation of target genes.   
Although RNAi is a naturally occurring process, it is nowadays considered as one of the most powerful 
and indispensable tools for gene silencing in molecular biology. Using short double-stranded RNA 
(dsRNA) molecules, essentially every gene in the genome can be selectively silenced, thus enabling the 
study of gene function in development, intracellular signaling, cancer, infection and more in endogenous 
context. By “knocking down” a gene with RNAi and determining the cellular responds, significant insight 
into the function of the gene can be gained.  
8.2 RNAi in cancer 
 
In different tumor cell models, various individual genes have been silenced with the use or RNAi technique 
and their knockdown led to significant physiological changes. Among these genes were genes involved in 
tumor development like oncogenes, growth factor receptor genes, genes encoding for anti-apoptotic 
molecules, signaling molecules, telomerase and others. The physiological effect of such genes for tumor 
survival can be then clearly determined in endogenous context. Some examples of this approach is the 
RNAi-mediated silencing of several members of Ets transcription factor family, BCR-ABL in CML or EWS-
FLI1 in Ewing’s sarcoma. The downregulation of BCR-ABL and EWS-FLI1 resulted in apoptosis and 
inhibition of tumor cell growth (Wohlbold et al., 2003; Scherr et al., 2005, Hu-Lieskovan et al., 2005). 
Another important transcription factor family involved in cancer development is myc transcription factor 
family. A member of this family, c-myc was downregulated in breast cancer cells, which also lead to 
apoptosis and inhibition of cell growth (Wang et al., 2005). Similarly, in our work, the antiapoptotic effect of 
PAX3/FKHR in aRMS and PAX3 in eRMS cells could be demonstrated using siRNA (manuscript under 
revision).  
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Moreover, endogenously expressed classes of siRNAs, miRNAs, have global effect on gene expression 
and may inhibit oncogenes or tumor-suppressor genes, thus itself acting as tumor suppressors or 
oncogenes. This hypothesis was supported by the finding, that more than 50% of genes encoding for 
miRNAs were localized in cancer-associated genomic regions or in fragile sites (Calin et al., 2004). 
Indeed, tumor suppression function of miRNA could be determined in CLL (Calin et al., 2002) and the 
oncogene function of miRNA was reported for B-cell lymphomas (Eis et al., 2005), Hodgkin’s lymphomas 
(Kluvier et al., 2005) and human breast cancer cells (Iorio et al., 2005). 
8.3 RNAi as tool for functional genomic 
 
The extraordinary selectivity of RNAi quickly made it the tool of choice for functional genomics. In this 
approach, siRNA-mediated gene silencing can be coupled with microarray screening and putative targets 
of the silenced genes can be identified. Furthermore, systematic pathway analysis can be performed with 
microarray data to determine of the role of the silenced gene in intracellular pathways. Thus, 
determination of what a gene product does and with what other products it interacts is faster and easier 
combining these techniques.  
Moreover, identification of downstream target genes of distinct cancer-associated transcription factors 
may help us to understand the role of the fusion products in tumor development. Previously, downstream 
targets were mainly identified by transfection of fusion genes into different cell lines followed by microarray 
analysis to identify differentially expressed genes. The opposite approach, previously achieved by 
generation of loss-of-function mutants through different methods like chemical mutagenesis or expression 
of anti-sense library (Deiss and Kimchi, 1991), became a faster and more specific with the development of 
RNAi techniques. There are numerous studies determining various downstream targets of transcription 
factors associated with cancer, as for example EWS-FLI1 in Ewing’s sarcoma (Prieur et al., 2004) or c-
myc in breast cancer cells (Cappellen et al., 2007). However, not all of the putative targets identified by 
this approach turned out to be true when analysed in vivo.  
Similarly, we sought to identify target genes of the chimaeric transcription factor PAX3 and PAX3/FKHR 
combining RNAi technique with microarray analysis. In order to identify target genes relevant in vivo, we 
compared the microarray data obtained in cell culture to data acquired from tumor biopsies and to 
published microarray data derived from experiments performed with different cell lines. Moreover, direct 
targets had to be distinguished from unspecific effects caused by RNAi or secondary effects based on the 
gene expression changes in response to the knockdown of the target.  
In our work, we performed a time course assuming that direct target genes are the first genes showing 
different expression. Indeed, we could discriminate between direct and indirect effects and thus conclude 
whether the identified gene is a direct or indirect target. In our case, we could identify 51 putative target 
genes of PAX3/FKHR which are relevant in vivo and one of them, TFAP2beta, was characterized as a 
direct target of PAX3/FKHR. We validated the microarray data by additional methods, as the direct binding 
of PAX3/FKHR to the promoter region of TFAP2beta was shown by promoter studies and the 
physiological link between the two genes was confirmed by rescue approach. Moreover, PAX3 and 
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PAX3/FKHR targets that play a role in other oncogenic pathways, in our case the repression of myogenic 
differentiation or enhanced tissue invation and metastasis could be detected by microarray analysis. 
However, the challenging issue in this field is the correct analysis, interpretation and validation of 
microarray data and finally, a functional link between discovered genes and the observed phenotype 
should be provided. 
8.4 RNAi therapy 
 
The use of RNAi technique as novel therapy for clinical applications is a promising approach. The great 
advantage of treatment with small interference RNA (siRNA) is the selectivity of which siRNA destroys its 
target without affecting other genes. Wide range of clinical applications are imaginable as any gene whose 
expression contributes to disease is a potential target for therapy, from oncogenes in cancer therapy to 
genes responsible for heart disease, Alzheimer's disease, diabetes, and more. 
Several biotech companies are already developing RNAi-based therapy, one of them, called Sirna 
Therapeutics aim to deliver siRNAs to key cellular targets through systemic, local and topical applications. 
Sirna’s most advanced programs are in age-related macular degeneration AMD, viral hepatitis, respiratory 
disease and dermatology. Sirna is also developing programs in diabetes, Huntington’s Disease and 
oncology. Currently, different siRNA molecules are in preclinical phase and some of them are even tested 
in phase I and phase II clinical studies. For example, siRNA for Hepatitis C is in phase I clinical study and 
ongoing phase II clinical study with siRNA for AMD has been published. 
However, there are technological hurdles need to overcome and the biological limitations need to consider 
for achieving effective therapeutics. The main prerequisite for successful siRNA therapy is generation of a 
stable molecule which can be efficiently delivered to its target cells. Furthermore, unspecific significant 
toxic effects or off-target effects neither in target nor in non-target tissue should be caused by the therapy. 
Therefore, to use siRNA as a compound, chemically optimized siRNA’s are needed because charged 
oligonucleotides would not pass through a lipid layer and unmodified RNA would be rapidly degraded in 
the bloodstream or excreted by the kidneys. Complexes of RNA with a lipid of backbone modifications 
have been developed in order to increase cell uptake and to improve stability in the blood stream. 
The delivery of siRNA is another major problem of RNAi therapy approach. To overcome this problem, 
nanoparticle delivery was developed by biotech companies. Therefore, novel nanoparticles were used that 
can deliver siRNAs at low doses to the cells of choice by local, systemic or topical delivery. However, in 
the phase II clinical study presented by the Sirna Therapeutics company, antisense has been applied in 
the eye. In other situations, like in cancer, delivery is more of an issue. Moreover, most effective antitumor 
drugs have multiple mechanisms of action. This has been shown with two other RNA-based therapies, 
antisense and ribozymes, both of which were promising tools for therapy but did not achieve this success. 
Therefore, it is possible that in some cases, the overspecificity of the RNAi could be even 
disadvantageous for the therapeutical outcome. Other obstacles for the RNAi therapy might be the toxicity 
level and the therapeutic effect of treatment. The target of interest may be in normal cells as well as 
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cancer cells. And as the number of RISC complexes in the cell is unknown, if the amount of RNA needed 
to have a therapeutic effect may occupy all the available complexes. RNAi is a natural cell system that is 
there for knocking out endogenous gene function. With the introduction of foreign RNA, will the system 
continue to perform its normal function as well, or will it become saturated. 
However, if these hurdles can be resolved, RNAi could revolutionize the identification and validation of 
new drug targets and with the development of RNAi as therapeutic agents personalized disease treatment 
could be achieved.  
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9  Conclusions and Outlook 
 
There are two main areas of RNAi applications: drug discovery and research, and potential therapeutic 
applications. In our work, we could prove that RNAi can be used for characterization of gene functions and 
as functional genomics tool for identification of new target genes. However, the entity of oncogenic 
pathways involved in RMS formation and progression still remains to be clarified.  
In our work, a “gene by gene” method was chosen, in which individual transfection for silencing of a 
distinct gene has been performed. Recently established novel high-throughput systems however allow 
large-scale analyses of gene function. Large collections of synthetic siRNAs have been developed, some 
of them targeting smaller set of genes of interest, like various kinases and phosphatases. But also whole-
genome libraries have been developed which consist of at least 3 distinct siRNA molecules specifically 
targeting virtually all annotated genes in the human, mouse and rat genomes.  
In order to study multiple cellular processes, protein detection technologies have been adopted by large-
scale screening platforms, with analogy to the analysis of gene expression using DNA microarrays. Thus, 
novel cell microarrays have been developed enabling robust and automated transfection in order to be 
able to introduce the siRNA molecules under constant conditions in mammalian cells. In this RNAi 
microarray platform, a transfection matrix is first arrayed on glass slides overlaid with a monolayer of 
adherent cells which take up siRNA molecules that had been deposited on the slide before cells were 
plated. This technique of reverse transfection combined with large-scale RNAi libraries allow the 
measurement of effects of gene silencing by digital image analysis by specific fluorescent monoclonal 
antibodies at a single cell level. Selective silencing of any gene in the genome combined with high-
throughput functional genomics studies enables identification of gene functions on a whole genome scale 
which could be a future method to screen for potential therapeutic targets associated with diseases. 
Moreover, a database of gene expression signatures for various perturbations such as siRNA-mediated 
gene knockdowns could be created in future. This database would then be used as a reference to analyze 
new profiles obtained for novel inhibitors, thus providing value in drug target identification and candidate 
compound selection. 
Despite the fact that the use of genome-wide RNAi libraries is a new technology, this approach holds 
great promise for better understanding of cancer-related processes and the consequences of alterations 
in these processes in different cancer types, among them RMS. In future, using the RNAi libraries and 
large-scale platforms, we could use RNAi cell arrays for identification of further target genes of 
transcription factors. Predicted promoter regions can be cloned in vectors upstream of reporter genes, and 
cell lines stably expressing the reporter construct can be subjected to genome-wide siRNA arrays.  
Because of its exquisite specificity and efficiency, RNAi is an important tool not only for functional 
genomics, but also for gene-specific therapy. Genome-wide screens using RNAi can help to identify 
components of functionally related pathways and therefore be used for the development of new and 
improved therapeutic targets. Thus, combination of microarray technology and cellular biology methods 
should in the future provide additional tool for development of robust RNAi-based screening methods and 
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consequently toward efficient drug target selection and evaluation. Discovery of new drug targets by 
microarray and determination whether reducing its gene expression is likely to be therapeutically useful 
makes then the validation of potential drug targets faster more specific and thus, more effective. This is 
especially important for aggressive tumour types like aRMS. Although the conventional treatment of RMS 
with chemo- and radiotherapy has been greatly improved, the 5-year survival rate is still quite low (30% for 
aRMS, 60% for eRMS). Especially for the more aggressive aRMS subtype, new therapy forms are 
required, as aRMS cells become resistant to conventional chemo- and radiotherapy. Targeting of the 
mRNAs of cancer-related genes would allow a specific and efficient treatment of RMS, therefore more 
detailed investigation of RNAi against clinically relevant gene targets in appropriate model systems should 
be performed. 
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11 Abbreviations 
 
ALL  acute lymphoblastic leukemia 
AML  acute myelogenous leukaemia 
ARMS  alveolar rhabdomyosarcoma 
cDNA  complementary DNA 
CDK  cyclin-dependent kinase 
ChIP  Chromatin immunoprecipitation 
CML  chromic myelogenous leukaemia 
EMSA  Electrophoretic Mobility Schift Assay 
ERMS  embryonal Rhabdomyosarcoma 
EWS  Ewing’s sarcoma 
FKHR  forkhead related gene 
HLH  helix-loop-helix 
HM  Homeodomain 
LZ  Leucine zipper 
MDS  myelodysplastic syndrome 
MTTassay 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay 
PAX3  Paired box 3 
PD  Paired domain 
Rb  Retinoblastoma 
RMS  Rhabdomyosarcoma 
RT-PCR reverse transcriptase polymerase chain reaction 
scRNA  scrambled RNA 
siRNA  small inhibitory RNA 
T-ALL  T-cell acute leukaemia 
TFAP2b Transcription factor activating enhancer binding protein 2 beta 
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